WO2009084970A1 - 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use - Google Patents

5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use Download PDF

Info

Publication number
WO2009084970A1
WO2009084970A1 PCT/PT2008/000054 PT2008000054W WO2009084970A1 WO 2009084970 A1 WO2009084970 A1 WO 2009084970A1 PT 2008000054 W PT2008000054 W PT 2008000054W WO 2009084970 A1 WO2009084970 A1 WO 2009084970A1
Authority
WO
WIPO (PCT)
Prior art keywords
cio
alkyl
aryl
amino
fluoro
Prior art date
Application number
PCT/PT2008/000054
Other languages
French (fr)
Inventor
David Alexander Learmonth
Laszlo Erno Kiss
Alexander Beliaev
Humberto Dos Santos Ferreira
Patrício Manuel Vieira Araújo Soares da SILVA
Original Assignee
Bial-Portela & Companhia, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial-Portela & Companhia, S.A. filed Critical Bial-Portela & Companhia, S.A.
Priority to EP08866782A priority Critical patent/EP2238131A1/en
Priority to MX2010006995A priority patent/MX2010006995A/en
Priority to CN2008801276810A priority patent/CN101959881A/en
Priority to BRPI0821482-4A priority patent/BRPI0821482A2/en
Priority to CA2710743A priority patent/CA2710743A1/en
Priority to JP2010540610A priority patent/JP2011507952A/en
Priority to AU2008344032A priority patent/AU2008344032A1/en
Publication of WO2009084970A1 publication Critical patent/WO2009084970A1/en
Priority to IL206419A priority patent/IL206419A0/en
Priority to ZA2010/05306A priority patent/ZA201005306B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds having a 5-0-substituted 3-N-phenyl- 1,3,4- oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase).
  • FAAH is an integral membrane protein (IMP) that hydrolyzes bioactive amides, such as the endocannabinoid anandamide, which is an agonist of cannabinoid receptors and TRPVl vanilloid receptors to free fatty acid and ethanolamine, see e.g. McKinney M.K., Cravatt B.F., Ann. Rev. Biochem. 74:411 (2005).
  • bioactive amides such as the endocannabinoid anandamide, which is an agonist of cannabinoid receptors and TRPVl vanilloid receptors to free fatty acid and ethanolamine
  • FAAH Due to its ability to regulate anandamide levels, FAAH is currently viewed as an attractive drug target.
  • inhibitors of FAAH include PMSF
  • MAFP methoxyarachidonylfluorophosphonate
  • ATMK arachidonoyltrifluoromethylketone
  • FAAH inhibition is considered to play an important role in a wide variety of medical consitions, see for example Pacher et al Pharmacol. Rev. 58:389-462 (2006) which is fully incorporated into the description by reference thereto.
  • pain in particular acute or chronic neurogenic pain such as migraine and neuropathic pain (for example diabetic neuropathic pain, post-herpetic neuralgia, trigeminal neauralgia); acute or chronic pain associated with inflammatory diseases such as arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, and irritable bowel syndrome; acute or chronic peripheral pain; (ii) dizziness, vomiting, and nausea, in particular resulting from chemotherapy;
  • neurological and psychiatric pathologies such as tremors, dyskinesias, dystonias, spasticity, obsessive-compulsive behaviour, Tourette's syndrome, all forms of depression and anxiety of any nature and origin, mood disorders, and psychoses;
  • cardiovascular diseases such as heart failure, hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, cardiac ischaemia, and renal ischaemia;
  • cancers for example benign skin tumours, brain tumours and papillomas, prostate tumours, and cerebral tumours (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumours of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, plexus tumour, neuroepitheliomas, epiphyseal tumour, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, and schwannomas);
  • autoimmune diseases such as psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, autoimmune haemolytic anaemia, multiple sclerosis, amylotrophic lateral sclerosis, amyloidosis, graft rejection, diseases affecting the plasmacytic line, allergic diseases; immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis; (xi) parasitic, viral or bacterial infectious diseases such as AIDS, and meningitis;
  • autoimmune diseases such as psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, autoimmune haemolytic anaemia,
  • inflammatory diseases in particular joint diseases such as arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome;
  • pulmonary conditions including diseases of the respiratory tracts, bronchospasm, coughing, asthma, chronic bronchitis, chronic obstruction of the respiratory tract, and emphysema;
  • gastrointestinal diseases such as irritable bowel syndrome, inflammatory intestinal disorders, ulcers, diarrhoea, urinary incontinence and bladder inflammation.
  • the compounds of the present invention may be used to treat the above-mentioned conditions as well as in the preparation of medicaments to treat such methods.
  • the invention also includes methods of treating such diseases comprising administering a compound of the invention to a patient in need thereof, as well as pharmaceutical compositions containing a compound or compounds of the present invention.
  • the most preferred envisaged use for the compounds of the invention is the treatment of pain, in particular:
  • neuropathic pain for example, migraine
  • neuropathic pain including diabetic neuropathic pain, post-herpetic neuralgia, trigeminal neauralgia
  • treatment and variations such as 'treat' or 'treating' refers to any regime that can benefit a human or non-human animal.
  • the treatment may be in respect of an existing condition or may be prophylactic (preventative treatment).
  • Treatment may include curative, alleviation or prophylactic effects.
  • Treatment may prevent or delay the onset, retard the progression or ameliorate the symptoms of the disease or condition.
  • the present invention relates to a compound of formula (I),
  • R 1 to R 5 independently from each other represent: hydrogen
  • Ci-Ce-alkylcarbonyl Ci-Co-alkylcarboxy, Ce-Cio-arylcarboxy, d-C ⁇ -alkylmercaptyl,
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro;
  • n 0 or 1
  • m 0, 1, 2, 3, 4, 5 or 6;
  • X represents O or S
  • Y represents: a) hydrogen; b) Ci-Ci 8 -alkyl, mono or polyunsaturated C 2 -Cig-alkylene, C 3 -Cg-cycloalkyl, C ⁇ -Cio-aryl, C ⁇ -Cio-aryl-Ci-Cs-alkyl, Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, C ⁇ -Cio-aryl-Ci-Cg-alkoxy, C 1 -C ⁇ -alkoxycarbonyl, CO-C 10 -aryloxycarbonyl, Ce-C 10 -aryl-C 1 -Cg-alkoxycarbonyl, Cj-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, C ⁇ -Cio-aryl-Ci-Cg-alkylcarbonyl,
  • Ci-C ⁇ -alkylsulfonyl C ⁇ -Cio-arylsulfonyl, Cj-C ⁇ -alkylsulfoxy, C 6 -Cio-arylsulfoxy; wherein each is optionally substituted once or several times by Ci-C 6 -alkyl; Ci-C 6 -alkoxy; COhJH 2 , SO 2 ISfH 2 ; CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted once or twice with Ci-C 6 -alkyl; SO 3 H; CO 2 H; amino; amino substituted one or more times with residues g
  • Ci-C ⁇ -alkyl selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl, C ⁇ -Cio-aryl-Ci-Ce-alkyl, Ci-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and
  • alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C 6 -Ci 0 -aryl, C 6 -Cio-aryl-Ci-C 8 -alkyl, Ci-Ce-alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, Ci-C 6 -alkylsulfonyl and C ⁇ -Cio-arylsulfonyl; or a disubstituted amino of the following formula (II)
  • o represents O or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C 6 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro; or by b3) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C ⁇ -alkyl; Ci-C ⁇ -alkoxy; COOH;
  • Ci-Ce-alkyl C 6 -Ci 0 -JUyI, C 6 -Ci 0 -aryl-Ci-C 8 -alkyl, Cj-Cs-alkylcarbonyl, C 6 -C
  • a further embodiment relates to the use of the above-described compound for the inhibition of fatty acid amide hydrolase (FAAH) and also for the treatment of medical conditions which are positively influenced by the inhibition of FAAH.
  • FAAH fatty acid amide hydrolase
  • the above compounds are in particular indicated for the treatment of the above-mentioned diseases and medical conditions.
  • the present invention relates also to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the above formula (I) or an enantiomer, pharmaceutically acceptable salt or a prodrug thereof, as well as to a method for treating the above-mentioned diseases and conditions by administering a pharmaceutically active amount of a compound of above formula (I), an enantiomer, pharmaceutically acceptable salt or a prodrug thereof.
  • Ci-C 4 -alkyl represents preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.
  • Ci-C 6 -alkyl represents preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl or hexyl.
  • Ci-Cig-alkyl represents preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, octyl, decyl, dodecyl, tetradecyl and octadecyl.
  • mono or polyunsaturated C ⁇ -Cig-alkylene preferably represents ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, tert-butenyl, pentenyl, hexenyl, octenyl, decenyl, dodecenyl, tetradecenyl, octadecenyl, dodecdienyl, tetradecdienyl and octadecdienyl.
  • Cs-Cs-cycloalkyl preferably represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • C ⁇ -Cio-aryl preferably represents phenyl, pentalenyl, indenyl, indanyl, isoindolinyl, chromanyl, naphthyl, fluorenyl, anthryl, phenanthryl or pyrenyl.
  • C ⁇ -Cio-aryl-d-Cg-alkyl, C 6 -Cio-aryl- Ci-C 6 -alkyl and C 6 -Cio-aryl-Ci-C4-alkyl preferably represent phenyl or naphthyl being substituted with methyl, ethyl, propyl or butyl. Particularly preferred residues are benzyl and phenethyl.
  • Ci-C 4 -alkoxy preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, and tert-butoxy.
  • Ci-C ⁇ -alkoxy preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy or hexoxy.
  • C ⁇ -Cio-aryloxy preferably represents phenoxy, naphthoxy, indenoxy, fluorenoxy or phenanthroxy.
  • the terms Co-Qo-aryl-Q-Cg-alkoxy, Ce-C w-aryl- Ci-C ⁇ -alkoxy and C 6 -Ci 0 -aryl-Ci-C 4 -alkoxy preferably represent benzoxy, phenethoxy, phenpropoxy, or phenbutoxy. Particularly preferred residues are benzoxy and phenethoxy.
  • Ci-C ⁇ -alkoxycarbonyl preferably represents methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl or butoxycarbonyl.
  • Ce-C ⁇ -aryloxycarbonyl preferably represents phenoxycarbonyl or naphthoxycarbonyl.
  • C ⁇ -Cio-aryl-Ci-Cg-alkoxycarbonyl preferably represents represents benzoxycarbonyl or phenethoxycarbonyl.
  • Ci-C ⁇ -alkylcarbonyl preferably represents methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl or butylcarbonyl.
  • C ⁇ -Cio-arylcarbonyl preferably represents phenylcarbonyl or naphthylcarbonyl.
  • C ⁇ -Cio-aryl-Ci-Cg-alkylcarbonyl preferably represents benzylcarbonyl or phenethylcarbonyl.
  • Ci-C ⁇ -alkylcarboxy preferably represents methylcarboxy, ethylcarboxy, n-propylcarboxy, isopropylcarboxy or butylcarboxy.
  • Ce-Cio-arylcarboxy preferably represents phenylcarboxy or naphthylcarboxy.
  • the term d-C ⁇ -alkylmercaptyl preferably represents methylmercaptyl, ethylmercaptyl, n-propylmercaptyl, isopropylmercaptyl or butylmercaptyl.
  • the term Ce-Cio-arylmercaptyl preferably represents phenylmercaptyl or naphthylmercaptyl.
  • Ci-Ce-alkylmercaptocarbonyl preferably represents methylmercaptocarbonyl, ethylmercaptocarbonyl, n-propylmercaptocarbonyl, isopropylmercaptocarbonyl or butylmercaptocarbonyl.
  • Cs-C ⁇ -cycloalkylmercaptocarbonyl preferably represents cyclopropylmercaptocarbonyl, cyclobutylmercaptocarbonyl, cyclopentylmercaptocarbonyl or cyclohexylmercaptocarbonyl.
  • C ⁇ -Cio-arylmercaptocarbonyl preferably represents phenylmercaptocarbonyl or naphthylmercaptocarbonyl.
  • Ci-C ⁇ -alkylmercaptocarboxy preferably represents methylmercaptocarboxy, ethylmercaptocarboxy, n-propylmercaptocarboxy, isopropylmercaptocarboxy or butylmercaptocarboxy.
  • C ⁇ -Cio-arylmercaptocarboxy preferably represents phenylmercaptocarboxy or naphthylmercaptocarboxy.
  • d-Ce-alkylsulfonyl preferably represents methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl, tert- butylsulfonyl, pentylsulfonyl or hexylsulfonyl.
  • C ⁇ -Cio-arylsulfonyl preferably represents phenylsulfonyl or naphthylsulfonyl.
  • C]-C 6 -alkylsulfoxy preferably represents methylsulfoxy, ethylsulfoxy, n-propylsulfoxy, n-butylsulfoxy, sec-butylsulfoxy or tert- butylsulfoxy.
  • C 6 -Cio-arylsulfoxy preferably represents phenylsulfoxy or naphthylsulfoxy.
  • substituents are optionally substituted once or several times by Ci-C ⁇ -alkyl, d-C ⁇ -alkoxy, C 6 -C 10 -aryloxy, CO 2 H, CONH 2 , SO 2 NH 2 , SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 .
  • Ci-C ⁇ -alkyl, Ci-C ⁇ -alkoxy, and C ⁇ -Cio-aryloxy preferably represent the same residues as mentioned above.
  • the term “optionally substituted once or several times by” is meant to include no substitution, single substitution or multiple substitution with one or more of the mentioned optional substituents. In case of a multiple substitution, the substituents can be selected independently from each other.
  • amino substituted one or more times with residues selected from Ci-C 6 -alkyl, C 6 -C 10 -aryl, C 6 -Ci 0 -aryl-Ci-C 4 -alkyl, C 6 -Cio-aryl-Ci-C 6 -alkyl, Ce-Cio-aryl-Ci-Cs-alkyl jCi-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and C ⁇ -Cio-arylsulfonyl is preferably represented by an amino group that is once or twice and independently from each other substituted by methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl or hexyl in case of Ci-C 6 -alkyl; by
  • CONH 2 or SO2NH 2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl, C ⁇ -Cio-aryl-Ci-Gi-alkyl or C ⁇ -Cio-aryl-Ci-C ⁇ -alkyl and wherein in case of a di-Ci-C ⁇ -alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings is preferably represented by the respective residues derivable from N,N-dimethylamide, N-methylamide, N-ethylamide, N-phenylamide,
  • N,N-dimethylsulfonamide, N-methylsulfonamide, N-ethylsulfonamide, and N-phenylsulfonamide are also a preferred alternative that both residues are combined to form 5 or 6-membered rings.
  • amino functionalities include but are not limited to pyrrolidin and piperidine.
  • C 6 -Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF 3 or OCF 3 " is preferably represented by a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms containing one to four heteroatoms selected from N, O or S.
  • Examples of such preferred saturated, unsaturated or aromatic heterocycles of up to 10 atoms include but are not limited to benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, carbazole, cinnoline, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, imidazoline, imidazolidine, indole, indoline, indolizine, indazole, isoindole, isoquinoline, isoxazole, isothiazole, morpholine, napthyridine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, phenazine, phenothiazine, phenoxazine, phthalazine, pipe
  • heterocycles may be substituted once or several times by d-C 6 -alkyl, Ci-C 6 -alkoxy, COOH, SO 3 H, CONH 2 , SO 2 NHa. CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C 6 -Cio-aryl or C 6 -Cio-aryl-Ci-C 4 -alkyl and wherein in case of a di-Ci-C ⁇ -alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino, amino substituted one or more times with residues selected from Ci-C 6 -alkyl, C ⁇ -Cio-aryl, Ci-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and C ⁇ -Cio-ary
  • the most preferred saturated, unsaturated or aromatic heterocyclic ring systems of up to 10 atoms comprise 2-pyridine, 3-pyridine and 4-pyridine, all three optionally substituted with one or more residues selected from methyl, amino, fluoro, chloro or CF 3 ; and N-linked pyrrole, optionally substituted with one or more residues selected from methyl, amino, fluoro, chloro or CF 3 .
  • R 1 to R 5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring sytsems.
  • ring systems include but are not limited to benzimidazole, benzofuran, benzothiophene, benzoxazole, and benzothiazole.
  • R 1 to R 5 independently from each other represent hydrogen; hydroxyl; Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl, Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, C 6 -Cio-aryl-Ci-C 6 -alkoxy,
  • Ci-C 6 -alkylcarboxy C ⁇ -Cio-arylcarboxy, Ci-C 6 -alkylsulfonyl, C 6 -Ci 0 -arylsulfonyl, wherein each is optionally substituted once or several times by Ci-C ⁇ -alkyl, Q-C ⁇ -alkoxy, amino, CrC ⁇ -alkylamino, di-Ci-C ⁇ -alkylamino, hydroxy, fluoro, chloro, bromo, cyano,
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with d-C ⁇ -alkyl, fluoro or chloro;
  • R 1 to R 5 represent hydrogen, fluorine or chlorine. It is more preferred that either R 1 or R 5 represents hydrogen or fluorine. It is most preferred that either R 1 or R 5 represents fluorine.
  • R 1 to R 5 represent hydroxy; Ci-C ⁇ -alkoxy, Co-Cio-aryloxy, C 6 -Cio-aryl-Ci-C 6 -alkoxy, Ci-C ⁇ -alkylcarboxy, C ⁇ -Cio-arylcarboxy, Ci-Ce-alkylsulfonyl, C ⁇ -Cio-arylsulfonyl, each of which is optionally substituted once or several times by Ci-C ⁇ -alkyl, Ci-C ⁇ -alkoxy, amino, C 1 -C h alky lamino, di-Ci-C 4 -alkylamino, CONH 2 or SO 2 NH 2 optionally substituted once or twice with Ci-C ⁇ -alkyl or C ⁇ -Cio-aryl, hydroxy, fluoro, chloro, bromo, cyano, CF 3 or OCF 3 .
  • one of R 2 , R 3 or R 4 represents hydroxy; d-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, C ⁇ -Cio-aryl-d-C ⁇ -alkoxy, each of which is optionally substituted once or several times by Ci-C 4 -alkyl, Ci-C 4 -alkoxy, amino, Ci-C 4 -alkylamino, di- Ci-C4-alkylamino, CONH 2 or SO 2 NH 2 optionally substituted once or twice with d-C ⁇ -alkyl or C ⁇ -Cio-aryl, hydroxy, fluoro, chloro, or bromo.
  • one or more of R 1 to R 5 represent amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, Cg-Ci o-aryl; or a disubstituted amino of the following formula (II)
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C 4 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro.
  • one of R 2 , R 3 or R 4 represents amino; amino substituted once or twice with residues selected from d-Ce-alkyl, C 6 -Cio-aryl; or a disubstituted amino of the following formula (II)
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-Gj-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro.
  • Ci-C ⁇ -alkyl C 6 -Cio-aryl, C 6 -Cio-aryl-Ci-C 4 -alkyl, C r C 6 -alkoxy, C 6 -C 10 -aryloxy, C ⁇ -Cio-aryl-Ci-G t -alkoxy, wherein each is optionally substituted once or several times by;
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-G t -alkyl, fluoro or chloro;
  • n O
  • m O or 1
  • Y represents a phenyl, 1-naphthyl, 2-naphthyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl ring system.
  • Y is substituted once or several times by Ci-C 4 -alkyl; phenyl; Ci-C 4 -alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; CONH 2 or SO 2 NH 2 , optionally substituted once or twice with Ci-C4-alkyl, wherein these optional Ci-C 4 -alkyl residues may be combined to form 5 or 6-membered rings; or amino.
  • m represents O and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo. It is most preferred in this aspect that m represents O and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
  • Y represents C6-Cio-aryl, preferably phenyl; benzyl, phenethyl, phenpropyl, phenbutyl or phenhexyl, which is optionally substituted once or several times by
  • Ci-Ce-alkyl C 3 -C 8 -cycloalkyl, C 6 -Ci 0 -aryl, C ⁇ -Qo-aryl-Ci-Cg-alkyl, C r C 6 -alkoxy, C ⁇ -Cio-aryloxy, C ⁇ -Cio-aryl-Ci-C ⁇ -alkoxy, hydroxyl, CO 2 H, Ci-C ⁇ -alkoxycarbonyl,
  • Ci-C6-alkyl each of which is optionally substituted once or several times by Ci-C6-alkyl, Ci-C ⁇ -alkoxy, COOH; CONH 2 , optionally substituted once or twice with Ci-C ⁇ -alkyl; SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo,
  • Ci-C 6 -alkyl a saturated, unsaturated or aromatic heterocycle optionally substituted once or several times by Ci-C 6 -alkyl, Ci-C 6 -alkoxy, COOH; CONH 2 , optionally substituted once or twice with CpC ⁇ -alkyl; SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 ;
  • Ce-Cio-arylcarbonyl Ci-C 6 -alkylsulfonyl and C 6 -Cio-arylsulfonyl; CONH 2 , SO 2 NH 2 ,
  • R 1 to R 5 independently from each other represent hydrogen, hydroxyl, Ci-C 4 -alkyl, C 6 -Ci 0 -aryl, C r C 4 -alkoxy, C 6 -Cio-aryloxy, C 6 -C 10 -aryl-
  • Ce-C 10 -arylmercaptyl Ci-C ⁇ -alkylsulfonyl, C ⁇ -Cio-arylsulfonyl, Ci-C ⁇ -alkylsulfoxy,
  • R 1 to R 5 are selected from hydroxyl, methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF 3 , OCF 3 , pyridine, CONH 2 , SO 2 NH 2 , tetrazole or triazole.
  • any one of R 1 to R 5 is phenyl further substituted once or several times by hydroxyl, Ci-C 6 -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 .
  • Y represents phenyl or benzyl which is substituted in ortho-, meta- and/or para-positions by Ci-C ⁇ -alkoxy, C 6 -Ci 0 -aryloxy, hydroxyl, nitro, amino, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 .
  • Y represents phenyl which is substituted once, twice or three times in ortho- and/or para-positions with substituents independently selected from methoxy, ethoxy, tert-butoxy, phenoxy, hydroxy, nitro, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 .
  • R 1 to R 5 are selected from methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF 3 , OCF 3 , pyridine, CONH 2 , SO 2 NH 2 , tetrazole, triazole or phenyl further substituted once or several times by Ci-C 6 -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 , and Y represents phenyl which is substituted in ortho- and/or para-positions by Cj-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, hydroxyl, nitro, CONH 2
  • the present invention relates to a compound of formula (I),
  • R 1 to R 5 independently from each other represent: hydrogen; Ci-C 6 -alkyI, C 3 -C 8 -cycloalkyl, C 6 -Ci 0 -aryl, C 6 -Cio-aryl-Ci-C 8 -alkyl, Ci-C 6 -alkoxy, C 6 -Cio-aryloxy, C ⁇ -Cio-aryl-Ci-C ⁇ -alkoxy, Ci-C ⁇ -alkoxycarbonyl, Ce-Cio-aryloxycarbonyl, C ⁇ -Cio-aryl-Ci-C ⁇ -alkoxycarbonyl, Ci-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, C ⁇ -Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-C 6 -alkylcarboxy, C ⁇ -Cio-arylcarboxy, Ci-Ce-alkylmercaptyl, Ce-Cio
  • Ci-Gj-alkyl Ci-C ⁇ -alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and C ⁇ -Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF 3 ;
  • o represents O or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro; CONH 2 ; SO 2 NH 2 ;
  • Ci-C 6 -alkyl or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C 6 -alkyl; C,-C 6 -alkoxy; COOH; SO 3 H; CONH 2; SO 2 NH 2 ; CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C 6 -Cio-aryl or C ⁇ -Cio-aryl-Ci-G t -alkyl and wherein in case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl, C ⁇ -Cio-aryl-Ci-C-i-alkyl,
  • Ci-C ⁇ -alkylcarbonyl C ⁇ -Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and
  • Y represents phenyl which is optionally substituted once or several times by
  • Ci-Ce-alkyl C 6 -Ci 0 -aryl, Ce-Cio-aryl-Ci-Cg-alkyl, C r C 6 -alkoxy, C 6 -C 10 -aryloxy, C ⁇ -Cio-aryl-d-Cg-alkoxy, Ci-C ⁇ -alkoxycarbonyl, C ⁇ -Cio-aryloxycarbonyl, C ⁇ -Cio-aryl- CpCe-alkoxycarbonyl, Ci-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, C ⁇ -Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-C ⁇ -alkylcarboxy, Co-Cw-arylcarboxy, Ci-C ⁇ -alkyhnercaptyl, C ⁇ -Cio-arylmercaptyl, Ci-C ⁇ -alkylmercaptocarbonyl, C 3
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and CrC 4 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro;
  • R 1 to R 5 independently from each other do not represent hydrogen, fluoro, bromo, chloro, iodo or an alkyl radical when Y represents unsubstituted phenyl; that
  • R 2 or R 4 do not represent a pyrazol-3-yl-derivative
  • R 1 to R 5 independently from each other represent hydrogen; hydroxyl;
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Cj-C 6 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with C ⁇ -C 6 -alkyl, fluoro or chloro; CONH 2 ;
  • R 1 to R 5 represent hydrogen, fluorine or chlorine. It is most preferred that either R 1 or R 5 represents hydrogen or fluorine.
  • R 1 to R 5 represent hydroxy
  • one of R 2 , R 3 or R 4 represents hydroxy; or Ci-C ⁇ -alkoxy, Co-Cio-aryloxy, or C ⁇ -Cio-aryl-CrC ⁇ -alkoxy, each of which is optionally substituted once or several times by Ci-C ⁇ -alkyl, Ci-C 6 -alkoxy, amino, Ci-Ce-alkylamino, di-Ci-C ⁇ -a ⁇ cylamino, CONH 2 or SO 2 NH 2 optionally substituted once or twice with Ci-C 6 -alkyl or C ⁇ -Cio-aryl, hydroxy, fluoro, chloro, or bromo.
  • one or more of R 1 to R 5 represent amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl; or a disubstituted amino of the following formula (II)
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C-j-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro.
  • one of R 2 , R 3 or R 4 represents amino; amino substituted once or twice with residues selected from Cj-C ⁇ -alkyl, C ⁇ -Cio-aryl; or a disubstituted amino of the following formula (II)
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C 4 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro.
  • Ci-C 6 -alkyl C 6 -C ⁇ 0 -aryl, C 6 -Cio-aryl-Ci-C 6 -alkyl, Ci-C ⁇ -alkoxy, C 6 -Cio-aryloxy,
  • Ci-C ⁇ -alkyl Ci-C ⁇ -alkoxy
  • SO 3 H Ci-C ⁇ -alkoxy
  • CO 2 H amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cto-aryl, C ⁇ -Cio-aryl- d-C ⁇ -alkyl, Ci-C ⁇ -alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and C ⁇ -Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3;
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and d-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with C]-C 6 -alkyl, fluoro or chloro; or by c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by d-C 6 -alkyl; d-C 6 -alkoxy; COOH; CONH 2 ; SO 2 NH 2 ; CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted once or twice with Ci-C 6 -alkyl which may be combined to form 5 or 6-membered rings; SO 3 H; amino; amino substituted one or more times with residues selected from
  • Y represents phenyl which is substituted once or several times by d-C 6 -alkyl; phenyl; d-C 6 -alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; amino; or CONH 2 or SO 2 NH 2 optionally substituted once or twice with Cj-C 6 -alkyl wherein these optional Ci-C 6 -alkyl residues may be combined to form 5 or 6-membered rings.
  • m represents O and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo. It is most preferred that m represents O and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
  • m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that any one of R 2 to R 4 represents OR 7 wherein R 7 is selected from hydrogen and Ci-C 4 -alkyl; and that R 1 represents fluorine.
  • m is O; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; that R 3 or R 3 and R 4 represent hydroxyl; and that R 1 represents fluorine.
  • R 1 to R 5 are selected from hydroxyl, methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF 3 , OCF 3 , pyridine, CONH 2 , SO 2 NH 2 , tetrazole or triazole.
  • R 1 to R 5 is a saturated, unsaturated or aromatic heterocycle optionally substituted once or several times by Ci-C ⁇ -alkyl, Q-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF 3 or phenyl further substituted once or several times by Ci-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF3.
  • R 1 to R 5 is CONH 2 ; SO 2 NH 2 ; or CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl or C 6 -Cio-aryl-Ci-C 4 -alkyl.
  • Y represents phenyl which is substituted in ortho- and/or para-positions by CpC ⁇ -alkoxy, C ⁇ -Cio-aryloxy, hydroxyl, nitro, amino, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 .
  • Y represents phenyl which is substituted once, twice or three times in ortho- and/or para-positions with substituents independently selected from methoxy, ethoxy, tert-butoxy, phenoxy, hydroxyl, nitro, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 . It is also preferred that Y represents phenyl which is substituted in ortho- and/or para- positions by Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, hydroxyl, nitro, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 .
  • R 1 to R 5 are selected from methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF 3 , OCF 3 , pyridine, CONH 2 , SO 2 NH 2 , tetrazole, triazole or phenyl further substituted once or several times by Ci-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 , and Y represents phenyl which is substituted in ortho- and/or para-positions by CrC ⁇ -alkoxy, C 6 -Cio-aryloxy, hydroxyl, nitro, CONH 2 , SO 2 NH 2 , fluoro, chloro or
  • the present invention relates to a compound of formula
  • R 1 to R 5 independently from each other represent: hydrogen
  • o represents O or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro; CONH 2 ; SO 2 NH 2 ; CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted once or twice with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl or C ⁇ -Cio-aryl-Cj-C ⁇ -alkyl and wherein in the case of a di-CrCo-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
  • Y represents phenyl which is optionally substituted once or several times by a) Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl, C ⁇ -Cio-aryl-Ci-Cs-alkyl, Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, C 6 -Cio-aryl-Ci-C 8 -alkoxy, d-C ⁇ -alkoxycarbonyl, C ⁇ -do-aryloxycarbonyl, C ⁇ -Cio-aryl- d-Cg-alkoxycarbonyl, Ci-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, C ⁇ -Cio-aryl- d-Cg-alkylcarbonyl, d-C ⁇ s-alkylcarboxy, C ⁇ -Cio-arylcarboxy, Ci-Co-alkylmercapt
  • Ci-C 6 -alkyl a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C 6 -alkyl; Ci-C ⁇ -alkoxy; COOH; CONH 2 or S ⁇ 2NH 2 , optionally substituted once or twice with Ci-C ⁇ -alkyl; SO 3 H; amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C 6 -Ci O -aryl, C6-C 10 -aryl-Ci-C4-alkyl, Ci-C ⁇ -alkylcarbonyl, Co-Cio-arylcarbonyl, Ci-C 6 -aIkylsulfonyI and C ⁇ -Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF 3 or OCF 3 ; or
  • o represents O or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and C ⁇ -C4-alkyl and wherein the methylene groups in formula (FV) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro; with the proviso that Y does not represent unsubstituted phenyl if R 1 , R 2 and R 5 represent hydrogen, R 4 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, benzyloxy, phenoxy, phenyl, 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl and R 3 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, phenoxy, 4-chlorophenoxy, cyclohexyl, phenyl, morpholinosulfonyl
  • Y represents phenyl which is substituted once or several times by Ci-C ⁇ -alkyl; phenyl; Cj-C ⁇ -alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; amino; or CONH 2 or SO 2 NH 2 optionally substituted once or twice with Ci-C6-alkyl wherein these optional Ci-C ⁇ -alkyl residues may be combined to form 5 or 6-membered rings.
  • m represents 0 and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo.
  • m represents 0 and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
  • R 1 to R 5 are selected from methyl, tert- butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF 3 , OCF 3 , pyridine; CONH 2 , SO 2 NH 2 , wherein the amino functionality is substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C 6 -Cio-aryl or C 6 -Cio-aryl-Ci-C 4 -alkyl; tetrazole or triazole.
  • any one of R 1 to R 5 is phenyl further substituted once or several times by Ci-C 6 -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 .
  • Y represents phenyl which is substituted in ortho- and/or para-positions by Ci-C 6 -alkoxy, C ⁇ -Cio-aryloxy, hydroxyl, nitro, amino, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 .
  • Y represents phenyl which is substituted once, twice or three times in ortho- and/or para-positions with substituents independently selected from methoxy, ethoxy, tert-butoxy, phenoxy, hydroxyl, nitro, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 .
  • Y represents phenyl which is substituted in ortho- and/or para-positions by Ci-C ⁇ -alkoxy, C 6 -Ci 0 -aryloxy, hydroxyl, nitro, CONH 2 , SO 2 NH 2 , fluoro, chloro or OCF 3 .
  • R 1 to R 5 are selected from methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF 3 , OCF 3 , pyridine, CONH2, SO 2 NH 2 , tetrazole, triazole or phenyl further substituted once or several times by Ci-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 , and Y represents phenyl which is substituted in ortho- and/or para-positions by Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, hydroxyl, nitro, CONH 2 , SO 2 NH 2 , fluoro, chloro
  • the present invention relates to a compound of formula (I),
  • any one of R 2 to R 4 represents hydroxy, and remaining R residues are hydrogen; Ci-C 6 -alkyl, C 3 -C 8 -cycloalkyl, C 6 -C 10 -aryl, Ce-Cio-aryl-d-Cg-alkyl, Ci-C 6 -alkoxy, C ⁇ -Cio-aryloxy, C ⁇ -Cio-aryl-Ci-Cg-alkoxy, C
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro; CONH 2 ; SO 2 NH 2 ; CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C 6 -alkyl, C 6 -Cio-aryl or C ⁇ -Cio-aryl-Ci-C ⁇ -alkyl and wherein in the case of a di-Ci-C ⁇ -alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or io
  • CF 3 ; OCF 3 ; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C ⁇ -alkyl, Ci-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF 3 ; and wherein two or more of R 2 to R 4 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
  • n and m are 0;
  • Y is phenyl substituted once or several times by Ci-C 6 -alkyl; phenyl; d-C ⁇ -alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; amino; or CONH 2 optionally substituted once or twice with Ci-C ⁇ -alkyl wherein these optional Ci-C ⁇ -alkyl residues may be combined to form 5 or 6-membered rings; or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
  • the present invention relates to a compound of formula (I),
  • any one of R 2 to R 4 represents amino and remaining R residues are hydrogen; Ci-C 6 -alkyl, C 3 -C 8 -cycloalkyl, C 6 -C ⁇ 0 -aryl, C 6 -Cio-aryl-Ci-C 8 -alkyl, Ci-C 6 -alkoxy, C ⁇ -Cio-aryloxy, C ⁇ -Cio-aryl-Ci-C ⁇ -alkoxy, Ci-C ⁇ -alkoxycarbonyl, C ⁇ -Cio-aryloxycarbonyl, C ⁇ -Cio-aryl-Ci-Cg-alkoxycarbonyl, Ci-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, C 6 -Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-C ⁇ -alkylcarboxy, C ⁇ -Cio-arylcarboxy, Ci-
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro; CONH 2 ; SO 2 NH 2 ; CONH 2 or SO 2 NH 2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C 6 -alkyl, C 6 -Ci 0 -aryl or C 6 -C 10 -aryl-Ci-C 6 -alkyl and wherein in the case of a di-Ci-C ⁇ -alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxy 1; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo
  • CF 3 ; OCF 3 ; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C ⁇ -alkyl, d-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 ; and wherein any two or more of R 2 to R 4 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
  • n and m are 0;
  • Y is phenyl substituted once or several times by Ci-C ⁇ -alkyl; phenyl; d-C ⁇ -alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; amino; or CONH 2 optionally substituted once or twice with Ci-C 6 -alkyl wherein these optional d-C 6 -alkyl residues may be combined to form 5 or 6-membered rings, or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
  • the present invention relates to a compound of formula (I),
  • R 3 or R 4 is Ci-C ⁇ -alkoxy, C 6 -Cio-aryloxy, C 6 -C t o-aryl-Ci-C8-alkoxy, Ci-C ⁇ -alkylcarboxy, C ⁇ -C t o-arylcarboxy, Ci-C 6 -alkylmercaptocarboxy, Q-Cio-arylmercaptocarboxy, Cj-C 6 -alkylsulfoxy, C ⁇ -Cjo-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-C ⁇ -alkyl, Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, CO 2 H, SO 3 H, amino, Ci-C ⁇ -alkylamino, di-Ci-C ⁇ -alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo
  • R 3 or R 4 is amino substituted one or more times with residues selected from Ci-C 6 -aIkyl, C 6 -Ci 0 -aryl, C 6 -Cio-aryl-CrC 6 -alkyl, d-C ⁇ -alkylcarbonyl,
  • R 2 is: hydrogen
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Cj-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro;
  • OCF 3 or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C ⁇ -alkyl, Cj-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 ;
  • n and m are 0;
  • Y is phenyl substituted once or several times by Ci-C ⁇ -alkyl; phenyl; Ci-C ⁇ -alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; amino; or CONH 2 optionally substituted once or twice with Ci-C ⁇ -alkyl wherein these optional Cj-Ce-alkyl residues may be combined to form 5 or 6-membered rings, or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
  • Y is phenyl substituted once or several times by Ci-C ⁇ -alkyl; phenyl; Ci-C ⁇ -alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; amino; or CONH 2 optionally substituted once or twice with Q-Q-alkyl, wherein these optional Ci-C ⁇ -alkyl residues may be combined to form 5 or 6- membered rings.
  • Y is phenyl substituted once or twice by hydroxy, fluoro, chloro or bromo.
  • Y is phenyl substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
  • R 1 to R 5 independently from each other do not represent hydrogen, fluoro, bromo, chloro, iodo or an alkyl radical when Y represents unsubstituted phenyl
  • R 2 or R 4 do not represent a pyrazol-3-yl-derivative
  • the phenyl ring substituted with R 1 to R 5 and Y do not represent the following combinations:
  • Y does not represent unsubstituted phenyl if R 1 , R 2 and R s represent hydrogen, R 4 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, benzyloxy, phenoxy, phenyl, 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl and R 3 represents hydrogen, trifluoromethoxy, trifluorobutoxy,
  • Y does not represent unsubstituted phenyl.
  • R 1 or R 5 does not represent a substituent selected from halogen, in particular F, Cl, NO 2 , CHj, OCH 3 or CF 3 or CN, when at least one of the remainder of the substituents R 1 to R 5 represents a substituent selected from halogen, in particular F, Cl, Br, CH 3 , OCH 3 , NO 2 , CN and when the phenyl ring representing Y is substituted with F, Cl, Br, CH 3 , OCH 3 , NO 2 or CN.
  • Y does not represent phenyl which is substituted by phenoxy or C ⁇ -Cu-alkyl.
  • Y does not represent unsubstituted phenyl.
  • Y does not represent phenyl or lower alkyl radical when R 1 to R 5 represent a hydrogen or halogen atom or a methyl radical.
  • all of these compounds can be substituted once or several times by C 1 -C 9 alkyl, C 1 -C 9 alkyloxy, halogen, and trifluoromethyl in case of aryl; and by C 1 -C 4 alkyl or C ⁇ -Cio aryl in case of cycloalkyl; and by hydroxyl, di-Ci-C 4 alkylamino and fiuoro in case of alkyl.
  • Y does not represent phenyl substituted by alkyl having 1 to 4 carbon atoms; alkoxy having 1 to 4 carbon atoms; alkylthio having 1 to 4 carbon atoms; halogenoalkyl having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; halogenoalkoxy having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; or halogenoalkylthio having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; alkylenedioxy having 1 or 2 carbon atoms; halogensubstituted alkylenedioxy having 1 or 2 carbon atoms and 1 to 4 halogen atoms, the halogen atoms being identical or different
  • R 1 or R 5 does not represent a substituent selected from halogen, in particular F, CI, NO 2 , CH 3 , OCH 3 or CF 3 or CN, when at least one of the remainder of the substituents R 1 to R 5 represents a substituent selected from halogen, in particular F, Cl, Br, CH 3 , OCH 3 , NO 2 , CN and when the phenyl ring representing Y is substituted with F, Cl, Br, CH 3 , OCH 3 , NO 2 or CN.
  • Y does not represent Cj-C ⁇ -alkyl or C 3 -C ⁇ >-cycloalkyl, optionally substituted once or several times by phenyl which in turn may be substituted once or several times by halogen, Ci-C 4 -alkyl, Ci-C 4 -alkyloxy, nitro, CF 3 ; or by O-d-C ⁇ alkyl, S-Ci-C 4 -alkyl, N(C,-C 4 -alkyl) 2 .
  • Y does not represent Ci-C ⁇ -alkyl or C 3 -C 9 -cycloalkyl, optionally substituted once or several times by phenyl which in turn may be substituted once or several times by halogen, d-C 4 -alkyl, Ci-C 4 -alkyloxy, nitro, CF 3 ; or by O-C,-C 4 -alkyl, S-C,-C 4 -alkyl, N(Ci-C 4 -alkyl) 2 .
  • the present invention also relates to the use of a pharmacophore of the following structure (III),
  • FAAH fatty acid amide hydrolase
  • the present invention also relates to compounds comprising a pharmacophore of the following structure (III),
  • FAAH fatty acid amide hydrolase
  • pharmacophore is to be understood as a molecular sub-unit, or substructure or part of the molecule which is essential for the interaction with the FAAH enzyme. It is to be understood that the pharmacophore of formula (III) may be further substituted.
  • the present invention also relates to a process for the preparation of a compound according to any one of claims 1 to 17, and 24 to 79 wherein a compound of formula (IV), Y
  • R 1 to R 5 independently from each other represent: hydrogen
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C 6 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Cj-C ⁇ -alkyl, fluoro or chloro; CONH 2 ;
  • OCF 3 or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C ⁇ -alkyl, Ci-C ⁇ -alkoxy, COOH, SO 3 H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF 3 or OCF 3 ; and wherein any two or more of R 1 to R 5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
  • n 0, 1, 2, 3, 4, 5 or 6;
  • Y represents: a) hydrogen; b) Ci-Ci ⁇ -alkyl, mono or polyunsaturated C 2 -Cig-alkylene, Cs-C ⁇ -cycloalkyl, C ⁇ -Cio-aryl, C 6 -Cio-aryl-Ci-C 8 -alkyl, Ci-C 6 -alkoxy, C 6 -Ci 0 -aryloxy, C ⁇ -Cio-aryl-Ci-Cg-alkoxy, C 1 -C ⁇ -alkoxycarbonyl, C ⁇ -C 10 -aryloxycarbonyl, C ⁇ -C 1 o-aryl-C 1 -Cg-alkoxycarbonyl, Ci-C ⁇ -alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, CO-CJ o-aryl-Ci-Cg-alkylcarbonyl,
  • Ci-C ⁇ -alkylcarbonyl C ⁇ -Cio-arylcarbonyl, Ci-C 6 -alkylsulfonyl and
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Cj-C ⁇ -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C ⁇ -alkyl, fluoro or chloro; or by b3) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C ⁇ -alkyl; Cj-C ⁇ -alkoxy; COOH;
  • Ci-Ce-alkylcarbonyl C ⁇ -Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and
  • the cyclisation step to the oxadiazolone ring system is achieved by phosgene, carbonyldiimidazole, or a carbonic acid ester.
  • Suitable carbonic acid esters are in particular the Cj -Chalky 1 carbonic acid esters.
  • R 1 to R 5 independently from each other represent hydrogen; hydroxyl; Ci-C 6 -alkyl, C 6 -Cio-aryl, Ci-C 6 -alkoxy, C 6 -Cio-aryloxy, C6-Cio-aryl-Ci-C 6 -alkoxy, C
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci -C h alky I, fluoro or chloro; CONH 2 ; SO 2 NH 2 ; CONH 2 or SO 2 NH 2 wherein the amino functionality is optionally substituted one or more times with residues selected from Ci-C ⁇ -alkyl or C ⁇ -Cio-aryl; fluoro; chloro; bromo; CF 3 ; or OCF 3 .
  • R 1 to R 5 represent fluorine or chlorine. It is most preferred that either R 1 or R 5 represents fluorine.
  • R 1 to R 5 represent hydroxy; Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, Ce-Cio-aryl-Ci-C ⁇ -alkoxy, Ci-C ⁇ -alkylcarboxy, C ⁇ -Cio-arylcarboxy, Ci-C ⁇ -alkylsulfonyl, C ⁇ -Cio-arylsulfonyl, each of which is optionally substituted once or several times by Ci-C ⁇ -alkyl, Ci-C ⁇ -alkoxy, CONH 2 or SO 2 NH 2 optionally substituted once or twice with Ci-C 6 -alkyl or C 6 -Cio-aryl; amino, Ci-C 4 -alkylamino, di-C 1 -C 4 -alkylam.no, hydroxy, fluoro, chloro, bromo, CF 3 or OCF 3 .
  • one of R 2 , R 3 or R 4 represents hydroxy; Ci-C ⁇ -alkoxy, C ⁇ -Cio-aryloxy, C ⁇ -Cio-aryl-Ci-C ⁇ -alkoxy, each of which is optionally substituted once or several times by Ci-C4-alkyl, Ci-C 4 -alkoxy, CONH 2 or SO2NH2 optionally substituted once or twice with Ci-C ⁇ -alkyl or C ⁇ -Cio-aryl; amino, Ci-C 4 -alkylamino, di- Ci-C 4 -alkylamino, hydroxy, fluoro, chloro, or bromo.
  • R 1 to R 5 represent amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl; or a disubstituted amino of the following formula (II)
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and d-C 4 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro.
  • one of R 2 , R 3 or R 4 represents amino; amino substituted once or twice with residues selected from Ci-C ⁇ -alkyl, C ⁇ -Cio-aryl; or a disubstituted amino of the following formula (II)
  • o represents 0 or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro.
  • Ci-C ⁇ -alkyl C 6 -Ci 0 -aryl, C 6 -C 10 -aryl-Ci-C4-alkyl, Ci-C ⁇ -alkoxy, C ⁇ -Cw-aryloxy, C 6 -C 1 o-aryl-C 1 -C 4 -alkoxy , each of which is optionally substituted once or several times by Ci-C ⁇ -alkyl; Ci-C 6 -alkoxy; CONH 2 or SOaNH 2 , optionally substituted once or twice with Ci-C ⁇ -alkyl; SO3H; CO 2 H; amino; amino substituted one or more times with residues selected from Ci-C ⁇ -alkyl, C 6 -Cio-aryl, C6-Ci O -aryl-C 1 -C4-alkyl, Ci-C ⁇ -alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfon
  • Ci-C ⁇ -alkyl residues may be combined to form 5 or 6- membered rings; amino; amino substituted once or several times with Ci-C ⁇ -alkyl or phenyl; a disubstituted amino of the following formula (II)
  • o represents O or 1 and W represents O, CH 2 , or NR 6 with R 6 being selected from hydrogen and Ci-C 4 -alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C 4 -alkyl, fluoro or chloro;
  • Ci-C ⁇ -alkyl a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C ⁇ -alkyl; d-C ⁇ -alkoxy; COOH; CONH 2 or SO 2 NH 2 , optionally substituted once or twice with Ci-C ⁇ -alkyl, wherein these optional Ci-C ⁇ -alkyl residues may be combined to form 5 or 6-membered rings; SO 3 H; amino; amino substituted one or more times with residues selected from Ci-C 6 -alkyl, C 6 -Cio-aryl, Ci-Ce-alkylcarbonyl, C ⁇ -Cio-arylcarbonyl, Ci-C ⁇ -alkylsulfonyl and C ⁇ -C t o-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF 3
  • Y is substituted once or several times by Ci-C-j-alkyl; phenyl; Ci-C4-alkoxy; hydroxy; fluoro; chloro; bromo; CF 3 ; OCF 3 ; CONH 2 or SO 2 NH 2 , optionally substituted once or twice with Ci-C 4 -alkyl, wherein these optional Ci-C 4 -alkyl residues may be combined to form 5 or 6-membered rings; or amino.
  • m represents 0 and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo.
  • m represents 0 and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
  • the reaction mixture was stirred at -5 0 C for 1 h and then allowed to warm to room temperature.
  • the beige suspension was filtered, the filter cake was dissolved in water and the resulting solution was made basic by the addition of 3 N aqueous sodium hydroxide solution.
  • the mixture was then extracted with dichloromethane and the combined extracts washed with water and brine, then dried (MgSO 4 ), filtered and evaporated.
  • the resulting dark red-brown solid was was crystallized from diethyl ether/petroleum ether to afford (2-fluoro-4- methoxyphenyl)hydrazine as a dark pink solid (1.24 g, 53 %).
  • Table 1 shows further compounds that were prepared in a similar manner. For solid materials, the melting point is given. For oils, the NMR data is given in Table 2. Table 1
  • Frozen brains (without cerebellum) from Wistar rats were used, and each brain was homogenized in 15 mL 1 mM MgCl 2 , 2OnM HEPES pH 7.0 with Potter Elvejhem (8 strokes at 500 rpm). Homogenates were centrifuged for 20 min at 3600Og at 4°C (Beckman, 70Ti rotor). Pellets were resuspended in 15 mL of the same buffer and centrifuged under the same conditions. Pellets were resuspended in 15 mL of the same buffer and incubated for 15 min at 37 0 C after which they were centrifuged for 20 min at 3600Og at 4 0 C.
  • the FAAH activity was determined using AEA (labelled with 3 H in the ethanolamine part of the molecule) as substrate and measuring the 3 H-ethanolamine formed.
  • Reaction mix (total volume of 200 ⁇ l) contained: 2 ⁇ M AEA (2 ⁇ M AEA + 5 nM 3 H-AEA), 0.1 % fatty acid free BSA, 5 ⁇ g protein, in 1 mM EDTA, 10 mM Tris pH 7.6 and 10 ⁇ M or 100 mM compounds.
  • Stock solutions of the compounds to test (1OmM) were prepared in 100 % DMSO and the DMSO concentration in the assay was 0.1 %.
  • mice Male NMRI mice (weighing 27-44 g) obtained from Interfauna Iberica (Spain). Mice were kept 5 per cage, under controlled environmental conditions (12 hr light/dark cycle and room temperature 22 ⁇ 1°C). Food and tap water were allowed ad libitum and the experiments were all carried out during daylight hours.
  • Anandamide [ethanolamine -1- 3 H-] (40-60Ci/mmol) was obtained from American Radiochemicals. All other reagents were obtained from Sigma-Aldrich. Optiphase Supermix was obtained from Perkin Elmer and activated charcoal were obtained from Sigma-Aldrich.
  • Tissues were thawed on ice and were homogenized in 10 volumes of membrane buffer (3 mM MgCl 2 , 1 mM EDTA, 50 mM Tris HCl pH 7.4) with either Potter-Elvejhem (brains - 8 strokes at 500 rpm) or Heidolph Diax (livers - 2 strokes at position 5 for 20 sec with 30 sec pauses).
  • membrane buffer 3 mM MgCl 2 , 1 mM EDTA, 50 mM Tris HCl pH 7.4
  • Reaction mix (total volume of 200 ⁇ l) contained: 2 ⁇ M AEA (2 ⁇ M AEA + 5 nM 3 H- AEA), 0.1 % fatty acid free BSA, 15 ⁇ g (brain), 5 ⁇ g (liver) or 50 ⁇ g (lung) protein, in 1 mM EDTA, 10 mM Tris pH 7.6. After a 15 min pre-incubation period at 37°C, reaction was started by the addition of the substrate solution (cold AEA + radiolabeled AEA + BSA).
  • the percentage of remaining enzymatic activity was calculated with respect to controls (no compound) and after blank subtraction.
  • the compounds of the invention all of which are characterized by a 5-0-substituted 3-N-phenyl-l,3,4-oxadiazolone structural unit, have unexpectedly high inhibition of FAAH, making these novel compounds promising candidates for medicaments for the treatment or prevention of FAAH-related medical conditions. Furthermore, the surprisingly high FAAH inhibition is evident not only in- vitro but also in-vivo. Furthermore, a comparison of the in-vivo data also demonstrates that the FAAH inhibitory activity of compounds having a 5-0-substituted 3-N-phenyl-l,3,4-oxadiazolone structural unit is characterized by a peripheral selectivity when compared with activity in the central nervous system (CNS).
  • CNS central nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)

Abstract

The present invention relates to compounds having a 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase). (I)

Description

5-O-SUBSTITUTED 3-N-PHENYL-13,4-OXADIAZOLONES FOR MEDICAL USE
The present invention relates to compounds having a 5-0-substituted 3-N-phenyl- 1,3,4- oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase).
FAAH is an integral membrane protein (IMP) that hydrolyzes bioactive amides, such as the endocannabinoid anandamide, which is an agonist of cannabinoid receptors and TRPVl vanilloid receptors to free fatty acid and ethanolamine, see e.g. McKinney M.K., Cravatt B.F., Ann. Rev. Biochem. 74:411 (2005).
Due to its ability to regulate anandamide levels, FAAH is currently viewed as an attractive drug target. Examples of inhibitors of FAAH include PMSF
(phenylmethylsulfonylfluoride), MAFP (methoxyarachidonylfluorophosphonate), and
ATMK (arachidonoyltrifluoromethylketone), while URB597
([3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate) is widely regarded as the current
"gold standard" FAAH inhibitor. In pre-clinical laboratory tests URB597 was found to increase the production of endocannabinoids resulting in measurable antidepressant and analgesic effects, see e.g. Russo R., et al, J Pharmacol Exp Ther. 322(l):236-42 (2007).
FAAH inhibition is considered to play an important role in a wide variety of medical consitions, see for example Pacher et al Pharmacol. Rev. 58:389-462 (2006) which is fully incorporated into the description by reference thereto.
FAAH inhibition has been implicated in the following conditions:
(i) pain, in particular acute or chronic neurogenic pain such as migraine and neuropathic pain (for example diabetic neuropathic pain, post-herpetic neuralgia, trigeminal neauralgia); acute or chronic pain associated with inflammatory diseases such as arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, and irritable bowel syndrome; acute or chronic peripheral pain; (ii) dizziness, vomiting, and nausea, in particular resulting from chemotherapy;
(iii) eating disorders, in particular anorexia and cachexia of various natures;
(iv) neurological and psychiatric pathologies such as tremors, dyskinesias, dystonias, spasticity, obsessive-compulsive behaviour, Tourette's syndrome, all forms of depression and anxiety of any nature and origin, mood disorders, and psychoses;
(v) acute and chronic neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, senile dementia, Huntington's chorea, lesions related to celebral ischaemia and to cranial and medullary trauma;
(vi) epilepsy;
(vii) sleep disorders, including sleep apnoea;
(viii) cardiovascular diseases such as heart failure, hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, cardiac ischaemia, and renal ischaemia;
(ix) cancers, for example benign skin tumours, brain tumours and papillomas, prostate tumours, and cerebral tumours (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumours of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, plexus tumour, neuroepitheliomas, epiphyseal tumour, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, and schwannomas);
(x) disorders of the immune system, in particular autoimmune diseases, such as psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, autoimmune haemolytic anaemia, multiple sclerosis, amylotrophic lateral sclerosis, amyloidosis, graft rejection, diseases affecting the plasmacytic line, allergic diseases; immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis; (xi) parasitic, viral or bacterial infectious diseases such as AIDS, and meningitis;
(xii) inflammatory diseases, in particular joint diseases such as arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome;
(xiii) osteoporosis;
(xiv) eye conditions such as ocular hypertension, and glaucoma;
(xv) pulmonary conditions including diseases of the respiratory tracts, bronchospasm, coughing, asthma, chronic bronchitis, chronic obstruction of the respiratory tract, and emphysema;
(xvi) gastrointestinal diseases such as irritable bowel syndrome, inflammatory intestinal disorders, ulcers, diarrhoea, urinary incontinence and bladder inflammation.
It was found that compounds having a 5-O-substituted 3-N-phenyl-l,3,4-oxadiazolone structural unit have unexpectedly high level of inhibition of FAAH, making these compounds promising candidates for medicaments for the treatment or prevention of FAAH-related medical conditions. Furthermore, it was confirmed that this activity was also present in in vivo tests.
Additionally in these in vivo tests, it was surprisingly found that compounds having a 5-O-substituted 3-N-phenyl-l,3,4-oxadiazolone structural unit show a FAAH inhibitory activity that is peripherally selective over activity in the CNS. Administration of these compounds is therefore expected to reduce the central nervous side effects seen with FAAH inhibitors that are not selective for the perhiphery.
Thus, the compounds of the present invention may be used to treat the above-mentioned conditions as well as in the preparation of medicaments to treat such methods. The invention also includes methods of treating such diseases comprising administering a compound of the invention to a patient in need thereof, as well as pharmaceutical compositions containing a compound or compounds of the present invention.
The most preferred envisaged use for the compounds of the invention is the treatment of pain, in particular:
- the treatment of acute or chronic neurogenic pain, for example, migraine, and neuropathic pain, including diabetic neuropathic pain, post-herpetic neuralgia, trigeminal neauralgia;
- acute or chronic pain associated with inflammatory diseases, such as arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; and
- acute or chronic peripheral pain.
As used herein, the term treatment and variations such as 'treat' or 'treating' refers to any regime that can benefit a human or non-human animal. The treatment may be in respect of an existing condition or may be prophylactic (preventative treatment). Treatment may include curative, alleviation or prophylactic effects. Treatment may prevent or delay the onset, retard the progression or ameliorate the symptoms of the disease or condition.
5-O-substituted 3-N-phenyl-l,3,4-oxadiazolones are described in several publications such as US 5,093,343, US 5,236,939, US 4,076,824, WO 03/043997 Al, EP 1 263 745 Bl, WO 03/072098 Al, WO 01/17981 Al, WO 03/072555 Al and JP-A 48 58 140. However, none of these publications is concerned with inhibition of FAAH or the treatment of FAAH- related medical conditions.
In one embodiment, the present invention relates to a compound of formula (I),
(I),
wherein
R1 to R5 independently from each other represent: hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Cio-aryl, Cβ-Cio-aryl-d-Cg-alkyl, d-C6-alkoxy,
C6-Cιo-aryloxy, Cβ-do-aryl-d-Cβ-alkoxy, Ci-Cβ-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl, Ce-C^-aryl-Ci-Cg-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Cβ-do-aryl-
Ci-Ce-alkylcarbonyl, Ci-Co-alkylcarboxy, Ce-Cio-arylcarboxy, d-Cδ-alkylmercaptyl,
Cβ-Cio-arylmercaptyl, C i-Cβ-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl,
Ce-C i o-arylmercaptocarbonyl, C i -Cδ-alkylmercaptocarboxy, Ce-C io-ary lmercaptocarboxy,
Ci-Cδ-alkylsulfonyl, Cδ-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cβ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by
Ci-C6-alkyl; d-C6-alkoxy; C6-C!0-aryloxy; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cή-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-Cδ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl, Cβ-Cio-aryl- Ci-C-i-alkyl, Ci-Cβ-alkylcarbonyl, Co-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl, Cδ-Cio-aryl-Ci-Cβ-alkyl, Ci-Cδ-alkylcarbonyl, Co-Cio-arylcarbonyl, Ci-Cό-alkylsulfonyl and Cό-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000007_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cό-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cό-alkyl, fluoro or chloro;
CONH2;
SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Cj-Cβ-alkyl, Cβ-Cio-aryl or Ce-Cio-aryl-CrCβ-alkyl and wherein in the case of a
Figure imgf000007_0002
amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo; CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
C-Ce-alkyl; CrC6-alkoxy; COOH; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or Cδ-Cio-aryl-Ci-C-j-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl,
Figure imgf000007_0003
Ci-Cό-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n represents 0 or 1; m represents 0, 1, 2, 3, 4, 5 or 6;
X represents O or S;
Y represents: a) hydrogen; b) Ci-Ci8-alkyl, mono or polyunsaturated C2-Cig-alkylene, C3-Cg-cycloalkyl, Cβ-Cio-aryl, Cδ-Cio-aryl-Ci-Cs-alkyl, Ci-Cβ-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cg-alkoxy, C 1 -Cό-alkoxycarbonyl, CO-C 10-aryloxycarbonyl, Ce-C 10-aryl-C 1 -Cg-alkoxycarbonyl, Cj-Cδ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Cβ-Cio-aryl-Ci-Cg-alkylcarbonyl,
Ci-Cβ-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Cδ-alkylmercaptyl, Cβ-Cio-arylmercaptyl, C 1 -Cό-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl,
C6-Cio-arylmercaptocarbonyl, d-Ce-alkylmercaptocarboxy, Cβ-Cio-arylmercaptocarboxy, Ci-Cό-alkylsulfonyl, Cδ-Cto-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cβ-Cio-arylsulfoxy, or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, wherein each is optionally substituted once or several times by: bl) Ci-Ce-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, Ce-Qo-aryl-C-Cg-alkyl, Ci-C6-alkoxy, Cβ-Cio-aryloxy, Cό-Cio-aryl-Ci-Cg-alkoxy, Ci-C6-alkoxycarbonyl, Cδ-C 1 o-aryloxycarbonyl, C6-C 10-aryl-C 1 -Cg-alkoxycarbonyl, C 1 -Cβ-alkylcarbonyl, Cό-Cio-arylcarbonyl, Co-Cio-aryl-Ci-Cg-alkylcarbonyl, Ci-Cβ-alkylcarboxy,
Co-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Cδ-Cio-arylmercaptyl,
Ci-Cδ-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl,
Ce-C 1 o-arylmercaptocarbonyl, C 1 -Cδ-alkylmercaptocarboxy,
Cδ-Cio-arylmercaptocarboxy, Ci-Cδ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Cj-Cδ-alkylsulfoxy, C6-Cio-arylsulfoxy; wherein each is optionally substituted once or several times by Ci-C6-alkyl; Ci-C6-alkoxy; COhJH2, SO2ISfH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-C6-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues g
selected from Ci-Cδ-alkyl, Cβ-Cio-aryl, Cβ-Cio-aryl-Ci-Ce-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and
Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3; wherein several of the substituents in bl) may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or by b2) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; CO2H; SO3H; OCF3; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cδ-alkyl, Cδ-Cio-aryl or
C6-Cio-aryl-Ci-C6-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality, the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Ci0-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-Ce-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and Cβ-Cio-arylsulfonyl; or a disubstituted amino of the following formula (II)
Figure imgf000009_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C6-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro; or by b3) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cδ-alkyl; Ci-Cβ-alkoxy; COOH;
SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl,
Cό-Cio-aryl, Cβ-Cio-aryl-Ci-Gt-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, CrCό-alkylsulfonyl and Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; c) SO3H; amino; amino substituted one or more times with residues selected from
Ci-Ce-alkyl, C6-Ci0-JUyI, C6-Ci0-aryl-Ci-C8-alkyl, Cj-Cs-alkylcarbonyl, C6-C|0-arylcarbonyl, Ci-C6-alkylsulfonyI and C6-Cio-arylsuIfonyl; CONH2; SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cδ-alkyl, C6-Cio-aryl or C6-Cio-aryI-Ci-C6-alkyI and wherein in the case of a di-Ci-Cδ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo; CF3; or OCF3;
or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
A further embodiment relates to the use of the above-described compound for the inhibition of fatty acid amide hydrolase (FAAH) and also for the treatment of medical conditions which are positively influenced by the inhibition of FAAH. As inter alia indicated in the article by Pacher et al, Pharmacol. Rev. 58:389-462 (2006), the above compounds are in particular indicated for the treatment of the above-mentioned diseases and medical conditions.
The present invention relates also to a pharmaceutical composition comprising a compound of the above formula (I) or an enantiomer, pharmaceutically acceptable salt or a prodrug thereof, as well as to a method for treating the above-mentioned diseases and conditions by administering a pharmaceutically active amount of a compound of above formula (I), an enantiomer, pharmaceutically acceptable salt or a prodrug thereof.
Within the meaning of this application, the term Ci-C4-alkyl represents preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.
Within the meaning of this application, the term Ci-C6-alkyl represents preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl or hexyl. Within the meaning of this application, the term Ci-Cig-alkyl represents preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, octyl, decyl, dodecyl, tetradecyl and octadecyl.
Within the meaning of this application, the term mono or polyunsaturated C∑-Cig-alkylene preferably represents ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, tert-butenyl, pentenyl, hexenyl, octenyl, decenyl, dodecenyl, tetradecenyl, octadecenyl, dodecdienyl, tetradecdienyl and octadecdienyl.
Within the meaning of this application, the term Cs-Cs-cycloalkyl preferably represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
Within the meaning of this application, the term Cδ-Cio-aryl preferably represents phenyl, pentalenyl, indenyl, indanyl, isoindolinyl, chromanyl, naphthyl, fluorenyl, anthryl, phenanthryl or pyrenyl.
Within the meaning of this application, the terms Cβ-Cio-aryl-d-Cg-alkyl, C6-Cio-aryl- Ci-C6-alkyl and C6-Cio-aryl-Ci-C4-alkyl preferably represent phenyl or naphthyl being substituted with methyl, ethyl, propyl or butyl. Particularly preferred residues are benzyl and phenethyl.
Within the meaning of this application, the term Ci-C4-alkoxy preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, and tert-butoxy.
Within the meaning of this application, the term Ci-Cβ-alkoxy preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy or hexoxy.
Within the meaning of this application, the term Cβ-Cio-aryloxy preferably represents phenoxy, naphthoxy, indenoxy, fluorenoxy or phenanthroxy. Within the meaning of this application, the terms Co-Qo-aryl-Q-Cg-alkoxy, Ce-C w-aryl- Ci-Cό-alkoxy and C6-Ci0-aryl-Ci-C4-alkoxy preferably represent benzoxy, phenethoxy, phenpropoxy, or phenbutoxy. Particularly preferred residues are benzoxy and phenethoxy.
Within the meaning of this application, the term Ci-Cβ-alkoxycarbonyl preferably represents methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl or butoxycarbonyl.
Within the meaning of this application, the term Ce-C^-aryloxycarbonyl preferably represents phenoxycarbonyl or naphthoxycarbonyl.
Within the meaning of this application, the term Cδ-Cio-aryl-Ci-Cg-alkoxycarbonyl preferably represents represents benzoxycarbonyl or phenethoxycarbonyl.
Within the meaning of this application, the term Ci-Cδ-alkylcarbonyl preferably represents methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl or butylcarbonyl.
Within the meaning of this application, the term Cδ-Cio-arylcarbonyl preferably represents phenylcarbonyl or naphthylcarbonyl.
Within the meaning of this application, the term Cδ-Cio-aryl-Ci-Cg-alkylcarbonyl preferably represents benzylcarbonyl or phenethylcarbonyl.
Within the meaning of this application, the term Ci-Cβ-alkylcarboxy preferably represents methylcarboxy, ethylcarboxy, n-propylcarboxy, isopropylcarboxy or butylcarboxy.
Within the meaning of this application, the term Ce-Cio-arylcarboxy preferably represents phenylcarboxy or naphthylcarboxy.
Within the meaning of this application, the term d-Cβ-alkylmercaptyl preferably represents methylmercaptyl, ethylmercaptyl, n-propylmercaptyl, isopropylmercaptyl or butylmercaptyl. Within the meaning of this application, the term Ce-Cio-arylmercaptyl preferably represents phenylmercaptyl or naphthylmercaptyl.
Within the meaning of this application, the term Ci-Ce-alkylmercaptocarbonyl preferably represents methylmercaptocarbonyl, ethylmercaptocarbonyl, n-propylmercaptocarbonyl, isopropylmercaptocarbonyl or butylmercaptocarbonyl.
Within the meaning of this application, the term Cs-Cβ-cycloalkylmercaptocarbonyl preferably represents cyclopropylmercaptocarbonyl, cyclobutylmercaptocarbonyl, cyclopentylmercaptocarbonyl or cyclohexylmercaptocarbonyl.
Within the meaning of this application, the term Cβ-Cio-arylmercaptocarbonyl preferably represents phenylmercaptocarbonyl or naphthylmercaptocarbonyl.
Within the meaning of this application, the term Ci-Cβ-alkylmercaptocarboxy preferably represents methylmercaptocarboxy, ethylmercaptocarboxy, n-propylmercaptocarboxy, isopropylmercaptocarboxy or butylmercaptocarboxy.
Within the meaning of this application, the term Cδ-Cio-arylmercaptocarboxy preferably represents phenylmercaptocarboxy or naphthylmercaptocarboxy.
Within the meaning of this application, the term d-Ce-alkylsulfonyl preferably represents methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl, tert- butylsulfonyl, pentylsulfonyl or hexylsulfonyl.
Within the meaning of this application, the term Cβ-Cio-arylsulfonyl preferably represents phenylsulfonyl or naphthylsulfonyl.
Within the meaning of this application, the term C]-C6-alkylsulfoxy preferably represents methylsulfoxy, ethylsulfoxy, n-propylsulfoxy, n-butylsulfoxy, sec-butylsulfoxy or tert- butylsulfoxy. Within the meaning of this application, the term C6-Cio-arylsulfoxy preferably represents phenylsulfoxy or naphthylsulfoxy.
Furthermore, it is preferred in alternative embodiments of the invention that the above- mentioned substituents are optionally substituted once or several times by Ci-Cό-alkyl, d-Cό-alkoxy, C6-C10-aryloxy, CO2H, CONH2, SO2NH2, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3. In this definition of optional substituents, Ci-Cβ-alkyl, Ci-Cβ-alkoxy, and Cδ-Cio-aryloxy preferably represent the same residues as mentioned above.
Within the meaning of this application, the term "optionally substituted once or several times by" is meant to include no substitution, single substitution or multiple substitution with one or more of the mentioned optional substituents. In case of a multiple substitution, the substituents can be selected independently from each other.
Within the meaning of this application, amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-C10-aryl, C6-Ci0-aryl-Ci-C4-alkyl, C6-Cio-aryl-Ci-C6-alkyl, Ce-Cio-aryl-Ci-Cs-alkyl jCi-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cδ-Cio-arylsulfonyl is preferably represented by an amino group that is once or twice and independently from each other substituted by methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl or hexyl in case of Ci-C6-alkyl; by phenyl, benzyl or phenethyl in case of C6-Cio-aryl, Cβ-Cio-aryl-Ci-d-alkyl, C6-Cio-aryl-Ci-C6-alkyl, or Cδ-Cjo-aryl-Ci-Cg-alkyl; by methylcarbonyl, ethylcarbonyl, or phenylcarbonyl in case of Ci-Cβ-alkylcarbonyl and Cβ-Cio-arylcarbonyl; and by methylsulfonyl, ethylsulfonyl or phenylsulfonyl in case of Ci-Cβ-alkylsulfonyl and Co-Cio-arylsulfonyl.
Within the meaning of this application, the term "disubstituted amino of the following formula (II)
-J~\ v-t/ι ' (II) wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro preferably represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, N-methyl piperazine or 2,2,6,6-tetramethyl piperidinyl.
Within the meaning of this application, CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl, Cβ-Cio-aryl-Ci-Gi-alkyl or Cβ-Cio-aryl-Ci-Cβ-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings is preferably represented by the respective residues derivable from N,N-dimethylamide, N-methylamide, N-ethylamide, N-phenylamide,
N,N-dimethylsulfonamide, N-methylsulfonamide, N-ethylsulfonamide, and N-phenylsulfonamide. In case of an alkyl-disubstitution of the amino functionality, it is also a preferred alternative that both residues are combined to form 5 or 6-membered rings. Examples of such amino functionalities include but are not limited to pyrrolidin and piperidine.
Within the meaning of this application, the term "a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by C|-C6-alkyl; Ci-C6-alkoxy; COOH; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Cj-C6-alkyl, Cβ-Cio-aryl or
Figure imgf000015_0001
and wherein in case of a di-Ci-Cό-allcyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cδ-alkyl, Cβ-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, Ci-Cδ-alkylcarbonyl, Co-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and
C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3" is preferably represented by a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms containing one to four heteroatoms selected from N, O or S. Examples of such preferred saturated, unsaturated or aromatic heterocycles of up to 10 atoms include but are not limited to benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, carbazole, cinnoline, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, imidazoline, imidazolidine, indole, indoline, indolizine, indazole, isoindole, isoquinoline, isoxazole, isothiazole, morpholine, napthyridine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, phenazine, phenothiazine, phenoxazine, phthalazine, piperazine, piperidine, pteridine, purine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrroline, quinoline, quinoxaline, quinazoline, quinolizine, tetrahydrofuran, tetrazine, tetrazole, thiophene, thiadiazine, thiadiazole, thiatriazole, thiazine, thiazole, thiomorpholine, thianaphthalene, thiopyran, triazine, triazole, and trithiane in all their isomeric configurations. These heterocycles may be substituted once or several times by d-C6-alkyl, Ci-C6-alkoxy, COOH, SO3H, CONH2, SO2NHa. CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-Cδ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino, amino substituted one or more times with residues selected from Ci-C6-alkyl, Cδ-Cio-aryl,
Figure imgf000016_0001
Ci-Cό-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cδ-Cio-arylsulfonyl; thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3. Particluarly preferred optional substituents are methyl, methoxy, amino, hydroxy, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 and OCF3.
The most preferred saturated, unsaturated or aromatic heterocyclic ring systems of up to 10 atoms comprise 2-pyridine, 3-pyridine and 4-pyridine, all three optionally substituted with one or more residues selected from methyl, amino, fluoro, chloro or CF3; and N-linked pyrrole, optionally substituted with one or more residues selected from methyl, amino, fluoro, chloro or CF3.
In further embodiments of the invention, two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring sytsems. Examples of such ring systems include but are not limited to benzimidazole, benzofuran, benzothiophene, benzoxazole, and benzothiazole. It is preferred that, in the above formula (I), R1 to R5 independently from each other represent hydrogen; hydroxyl; Ci-Cή-alkyl, Cό-Cio-aryl, Ci-Cβ-alkoxy, Cό-Cio-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy,
C]-C6-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-C6-alkylsulfonyl, C6-Ci0-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Q-Cβ-alkoxy, amino, CrCβ-alkylamino, di-Ci-Cδ-alkylamino, hydroxy, fluoro, chloro, bromo, cyano,
CF3 or OCF3; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl;
1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, optionally substituted with one or more residues selected from Ci-Cδ-alkyl, amino, fluoro, chloro or CF31 a disubstituted amino of the following formula (II)
Figure imgf000017_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with d-Cβ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cδ-alkyl or Cβ-Cio-aryl; fluoro; chloro; bromo;
CF3; or
OCF3. It is further preferred that, in the above formula (T), one or more of R1 to R5 represent hydrogen, fluorine or chlorine. It is more preferred that either R1 or R5 represents hydrogen or fluorine. It is most preferred that either R1 or R5 represents fluorine.
It is further preferred that, in the above formula (I), one or more of R1 to R5 represent hydroxy; Ci-Cβ-alkoxy, Co-Cio-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy, Ci-Cβ-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Ce-alkylsulfonyl, Cβ-Cio-arylsulfonyl, each of which is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cδ-alkoxy, amino, C1 -Chalky lamino, di-Ci-C4-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cδ-alkyl or Cβ-Cio-aryl, hydroxy, fluoro, chloro, bromo, cyano, CF3 or OCF3.
It is more preferred that one of R2, R3 or R4 represents hydroxy; d-Cβ-alkoxy, Cβ-Cio-aryloxy, Cδ-Cio-aryl-d-Cβ-alkoxy, each of which is optionally substituted once or several times by Ci-C4-alkyl, Ci-C4-alkoxy, amino, Ci-C4-alkylamino, di- Ci-C4-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with d-Cβ-alkyl or Cό-Cio-aryl, hydroxy, fluoro, chloro, or bromo.
It is further preferred that, in the above formula (I), one or more of R1 to R5 represent amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cg-Ci o-aryl; or a disubstituted amino of the following formula (II)
→T\
HO, ' (H)
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro.
It is more preferred that one of R2, R3 or R4 represents amino; amino substituted once or twice with residues selected from d-Ce-alkyl, C6-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000019_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Gj-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro.
It is further preferred that, in the above formula (I), wherein n represents 0; m represents 0, 1, 2, 3, 4, 5 or 6; and Y represents C3-C6-cycloalkyl or Cό-Cio-aryl, each of which is optionally substituted once or several times by:
a) Ci-Cβ-alkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, CrC6-alkoxy, C6-C10-aryloxy, Cβ-Cio-aryl-Ci-Gt-alkoxy, wherein each is optionally substituted once or several times by;
Ci-Cβ-alkyl; CrC6-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 substituted once or twice with Ci-Cβ-alkyl or Cβ-Cio-aryl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cό-Cio-aryl,
Figure imgf000019_0002
Ci-Cβ-alkylcarbonyl,
Ce-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
or by
b) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-d-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted once or several times with Ci-Cβ-alkyl or phenyl; a disubstituted amino of the following formula (II)
Figure imgf000020_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Gt-alkyl, fluoro or chloro;
or by
c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
Ci-C6-alkyl; Ci-Ce-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 substituted once or twice with Ci-C6-alkyl or C6-Cio-aryl; SO3H; amino; amino substituted one or more times with residues selected from Cj-Ce-alkyl, Ce-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, Ci-C6-alkylcarbonyl,
Cδ-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3.
It is more preferred that n represents O; m represents O or 1; and Y represents a phenyl, 1-naphthyl, 2-naphthyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl ring system.
It is even more preferred in this aspect that Y is substituted once or several times by Ci-C4-alkyl; phenyl; Ci-C4-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; CONH2 or SO2NH2, optionally substituted once or twice with Ci-C4-alkyl, wherein these optional Ci-C4-alkyl residues may be combined to form 5 or 6-membered rings; or amino.
It is still more preferred in this aspect that m represents O and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo. It is most preferred in this aspect that m represents O and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
It is particularly preferred that, in the above formula (I), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Cj-C4-alkyl.
It is also very preferred that, in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl.
It is also very preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo and that R3 or R3 and R4 represent hydroxy.
It is also very preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that R3 or R3 and R4 represent hydroxy.
It is particularly preferred that in the above formula (I), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl; and R1 represents hydrogen or fluorine.
It is particularly preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and C!-C4-alkyl; and that R1 represents hydrogen or fluorine. It is particularly preferred that in the above formula (I) m is O; n is O; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; that R3 or R3 and R4 represent hydroxyl; and that R1 represents hydrogen or fluorine.
It is particularly preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-ρosition by fluoro, or in the 2- and 4-position by chloro; that R3 or R3 and R4 represent hydroxyl; and that R1 represents hydrogen or fluorine.
Furthermore, it is also preferred that in the above formula (I), when n=0, m=0 or 1, Y represents C6-Cio-aryl, preferably phenyl; benzyl, phenethyl, phenpropyl, phenbutyl or phenhexyl, which is optionally substituted once or several times by
a) Ci-Ce-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, Cβ-Qo-aryl-Ci-Cg-alkyl, CrC6-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cβ-alkoxy, hydroxyl, CO2H, Ci-Cβ-alkoxycarbonyl,
Cβ-Cio-aryloxycarbonyl, Cβ-Cio-aryl-Ci-Cg-alkoxycarbonyl, CrCβ-alkylcarbonyl, C6-C10-arylcarbonyl, Cδ-Cio-aryl-Ci-Cg-alkylcarbonyl, Ci-Cβ-alkylcarboxy,
Cβ-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Cό-Cio-arylmercaptyl,
C i -Cδ-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, Cδ-Cio-arylmercaptocarbonyl, Ci-Cδ-alkylmercaptocarboxy, Cδ-Cio-arylmercaptocarboxy, Ci-C6-alkylsulfonyl, C6-Cio-arylsulfonyl, d-Cό-alkylsulfoxy, C6-Cio-arylsulfoxy;
each of which is optionally substituted once or several times by Ci-C6-alkyl, Ci-Cβ-alkoxy, COOH; CONH2, optionally substituted once or twice with Ci-Cβ-alkyl; SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo,
CF3 or OCF3;
wherein several of these optional substituents may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or
b) a saturated, unsaturated or aromatic heterocycle optionally substituted once or several times by Ci-C6-alkyl, Ci-C6-alkoxy, COOH; CONH2, optionally substituted once or twice with CpCβ-alkyl; SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
c) SO3H, amino, amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl, Cβ-Cio-aryl-Ci-Cg-alkyl, Q-Ce-alkylcarbonyl,
Ce-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and C6-Cio-arylsulfonyl; CONH2, SO2NH2,
CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cδ-alkyl, C6-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl; thiol, hydroxyl, nitro, cyano, fluorosulfonyl, halogen selected from fluoro, chloro, bromo or iodo; CF3, OCF3.
It is also preferred that in the above formula (I) n=0 and m=0 or 1.
It is also preferred that R1 to R5 independently from each other represent hydrogen, hydroxyl, Ci-C4-alkyl, C6-Ci0-aryl, CrC4-alkoxy, C6-Cio-aryloxy, C6-C10-aryl-
Ci-C4-alkoxy, COOH, Ci-Cβ-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl,
Ce-C 10-arylmercaptyl, Ci-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy,
C&-C 10-arylsulfoxy, SO3H, amino, amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl, C6-Cιo-aryl-Ci-C4-alkyl, Ci-Cδ-alkylcarbonyl, Ce-Qo-arylcarbonyl, Ci-Cή-alkylsulfonyl and Cδ-Cio-arylsulfonyl, thiol, hydroxyl, nitro, cyano, fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo; CF3, OCF3; or a saturated, unsaturated or aromatic heterocycle optionally substituted once or several times by Ci-Cδ-alkyl, Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3
More preferably, R1 to R5 are selected from hydroxyl, methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF3, OCF3, pyridine, CONH2, SO2NH2, tetrazole or triazole.
It is also preferred that any one of R1 to R5 is phenyl further substituted once or several times by hydroxyl, Ci-C6-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3. It is also preferred that in formula (I), Y represents phenyl or benzyl which is substituted in ortho-, meta- and/or para-positions by Ci-Cβ-alkoxy, C6-Ci0-aryloxy, hydroxyl, nitro, amino, CONH2, SO2NH2, fluoro, chloro or OCF3. Even more preferably, Y represents phenyl which is substituted once, twice or three times in ortho- and/or para-positions with substituents independently selected from methoxy, ethoxy, tert-butoxy, phenoxy, hydroxy, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3.
It is also preferred that in formula (I), when n=0 and m=0 or 1, R1 to R5 are selected from methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF3, OCF3, pyridine, CONH2, SO2NH2, tetrazole, triazole or phenyl further substituted once or several times by Ci-C6-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3, and Y represents phenyl which is substituted in ortho- and/or para-positions by Cj-Cδ-alkoxy, Cβ-Cio-aryloxy, hydroxyl, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3.
In an alternative embodiment, the present invention relates to a compound of formula (I),
Figure imgf000024_0001
(D.
wherein
R1 to R5 independently from each other represent: hydrogen; Ci-C6-alkyI, C3-C8-cycloalkyl, C6-Ci0-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-C6-alkoxy, C6-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cβ-alkoxy, Ci-Cβ-alkoxycarbonyl, Ce-Cio-aryloxycarbonyl, Cβ-Cio-aryl-Ci-Cβ-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Cή-Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-C6-alkylcarboxy, Cβ-Cio-arylcarboxy, Ci-Ce-alkylmercaptyl, Ce-Cio-arylmercaptyl, Ci-C6-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, Cβ-Cio-arylmercaptocarbonyl, Ci-Cβ-alkylmercaptocarboxy, Cβ-Cio-arylmercaptocarboxy, Ci-Cδ-alkylsulfonyl, Cβ-Cw-arylsulfonyl, d-Cβ-alkylsulfoxy, Cό-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by
C,-C6-alkyl; C,-C6-alkoxy; C6-Ci0-aryloxy; CO2H; SO3H; CONH2; SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-CiO-aryl, C6-Cio-aryl-
Ci-Gj-alkyl, Ci-Cβ-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
CO2H;
SO3H; amino; amino substituted one or more times with residues selected from Ci-Cό-alkyl, Cβ-Cio-aryl,
C6-Cio-aryl-Ci-C6-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, d-Cβ-alkylsulfonyl and Cό-Cio-arylsuIfonyl; a disubstituted amino of the following formula (II)
Figure imgf000025_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cό-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cό-alkyl, fluoro or chloro; CONH2; SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl or Cδ-Cio-aryl-Ci-Cβ-alkyl and wherein in the case of a di-Cj-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C6-alkyl; C,-C6-alkoxy; COOH; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cό-alkyl, C6-Cio-aryl or Cβ-Cio-aryl-Ci-Gt-alkyl and wherein in case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl, Cό-Cio-aryl-Ci-C-i-alkyl,
Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and
C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n represents 0; m represents 0;
Y represents phenyl which is optionally substituted once or several times by
a) Ci-Ce-alkyl, C6-Ci0-aryl, Ce-Cio-aryl-Ci-Cg-alkyl, CrC6-alkoxy, C6-C10-aryloxy, Cβ-Cio-aryl-d-Cg-alkoxy, Ci-Cβ-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl, Cδ-Cio-aryl- CpCe-alkoxycarbonyl, Ci-Cδ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Cβ-Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-Cβ-alkylcarboxy, Co-Cw-arylcarboxy, Ci-Cβ-alkyhnercaptyl, Cδ-Cio-arylmercaptyl, Ci-Cβ-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, C6-C 1 o-arylmercaptocarbonyl, C 1 -Cδ-alkylmercaptocarboxy, Ce-C 1 o-arylmercaptocarboxy, Ci-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-C6-alkylsulfoxy, C6-Cio-arylsulfoxy; each of which is optionally substituted once or several times by Cj-Cβ-alkyl; CpCβ-alkoxy; CONH2 or SO2NH2, optionally substituted once or twice with Ci-Cδ-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Ci0-aryl, Cδ-Cio-aryl-Ci-C-j-alkyl, Ci-C6-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and
Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
wherein several of these optional substituents may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or
b) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Cj-Cβ-alkyl; Ct-Cβ-alkoxy; COOH; CONH2 or SO2NH2, optionally substituted once or twice with Ci-Cβ-alkyl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, d-Cό-alkylsulfonyl and Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; or
c) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C$-alkyl, Ce-Cio-aryl or Cβ-Cio-aryl- Ci-C4-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cδ-alkyl, C6-Cio-aryl, C6-Cio-aryl- Ci-Cg-alkyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ct-Cβ-alkylsulfonyl and Cδ-Cjo-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000027_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and CrC4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro;
with the proviso that
a) R2 or R4 do not represent the substituent C(=A)-N(B)-SO2-NR6R7, wherein A represents O or S, B represents hydrogen, cyano, Ci-Cδ-alkyl, Ci-Cό-alkoxy-alkyl, C3-C7-cycloalkyl, C3-C6-alkenyl, C3-C6-alkynyl or optionally substituted benzyl derivatives, and R6 and R7 independently from each other represent hydrogen or an organic residue, or together an organic cyclic structure; that
b) R1 to R5 independently from each other do not represent hydrogen, fluoro, bromo, chloro, iodo or an alkyl radical when Y represents unsubstituted phenyl; that
c) R2 or R4 do not represent a pyrazol-3-yl-derivative; and that
d) the phenyl ring substituted with R1 to R5 and Y do not represent the following combinations:
Figure imgf000028_0001
Figure imgf000029_0002
It is preferred that in the above formula (I), R1 to R5 independently from each other represent hydrogen; hydroxyl;
Ci-Cό-alkyl, Cό-Cio-aryl, Ct-C6-alkoxy, C6-Ci0-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy,
Ci-Cό-alkylcarboxy, Cβ-Cio-arylcarboxy, d-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-Cό-alkyl, Ci-Cό-alkoxy, amino, Cj-Cό-alkylamino, di-Ci-Cβ-alkylamino, hydroxy, fluoro, chloro, bromo, cyano,
CF3 or OCF3; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl;
1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, optionally substituted with one or more residues selected from Ci-Cβ-alkyl, amino, fluoro, chloro or CF3, a disubstituted amino of the following formula (II)
Figure imgf000029_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Cj-C6-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Cι-C6-alkyl, fluoro or chloro; CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl or Q-Cio-aryl; fluoro; chloro; bromo; CF3; or OCF3.
It is further preferred that, in the above formula (I), one or more of R1 to R5 represent hydrogen, fluorine or chlorine. It is most preferred that either R1 or R5 represents hydrogen or fluorine.
It is further preferred that, in the above formula (I), one or more of R1 to R5 represent hydroxy; or
Ci-Cό-alkoxy, C6-Ci0-aryloxy, Cβ-Cio-aryl-Ci-Cό-alkoxy, CrCδ-alkylcarboxy, Cβ-Cio-arylcarboxy, d-Cβ-alkylsulfonyl, C6-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, d-Cβ-alkoxy, amino, Ci-Cβ-alkylamino, di-d-Cδ-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-C6-alkyl or Cβ-Cio-aryl, hydroxy, fluoro, chloro, bromo, cyano, CF3 or OCF3.
It is more preferred that one of R2, R3 or R4 represents hydroxy; or Ci-Cβ-alkoxy, Co-Cio-aryloxy, or Cό-Cio-aryl-CrCό-alkoxy, each of which is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-C6-alkoxy, amino, Ci-Ce-alkylamino, di-Ci-Cό-aϋcylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-C6-alkyl or Cβ-Cio-aryl, hydroxy, fluoro, chloro, or bromo.
It is further preferred that, in the above formula (I), one or more of R1 to R5 represent amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000031_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C-j-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro.
It is more preferred that one of R2, R3 or R4 represents amino; amino substituted once or twice with residues selected from Cj-Cβ-alkyl, Cβ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000031_0002
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro.
It is further preferred that, in the above formula (I), Y representing phenyl is substituted once or several times by:
a) Ci-C6-alkyl, C6-Cι0-aryl, C6-Cio-aryl-Ci-C6-alkyl, Ci-Cύ-alkoxy, C6-Cio-aryloxy,
C6-Cio-aryl-Ci-C6-alkoxy, wherein each is optionally substituted once or several times by: Ci-Cβ-alkyl; Ci-Cδ-alkoxy; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cό-Cto-aryl, Cβ-Cio-aryl- d-Cβ-alkyl, Ci-Cβ-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3;
CONH2; SO2NH2; OCF3; or CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cή-alkyl; or by b) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; or CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-C6-alkyl, C6-C10-aryl, C6-C10-aryl-Ci-C6-alkyl, wherein in the case of a (Ii-C1 -C6-alkyl substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted once or several times with Ci-C6-alkyl or phenyl; a disubstituted amino of the following formula (II)
Figure imgf000032_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and d-Cό-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with C]-C6-alkyl, fluoro or chloro; or by c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by d-C6-alkyl; d-C6-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-C6-alkyl which may be combined to form 5 or 6-membered rings; SO3H; amino; amino substituted one or more times with residues selected from
CrCe-alkyl, C6-C10-aryl, Ce-do-aryl-d-Ce-alkyl, d-Ce-alkylcarbonyl,
Cδ-do-arylcarbonyl, d-C6-alkylsulfonyl and Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3.
It is even more preferred that Y represents phenyl which is substituted once or several times by d-C6-alkyl; phenyl; d-C6-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 or SO2NH2 optionally substituted once or twice with Cj-C6-alkyl wherein these optional Ci-C6-alkyl residues may be combined to form 5 or 6-membered rings.
It is still more preferred that m represents O and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo. It is most preferred that m represents O and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
It is particularly preferred that, in the above formula (I), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-Ct-alkyl.
It is also very preferred that, in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl.
It is also very preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo and that R3 or R3 and R4 represent hydroxy.
It is also very preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that R3 or R3 and R4 represent hydroxy.
It is particularly preferred that in the above formula (I), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl; and R1 represents fluorine.
It is particularly preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl; and that R1 represents fluorine. It is particularly preferred that in the above formula (I) m is O; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; that R3 or R3 and R4 represent hydroxyl; and that R1 represents fluorine.
It is particularly preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that R3 or R3 and R4 represent hydroxyl; and that R1 represents fluorine.
Furthermore, it is also preferred that, in formula (I), R1 to R5 are selected from hydroxyl, methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF3, OCF3, pyridine, CONH2, SO2NH2, tetrazole or triazole.
It is also preferred that at least one of R1 to R5 is a saturated, unsaturated or aromatic heterocycle optionally substituted once or several times by Ci-Cδ-alkyl, Q-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3 or phenyl further substituted once or several times by Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3.
Alternatively, it is also preferred that at least one of R1 to R5 is CONH2; SO2NH2; or CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl.
It is also preferred that, in formula (I), Y represents phenyl which is substituted in ortho- and/or para-positions by CpCβ-alkoxy, Cβ-Cio-aryloxy, hydroxyl, nitro, amino, CONH2, SO2NH2, fluoro, chloro or OCF3.
Even more preferably, Y represents phenyl which is substituted once, twice or three times in ortho- and/or para-positions with substituents independently selected from methoxy, ethoxy, tert-butoxy, phenoxy, hydroxyl, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3. It is also preferred that Y represents phenyl which is substituted in ortho- and/or para- positions by Ci-Cδ-alkoxy, Cβ-Cio-aryloxy, hydroxyl, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3.
It is also preferred that, in formula (I), R1 to R5 are selected from methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF3, OCF3, pyridine, CONH2, SO2NH2, tetrazole, triazole or phenyl further substituted once or several times by Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3, and Y represents phenyl which is substituted in ortho- and/or para-positions by CrCβ-alkoxy, C6-Cio-aryloxy, hydroxyl, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3.
In still an alternative embodiment, the present invention relates to a compound of formula
(I),
Figure imgf000035_0001
(I)
wherein
R1 to R5 independently from each other represent: hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, C6-Cio-aryl-Ci-C8-alkyl, d-Cδ-alkoxy,
Figure imgf000035_0002
Cό-Cio-aryl-CrCs-alkoxy, Ci-Cό-alkoxycarbonyl, Cή-Cio-aryloxycarbonyl, C6-Cio-aryl-Ci-C8-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Cβ-Cio-aryl- Ci-Cs-alkylcarbonyl, Ci-Cδ-alkylcarboxy, Cβ-Cio-arylcarboxy, Cj-Cό-alkylmercaptyl, Ce-Cio-arylmercaptyl, Ci-C6-alkylmercaptocarbonyl, C3-Cg-cycloalkylmercaptocarbonyl, C6-C i o-arylmercaptocarbonyl, C i -Cβ-alkylmercaptocarboxy , Ce-C i o-arylmercaptocarboxy , d-Cβ-alkylsulfonyl, C6-Cio-arylsulfonyl, Ci-Cδ-alkylsulfoxy, C6-Ci0-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl; Ci-C6-alkoxy; C6-C10-aτyloxy; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl-C1-C4-alkyl and wherein in case of a di-Ci-Cό-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Cj-Cβ-alkyl, Cβ-Cio-aryl, C6-Cio-aryl- Ci-C4-alkyl, Q-Cβ-alkylcarbonyl, Co-Qo-arylcarbonyl, Ci-Cβ-alkylsulfonyl and C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; CO2H;
SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl,
Cδ-Cio-aryl-Ci-Cδ-alkyl, Ci-Cδ-alkylcarbonyl, Co-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and C6-C 1 o-ary lsulfonyl ; a disubstituted amino of the following formula (II)
Figure imgf000036_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or Cβ-Cio-aryl-Cj-Cδ-alkyl and wherein in the case of a di-CrCo-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3; OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
Ci-C6-alkyl; Ci-C6-alkoxy; COOH; SO3H; C0NH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cδ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl-Cι-C4-alkyl and wherein in case of a di-d-Cδ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-CiO-aryl, C6-Cio-aryl-C1-C4-alkyl,
Ci-C6-alkylcarbonyl, C6-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and Co-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n represents O; m represents 1;
Y represents phenyl which is optionally substituted once or several times by a) Ci-Cό-alkyl, Cδ-Cio-aryl, Cό-Cio-aryl-Ci-Cs-alkyl, Ci-Cό-alkoxy, Cδ-Cio-aryloxy, C6-Cio-aryl-Ci-C8-alkoxy, d-Cβ-alkoxycarbonyl, Cβ-do-aryloxycarbonyl, Cβ-Cio-aryl- d-Cg-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Cό-Cio-aryl- d-Cg-alkylcarbonyl, d-C<s-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-Co-alkylmercaptyl, Cβ-Cio-arylmercaptyl, Ci-Cβ-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, C6-Cio-arylmercaptocarbonyl, Ci-Cό-alkylmercaptocarboxy, C6-Cio-arylmercaptocarboxy, Ci-Cό-alkylsulfonyl, Cβ-Cio-arylsulfonyl, d-Cβ-alkylsulfoxy, Cβ-Cjo-arylsulfoxy;
each of which is optionally substituted once or several times by d-C6-alkyl; d-C6-alkoxy; CONH2 or SO2NH2, optionally substituted once or twice with CrC6-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-Q-alkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, CpCβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, CpCβ-alkylsulfonyl and
Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
wherein several of these optional substituents may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or
b) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C6-alkyl; Ci-Cδ-alkoxy; COOH; CONH2 or Sθ2NH2, optionally substituted once or twice with Ci-Cβ-alkyl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-CiO-aryl, C6-C10-aryl-Ci-C4-alkyl, Ci-Cβ-alkylcarbonyl, Co-Cio-arylcarbonyl, Ci-C6-aIkylsulfonyI and Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; or
c) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cό-alkyl, Cδ-Cio-aryl or Co-Cio-aryl- Ci-C4-alkyl and wherein in case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from d-Cβ-alkyl, Cό-Cio-aryl, Cδ-Cio-aryl- Ci-Cβ-alkyl, Ci-Cδ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Q-Cβ-alkylsulfonyl and Cβ-Cio-arylsulfonyl; a disubstituted amino of the following formula (IV)
Figure imgf000038_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Cι-C4-alkyl and wherein the methylene groups in formula (FV) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro; with the proviso that Y does not represent unsubstituted phenyl if R1, R2 and R5 represent hydrogen, R4 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, benzyloxy, phenoxy, phenyl, 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl and R3 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, phenoxy, 4-chlorophenoxy, cyclohexyl, phenyl, morpholinosulfonyl, 3,3,5-trimethylcyclohexylaminosulfonyl,
2,2,6,6-tetramethylpiperidin-4-ylaminosulfonyl, 2-(diisopropylaminoethyl)aminosulfonyl, 4-methylpiperazin-l-yl-sulfonyl, 3,3-dimethylpiperidinocarbonyl or 3,5-dichlorophenoxy 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl.
It is even more preferred that Y represents phenyl which is substituted once or several times by Ci-Cβ-alkyl; phenyl; Cj-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 or SO2NH2 optionally substituted once or twice with Ci-C6-alkyl wherein these optional Ci-Cό-alkyl residues may be combined to form 5 or 6-membered rings.
It is still more preferred that m represents 0 and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo.
It is most preferred that m represents 0 and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
It is particularly preferred that, in the above formula (I), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and d-C4-alkyl.
It is also very preferred that, in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl. It is also very preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo and that R3 or R3 and R4 represent hydroxy.
It is also very preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that R3 or R3 and R4 represent hydroxy.
It is particularly preferred that in the above formula (I), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl; and R1 represents fluorine.
It is particularly preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C-j-alkyl; and that R1 represents fluorine.
It is particularly preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; that R3 or R3 and R4 represent hydroxyl; and that R! represents fluorine.
It is particularly preferred that in the above formula (I) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that R3 or R3 and R4 represent hydroxyl; and that R1 represents fluorine.
Furthermore, it is also preferred that, in formula (I), R1 to R5 are selected from methyl, tert- butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF3, OCF3, pyridine; CONH2, SO2NH2, wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl; tetrazole or triazole. It is also preferred that any one of R1 to R5 is phenyl further substituted once or several times by Ci-C6-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3.
It is also preferred that, in formula (I), Y represents phenyl which is substituted in ortho- and/or para-positions by Ci-C6-alkoxy, Cβ-Cio-aryloxy, hydroxyl, nitro, amino, CONH2, SO2NH2, fluoro, chloro or OCF3.
Even more preferably, Y represents phenyl which is substituted once, twice or three times in ortho- and/or para-positions with substituents independently selected from methoxy, ethoxy, tert-butoxy, phenoxy, hydroxyl, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3.
It is also preferred that, in formula (I), Y represents phenyl which is substituted in ortho- and/or para-positions by Ci-Cβ-alkoxy, C6-Ci0-aryloxy, hydroxyl, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3.
It is also very preferred that, in formula (I), R1 to R5 are selected from methyl, tert-butyl, phenyl, methoxy, ethoxy, phenoxy, amino, thiol, hydroxyl, cyano, fluoro, chloro, bromo, nitro, CF3, OCF3, pyridine, CONH2, SO2NH2, tetrazole, triazole or phenyl further substituted once or several times by Ci-Cδ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3, and Y represents phenyl which is substituted in ortho- and/or para-positions by Ci-Cβ-alkoxy, Cβ-Cio-aryloxy, hydroxyl, nitro, CONH2, SO2NH2, fluoro, chloro or OCF3.
In first very preferred embodiment, the present invention relates to a compound of formula (I),
Figure imgf000041_0001
(I), wherein R1 or R5 is hydrogen or fluorine;
any one of R2 to R4 represents hydroxy, and remaining R residues are hydrogen; Ci-C6-alkyl, C3-C8-cycloalkyl, C6-C10-aryl, Ce-Cio-aryl-d-Cg-alkyl, Ci-C6-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cg-alkoxy, C|-C6-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl, Cβ-Cio-aryl-Ci-Cg-alkoxycarbonyl, Ci-Cό-alkylcarbonyl, Cό-Cio-arylcarbonyl, Co-Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-Cδ-alkylcarboxy, Q-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Cβ-C lo-arylmercaptyl, C i -Cδ-alkylmercaptocarbonyl, C3-Cg-cycloalkylmercaptocarbonyl, Cβ-Cio-arylmercaptocarbonyl, Ci-C6-alkylmercaptocarboxy, Ce-Cio-arylmercaptocarboxy, Ci-Cβ-alkylsulfonyl, Cβ-Cjo-arylsulfonyl, Cj-Cβ-alkylsulfoxy, Cβ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Cj-Cβ-alkoxy, Cδ-Cio-aryloxy, CO2H, SO3H, amino, d-Cβ-alkylamino, di-Ci-Cβ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, Cδ-Cio-aryl, Cβ-Cio-aryl-Ci-Cβ-alkyl, Cj-Ce-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and C6-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000042_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cδ-alkyl, fluoro or chloro; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl or Cδ-Cio-aryl-Ci-Cδ-alkyl and wherein in the case of a di-Ci-Cό-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3; OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; and wherein two or more of R2 to R4 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n and m are 0; and
Y is phenyl substituted once or several times by Ci-C6-alkyl; phenyl; d-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Ci-Cβ-alkyl wherein these optional Ci-Cδ-alkyl residues may be combined to form 5 or 6-membered rings; or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
In a second very preferred embodiment, the present invention relates to a compound of formula (I),
Figure imgf000043_0001
(Q, wherein R1 or R5 is hydrogen or fluorine;
any one of R2 to R4 represents amino and remaining R residues are hydrogen; Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Cι0-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-C6-alkoxy, Cδ-Cio-aryloxy, Cδ-Cio-aryl-Ci-Cβ-alkoxy, Ci-Cβ-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl, Cό-Cio-aryl-Ci-Cg-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, C6-Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-Cδ-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Cδ-C^-arylmercaptyl, Ci-Cδ-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, C6-Cio-arylmercaptocarbonyl, CrCδ-alkylmercaptocarboxy, C6-Cio-arylmercaptocarboxy, CrCδ-alkylsulfonyl, Cό-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cό-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Q-Cβ-alkoxy, Cδ-Cio-aryloxy, CO2H, SO3H, amino, d-Cβ-alkylamino, di-Ci-Cδ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl, Cδ-Cio-aryl-Ci-Cβ-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cό-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000044_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cδ-alkyl, fluoro or chloro; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C6-alkyl, C6-Ci0-aryl or C6-C10-aryl-Ci-C6-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxy 1; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3; OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl, d-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; and wherein any two or more of R2 to R4 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n and m are 0; and
Y is phenyl substituted once or several times by Ci-Cβ-alkyl; phenyl; d-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Ci-C6-alkyl wherein these optional d-C6-alkyl residues may be combined to form 5 or 6-membered rings, or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
In a third very preferred embodiment, the present invention relates to a compound of formula (I),
Figure imgf000045_0001
(I), wherein R1 or R5 is hydrogen or fluorine;
one of R3 or R4 is Ci-Cβ-alkoxy, C6-Cio-aryloxy, C6-Cto-aryl-Ci-C8-alkoxy, Ci-Cβ-alkylcarboxy, Cδ-Cto-arylcarboxy, Ci-C6-alkylmercaptocarboxy, Q-Cio-arylmercaptocarboxy, Cj-C6-alkylsulfoxy, Cβ-Cjo-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cδ-alkyl, Ci-Cβ-alkoxy, Cδ-Cio-aryloxy, CO2H, SO3H, amino, Ci-Cό-alkylamino, di-Ci-Cβ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
the other of R3 or R4 is amino substituted one or more times with residues selected from Ci-C6-aIkyl, C6-Ci0-aryl, C6-Cio-aryl-CrC6-alkyl, d-Cβ-alkylcarbonyl,
Cό-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cέ-Cio-arylsulfonyl;
and R2 is: hydrogen;
Cι-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, Ce-Cio-aryl-Ci-Cg-alkyl, CrC6-alkoxy, C6-Cio-aryloxy, Cβ-Cio-aryl-Cj-Cs-alkoxy, Ci-C6-alkoxycarbonyl, Ce-Cio-aryloxycarbonyl, C6-Cio-aryl-Ci-C8-alkoxycarbonyl, Ci-Cδ-alkylcarbonyl, Ce-Cio-arylcarbonyl, Cβ-Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-Cδ-alkylcarboxy, Ce-Cio-arylcarboxy, Cj-C6-alkylmercaptyl, Cβ-Cio-arylmercaptyl, Ci-Cβ-alkylmercaptocarbonyl, Ca-Cs-cycloalkylmercaptocarbonyl, C6-Cio-arylmercaptocarbonyl, Ci-Cβ-alkylmercaptocarboxy, Cό-Cio-arylmercaptocarboxy, Ci-C6-alkylsulfonyl, Cό-C^-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cδ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cό-alkoxy, Cό-Cio-aryloxy, CO2H, SO3H, amino, C]-C6-alkylamino, di-Ci-Cδ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cό-Cio-aryl, Cό-Qo-aryl-Ci-Ce-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cβ-Ciø-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000047_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Cj-Cδ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or Ce-C io-aryl-Ci-C6-alkyl and wherein in the case of a di-Ci-Cό-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl, Cj-Cό-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
n and m are 0; and
Y is phenyl substituted once or several times by Ci-Cδ-alkyl; phenyl; Ci-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Ci-Cβ-alkyl wherein these optional Cj-Ce-alkyl residues may be combined to form 5 or 6-membered rings, or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof. In all these three preferred embodiments, it is further preferred that Y is phenyl substituted once or several times by Ci-Cό-alkyl; phenyl; Ci-Cδ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Q-Q-alkyl, wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6- membered rings.
In all these three preferred embodiments, it is still further preferred that Y is phenyl substituted once or twice by hydroxy, fluoro, chloro or bromo.
In all these three preferred embodiments, it is still further preferred that Y is phenyl substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
In all aspects of the invention relating to the compounds perse, the following applies:
In the embodiments of the invention directed to the compounds perse, the following compounds of formula (I) are excluded:
5 -Dodecyloxy-3 - (4-trifluormethoxy-phenyl)-3H- (1,3 ,4)-oxadiazol-2-one 5-Hexadecyloxy-3- (4-trifluormethoxy-phenyl)-3H- (l,3»4)-oxadiazol-2-one 5-Octyloxy-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-Hexadecyloxy-3- (3-trifluormethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one 5-Hexadecyloxy-3-(4-(4-chlθφhenoxy)-phenyl)-3H-(l,3,4)-oxadiazol-2-one 5-Octyloxy-3-phenyl-3H- (1 ,3,4)-oxadiazol-2-one 5-Octyloxy-3- (3-fluor-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3- (3-fluor-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-Hexadecyloxy-3- (3-benzyloxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-Hexadecyloxy-3-phenyl-3H- ( 1 ,3,4)-oxadiazol-2-one 5-Hexadecyloxy-3- (4-nitro-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-Hexadecyloxy-3- (4-methoxy-phenyl)-3H- (l,3>4)-oxadiazol-2-one 5-Hexadecyloxy-3- (4-benzyloxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-Decyloxy-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-Undecyloxy-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-Tetradecyloxy-3- (4-trifluormethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one 5-Tridecyloxy-3-(4-trifluoromethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one 5- (2- (2-Hexyloxy-ethoxy)-ethoxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol- 2- one 5- ((Z)-Octadec-9-enyloxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5- (Dodecyloxy-ethoxy)-3- (4-trifluormethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one 5- (2- (4-Fluorphenyl)-ethoxy)-3- (4-trifluoπnethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-((3ss-Cholestan-3-yl)-oxy)-3-(4-trifluoromethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one 5-(2-Butoxy-ethoxy)-3-(4-trifluoπnethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one 5- (7-Phenyl-heptyloxy)-3- (4-trifluormethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one 5- (Docosyloxy-ethoxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5- (2- (l-Naphthloxy)-ethoxy)-3- (4-trifluoπnethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-(4-Octylphenoxy)-3-(4-trifluormethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one 5- (3-Phenoxy-phenoxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5- (Dodecyloxy)-3- (4-trifluormethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one 5- (Dodecyloxy)-3- (3, 4-dichlor-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5- (Dodecyloxy)-3- (3, 5-dichlor-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5- (Dodecyloxy)-3- (3-methoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5- (Dodecyloxy)-3- (4-methoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
In the embodiments of the invention directed to the compounds perse, Y does not represent Ci-C-t-alkyl when m=0 and n=0.
Furthermore, when m=0 and n=0, and Y an optionally substituted phenyl ring, R2 or R4 do not represent the substituent CC=A)-N(B)-SO2-NR6R7, wherein A represents O or S, B represents hydrogen, cyano, Ci-Cβ-alkyl, Ci-Cβ-alkoxy-alkyl, C3-C7-cycloalkyl,
C3-C6-alkenyl, Cs-Q-alkynyl or optionally substituted benzyl derivatives, and R6 and R7 independently from each other represent hydrogen or an organic residue, or together an organic cyclic structure; R1 to R5 independently from each other do not represent hydrogen, fluoro, bromo, chloro, iodo or an alkyl radical when Y represents unsubstituted phenyl; R2 or R4 do not represent a pyrazol-3-yl-derivative; and the phenyl ring substituted with R1 to R5 and Y do not represent the following combinations:
Figure imgf000050_0001
Furthermore, when m=l, n=0, and Y is an optionally substituted phenyl ring, Y does not represent unsubstituted phenyl if R1, R2 and Rs represent hydrogen, R4 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, benzyloxy, phenoxy, phenyl, 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl and R3 represents hydrogen, trifluoromethoxy, trifluorobutoxy,
3,3,5,5-tetramethylcyclohexyloxy, phenoxy, 4-chlorophenoxy, cyclohexyl, phenyl, morpholinosulfonyl, 3,3>5-trimethylcyclohexylaminosulfonyl,
2,2,6,6-tetramethylpiperidin-4-ylaminosulfonyl, 2-(diisopropylaminoethyI)aminosulfonyl, 4-methylpiperazin-l-yl-sulfonyl, 3,3-dimethylpiperidinocarbonyl or 3,5-dichlorophenoxy 2-dJmethylaminoethyloxy or 3-methylphenoxy-methyl.
Furthermore, when m=l, n=0 and R3 is trifluoromethoxy, Y does not represent unsubstituted phenyl.
In some alternative embodiments of the invention directed to the compounds perse, R2 to R5 do not represent 2-oxo-pyrrolidin-l-yl, 2,5-dimethylpyrrol-l-yl or a substituent connected to the phenyl ring by a non-aromatic nitrogen when n =0 and m=0 and when Y is represented by Ci-Cό-alkyl, Ca-Csrcycloalkyl, wherein both groups are optionally substituted one or more times by phenyl, Ci-C4-alkyloxy, S-Ci-C_j-alkyl, N(Ci-C4-alkyl)2, and wherein phenyl is optionally substituted one or more times by halogen, Ci-C4-alkyl, Ci-C4-alkyloxy, nitro, or CF3.
In some alternative embodiments of the invention directed to the compounds perse, in case n represents 0 and m represents 0, R1 or R5 does not represent a substituent selected from halogen, in particular F, Cl, NO2, CHj, OCH3 or CF3 or CN, when at least one of the remainder of the substituents R1 to R5 represents a substituent selected from halogen, in particular F, Cl, Br, CH3, OCH3, NO2, CN and when the phenyl ring representing Y is substituted with F, Cl, Br, CH3, OCH3, NO2 or CN.
In some alternative embodiments of the invention directed to the compounds perse, in case n represents 0 and m represents 0, Y does not represent phenyl which is substituted by phenoxy or Cβ-Cu-alkyl.
In some alternative embodiments of the invention directed to the compounds perse, in case n represents 0 and m represents 1 , Y does not represent unsubstituted phenyl.
In some additional alternative embodiments of the invention directed to the compounds perse, in case m=0 and n=0, Y does not represent phenyl or lower alkyl radical when R1 to R5 represent a hydrogen or halogen atom or a methyl radical. In some alternative embodiments of the invention directed to the compounds perse, R2 to R5 do not represent hydrogen, halogen, nitro, Ci-C4-alkyl, Ci-C9-alkyloxy, trifluoromethyl, trifluoromethoxy or C6-Cio-aryl-Ci-C4-alkyloxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl, C3-C8-cycloalkyl or 0-C3-C8-cycloalkyl when n =0 and m=0 and when Y is represented by C7-C22 alkyl, C2-C4 alkyl that is substituted by C-j-Cao-alkoxy, Cβ-Cio-aryl, Cβ-Cio-aryloxy or C4-C12-alkoxy-C2-C4-alkoxy, and represents C7-C20 alkenyl, 3 beta-cholestan-3-yl or is represented by phenyl which is substituted with phenoxy or C6-C12-alkyl. In still alternative embodiments of the invention directed to the compounds perse, all of these compounds can be substituted once or several times by C1-C9 alkyl, C1-C9 alkyloxy, halogen, and trifluoromethyl in case of aryl; and by C1-C4 alkyl or Cό-Cio aryl in case of cycloalkyl; and by hydroxyl, di-Ci-C4 alkylamino and fiuoro in case of alkyl.
In some additional alternative embodiments of the invention directed to the compounds perse, in case m=0 and n=0, Y does not represent phenyl substituted by alkyl having 1 to 4 carbon atoms; alkoxy having 1 to 4 carbon atoms; alkylthio having 1 to 4 carbon atoms; halogenoalkyl having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; halogenoalkoxy having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; or halogenoalkylthio having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; alkylenedioxy having 1 or 2 carbon atoms; halogensubstituted alkylenedioxy having 1 or 2 carbon atoms and 1 to 4 halogen atoms, the halogen atoms being identical or different; cyano; nitro; alkylcarbonyl having 2 to 4 carbon atoms; carbalkoxy having 2 to 4 carbon atoms; alkylsulphonyl having 1 to 4 carbon atoms; arylsulphonyl having 6 or 10 aryl carbon atoms; phenyl, naphthyl, phenoxy, naphthoxy, phenylthio or naphthylthio, when R1 or R5 represent halogen; alkyl having 1 to 4 carbon atoms; alkoxy having 1 to 4 carbon atoms; alkylthio having 1 to 4 carbon atoms; halogenoalkyl having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; halogenoalkoxy having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; or halogenoalkylthio having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; and when one or more of the remaining R1 to R5 represent hydrogen; alkyl having 1 to 4 carbon atoms; alkoxy having 1 to 4 carbon atoms; alkylthio having 1 to 4 carbon atoms; halogenoalkyl having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; halogenoalkoxy having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; or halogenoalkylthio having 1 to 4 carbon atoms and 1 to 5 halogen atoms, the halogen atoms being identical or different; alkylenedioxy having 1 or 2 carbon atoms; halogen-substituted alkylenedioxy having 1 or 2 carbon atoms and 1 to 4 halogen atoms, the halogen atoms being identical or different; halogen; cyano; nitro; amino; mono- and dialkylamino having 1 to 4 carbon atoms per alkyl group; alkylcarbonyl having 2 to 4 carbon atoms; carbalkoxy having 2 to 4 carbon atoms; alkylsulphonyl having 1 to 4 carbon atoms; arylsulphonyl having 6 or 10 aryl carbon atoms; phenyl, naphthyl, phenoxy, naphthoxy, phenylthio or naphthylthio.
In some additional alternative embodiments of the invention directed to the compounds perse, in case n represents 0 and m represents 0, R1 or R5 does not represent a substituent selected from halogen, in particular F, CI, NO2, CH3, OCH3 or CF3 or CN, when at least one of the remainder of the substituents R1 to R5 represents a substituent selected from halogen, in particular F, Cl, Br, CH3, OCH3, NO2, CN and when the phenyl ring representing Y is substituted with F, Cl, Br, CH3, OCH3, NO2 or CN.
In some alternative embodiments of the invention directed to the compounds perse, when R1, R2 and R5 represent hydrogen or when R1, R4 and R5 represent hydrogen, and when and m=l and n=0, Y does not represent Cj-Cό-alkyl or C3-C<>-cycloalkyl, optionally substituted once or several times by phenyl which in turn may be substituted once or several times by halogen, Ci-C4-alkyl, Ci-C4-alkyloxy, nitro, CF3; or by O-d-C^alkyl, S-Ci-C4-alkyl, N(C,-C4-alkyl)2.
In some alternative embodiments of the invention directed to the compounds perse, when R1 or R5 represent hydrogen and when and m=l and n=0, Y does not represent Ci-Cβ-alkyl or C3-C9-cycloalkyl, optionally substituted once or several times by phenyl which in turn may be substituted once or several times by halogen, d-C4-alkyl, Ci-C4-alkyloxy, nitro, CF3; or by O-C,-C4-alkyl, S-C,-C4-alkyl, N(Ci-C4-alkyl)2.
In another aspect, the present invention also relates to the use of a pharmacophore of the following structure (III),
Figure imgf000054_0001
(HI),
for the preparation of a compound for the inhibition of FAAH, and the treatment of a disorder which is positively influenced by the inhibition of fatty acid amide hydrolase (FAAH), in particular for the treatment of the above mentioned medical indications.
In still another aspect, the present invention also relates to compounds comprising a pharmacophore of the following structure (III),
Figure imgf000054_0002
("I),
for the inhibition of FAAH, and the treatment of a disorder which is positively influenced by the inhibition of fatty acid amide hydrolase (FAAH), in particular for the treatment of the above mentioned medical indications.
Within the meaning of the application, the term "pharmacophore" is to be understood as a molecular sub-unit, or substructure or part of the molecule which is essential for the interaction with the FAAH enzyme. It is to be understood that the pharmacophore of formula (III) may be further substituted.
In another aspect, the present invention also relates to a process for the preparation of a compound according to any one of claims 1 to 17, and 24 to 79 wherein a compound of formula (IV), Y
Figure imgf000055_0001
(IV), wherein
R1 to R5 independently from each other represent: hydrogen;
Ci-Cβ-alkyl, C3-C8-cycloalkyl, C6-C10-aryl, C6-C10-aryl-Ci-C8-alkyl, Ci-C6-alkoxy, Cδ-Cio-aryloxy, Cδ-Cio-aryl-Ci-Cs-alkoxy, d-Ce-alkoxycarbonyl, Cό-Cio-aryloxycarbonyl, C6-Cio-aryl-C]-C8-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Ce-Qo-arylcarbonyl, C6-Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-C6-alkylcarboxy, Cβ-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, C6-C j o-arylmercapty], C i -Ce-alkylmercaptocarbonyl, Cj-Cβ-cycloalkylmercaptocarbonyl, C6-Cio-arylmercaptocarbonyl, Ci-C6-alkylmercaptocarboxy, Cβ-Cio-arylmercaptocarboxy, Ci-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Cj-Cβ-alkylsulfoxy, Cβ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-C6-alkyl, Ci-Cβ-alkoxy, Cβ-Cio-aryloxy, CO2H, SO3H, amino, Ci-Cδ-alkylamino, di-Ci-Cδ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cό-Cio-aryl, Cδ-Qo-aryl-Ci-Cό-alkyl, d-Cβ-alkylcarbonyl, CO-C1 o-arylcarbonyl, Ci-Cδ-alkylsulfonyl and Cβ-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000055_0002
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C6-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Cj-Cβ-alkyl, fluoro or chloro; CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl-Ci-C6-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxy 1; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3,
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
m represents 0, 1, 2, 3, 4, 5 or 6;
Y represents: a) hydrogen; b) Ci-Ciβ-alkyl, mono or polyunsaturated C2-Cig-alkylene, Cs-Cβ-cycloalkyl, Cβ-Cio-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-C6-alkoxy, C6-Ci0-aryloxy, Cδ-Cio-aryl-Ci-Cg-alkoxy, C 1 -Cβ-alkoxycarbonyl, Cβ-C 10-aryloxycarbonyl, Cβ-C 1 o-aryl-C 1 -Cg-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, CO-CJ o-aryl-Ci-Cg-alkylcarbonyl,
Ci-Cβ-alkylcarboxy, Cβ-Cio-arylcarboxy, Ci-Co-alkylmercaptyl, Cβ-Cio-aryhnercaptyl, C|-C6-alkylmercaptocarbonyl, Cj-Cg-cycloalkylmercaptocarbonyl,
C6-C 1 o-arylmercaptocarbonyl, C 1 -Cβ-alkylmercaptocarboxy, Cδ-C 10-arylmercaptocarboxy, Ci-Cδ-alkylsulfonyl, C6-Cio-arylsulfonyl, Ci-Cδ-alkylsulfoxy, C6-Cio-arylsulfoxy, or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, wherein each is optionally substituted once or several times by: bl) d-Cδ-alkyl, C3-C8-cycloalkyl, C6-Ci0-aτyl,
Figure imgf000057_0001
Ci-Cό-alkoxy, C6-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cg-alkoxy, d-Cβ-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl, Cό-Cio-aryl-Ci-Cs-alkoxycarbonyl, Ci-Co-alkylcarbonyl,
Cό-Cio-arylcarbonyl, Cβ-Cio-aryl-Ci-Cg-alkylcarbonyl, Ci-Cβ-alkylcarboxy, Co-Cio-arylcarboxy, Cj-Ce-alkylmercaptyl, Cβ-Cio-arylmercaptyl,
C i -Cβ-alkylmercaptocarbonyl, Cs-Ce-cycloalkylmercaptocarbonyl,
C6-Cio-arylmercaptocarbonyl, Ci-C6-alkylmercaptocarboxy, C6-Cio-arylmercaptocarboxy, Ci-Cβ-alkylsulfonyl, C6-Cio-arylsulfonyl,
Ci-Cβ-alkylsulfoxy, Cβ-Cio-arylsulfoxy; wherein each is optionally substituted once or several times by Ci-C6-alkyl; Ci-C6-alkoxy; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cδ-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-Q-alkyl, C6-Ci0-aryl, C6-Cio-aryl-Ci-C6-alkyl,
Ci-Cβ-alkylcarbonyl, Cό-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and
Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3; wherein several of the substituents in bl) may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or by b2) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; CO2H; SO3H; OCF3; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cδ-alkyl, Cό-Cio-aryl or Cδ-Cio-aryl-Ci-Cδ-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality, the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Ci0-aryl, C6-CiO-aryl-Ci-Cg-alkyl, Ci-C6-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Ce-alkylsulfonyl and Cό-Cio-arylsulfonyl; or a disubstituted amino of the following formula (II)
Figure imgf000058_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Cj-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro; or by b3) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl; Cj-Cδ-alkoxy; COOH;
CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C^-Cio-aryl, Ce-Cw-aryl-Ci-Cβ-alkyl,
Ci-Ce-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and
C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3; c) SO3H; amino; amino substituted one or more times with residues selected from
Cj-Cβ-alkyl, C6-C10-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-Ce-alkylcarbonyl,
C6-Ci0-arylcarbonyl, Ci-C6-alkylsulfonyl and C6-Ci0-arylsulfonyl; CONH2; SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or Cβ-Cio-aryl-Ci-Gj-alkyl and wherein in the case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo; CF3; or OCF3;
is cyclised to form an oxadiazolone ring system.
It is preferred that the cyclisation step to the oxadiazolone ring system is achieved by phosgene, carbonyldiimidazole, or a carbonic acid ester.
Suitable carbonic acid esters are in particular the Cj -Chalky 1 carbonic acid esters.
Phosgene and carbonyldiimidazole are the most preferred reagents to achieve cyclization. It is preferred that in the above formula (FV), R1 to R5 independently from each other represent hydrogen; hydroxyl; Ci-C6-alkyl, C6-Cio-aryl, Ci-C6-alkoxy, C6-Cio-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy, C|-C6-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-C6-alkylsulfonyl, C6-Cio-arylsulfonyl, each of which is optionally substituted once or several times by Ci-Cό-alkyl, Ci-Cβ-alkoxy, CONH2 or SO2NH2 optionally substituted once or twice with Ci-C6-alkyl or Cβ-Cio-aryl; amino, Ci-C4-alkylamino, di-C1-C4-alkylam.no, hydroxy, fluoro, chloro, bromo, CF3 or OCF3; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl; a disubstituted amino of the following formula (II)
Figure imgf000059_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci -Chalky I, fluoro or chloro; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is optionally substituted one or more times with residues selected from Ci-Cβ-alkyl or Cβ-Cio-aryl; fluoro; chloro; bromo; CF3; or OCF3.
It is further preferred that, in the above formula (FV), one or more of R1 to R5 represent fluorine or chlorine. It is most preferred that either R1 or R5 represents fluorine.
It is further preferred that, in the above formula (IV), one or more of R1 to R5 represent hydroxy; Ci-Cβ-alkoxy, Cδ-Cio-aryloxy, Ce-Cio-aryl-Ci-Cβ-alkoxy, Ci-Cδ-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, each of which is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cό-alkoxy, CONH2 or SO2NH2 optionally substituted once or twice with Ci-C6-alkyl or C6-Cio-aryl; amino, Ci-C4-alkylamino, di-C1-C4-alkylam.no, hydroxy, fluoro, chloro, bromo, CF3 or OCF3.
It is more preferred that one of R2, R3 or R4 represents hydroxy; Ci-Cβ-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cβ-alkoxy, each of which is optionally substituted once or several times by Ci-C4-alkyl, Ci-C4-alkoxy, CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cβ-alkyl or Cβ-Cio-aryl; amino, Ci-C4-alkylamino, di- Ci-C4-alkylamino, hydroxy, fluoro, chloro, or bromo.
It is further preferred that, in the above formula (IV), one or more of R1 to R5 represent amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000060_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and d-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro.
It is more preferred that one of R2, R3 or R4 represents amino; amino substituted once or twice with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000060_0002
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro.
It is further preferred that, in the above formula (IV), n represents 0; m represents 0, 1 , 2, 3, 4, 5 or 6; and Y represents C3-Cβ-cycloalkyI or Cβ-Cio-aryl, each of which is optionally substituted once or several times by:
a) Ci-Cό-alkyl, C6-Ci0-aryl, C6-C10-aryl-Ci-C4-alkyl, Ci-Cβ-alkoxy, Cό-Cw-aryloxy, C6-C 1 o-aryl-C 1 -C4-alkoxy , each of which is optionally substituted once or several times by Ci-Cό-alkyl; Ci-C6-alkoxy; CONH2 or SOaNH2, optionally substituted once or twice with Ci-Cό-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl, C6-CiO-aryl-C1-C4-alkyl, Ci-Cβ-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and
Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3;
or by
b) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2 or SO2NH2, optionally substituted once or twice with d-Cβ-alkyl, wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6- membered rings; amino; amino substituted once or several times with Ci-Cβ-alkyl or phenyl; a disubstituted amino of the following formula (II)
Figure imgf000061_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C4-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro;
or by
c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cδ-alkyl; d-Cβ-alkoxy; COOH; CONH2 or SO2NH2, optionally substituted once or twice with Ci-Cβ-alkyl, wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6-membered rings; SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl,
Figure imgf000061_0002
Ci-Ce-alkylcarbonyl, Cό-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cβ-Cto-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3.
It is more preferred that n represents 0; m represents 0 or 1; and Y represents a phenyl, naphthyl or pyridinyl ring system.
It is even more preferred that Y is substituted once or several times by Ci-C-j-alkyl; phenyl; Ci-C4-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; CONH2 or SO2NH2, optionally substituted once or twice with Ci-C4-alkyl, wherein these optional Ci-C4-alkyl residues may be combined to form 5 or 6-membered rings; or amino.
It is still more preferred that m represents 0 and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo.
It is most preferred that m represents 0 and Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
It is particularly preferred that, in the above formula (IV), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl.
It is also very preferred that, in the above formula (IV) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl.
It is also very preferred that in the above formula (IV) m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo and that R3 or R3 and R4 represent hydroxy.
It is also very preferred that in the above formula (IV) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro and that R3 or R3 and R4 represent hydroxy.
It is particularly preferred that in the above formula (IV), m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C-i-alkyl; and R1 represents fluorine.
It is particularly preferred that in the above formula (IV) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-C4-alkyl; and that R1 represents fluorine.
It is particularly preferred that in the above formula (IV) m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; that R3 or R3 and R4 represent hydroxyl; and that R1 represents fluorine.
It is particularly preferred that in the above formula (IV) m is 0; n is 0; Y represents phenyl which is substituted in the 4-position by fluoro, in the 4-position by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro; that R3 or R3 and R4 represent hydroxyl; and that R1 represents fluorine.
In the following, the invention is illustrated by the following representative examples:
Example 1:
5-Phenoχy-3-(4-pyridin-3-y0phenyl-1.3.4-oxadiazol-2(3HVone
a) To an ice-cooled stirred solution of (4-bromophenyl)hydrazine (3.13 g, 14 mmol) in a mixture of NMP (2O mL) and pyridine (6.87 g, 87 mmol) ) was added phenyl carbonochloridate (2.412 g, 15.41 mmol) dropwise under argon. The reaction was stirred at 0 0C for 30 min., and then was allowed to warm up to room temperature and stirred for 1 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic phase was washed with water and brine respectively. After drying over MgSO4 was filtered and evaporated yielding 5.5 g of phenyl-2-(4-bromophenyl)hydrazinecarboxylate as yellow oil which was crystallized on standing.
b) To an ice-cooled mixture of the above intermediate (5.5 g) and pyridine (7.37 g, 83 mmol) was added 20 % solution of phosgene in toluene (22.6 mL, 43 mmol) dropwise.
The reaction mixture was stirred for 30 min. in the cold, then for 1 hour at room temperature. Whereupon argon was bubbled through the reaction mixture and diluted with water at 0 0C. The two phases were separated and the organic phase was washed with 2 N HCl solution, water and brine respectively. The organic phase was stirred with charcoal for 30 min. then filtered through a short silica pad. After evaporation of the solvent the crude product was recrystallized from DCM/IPA mixture to give 1.938 g of 3-(4-bromophenyl)- 5-phenoxy-l,3,4-oxadiazol-2(3/f)-one as white solid, (yield 32.5 % for two steps)
c) To a stirred solution of 3-(4-bromophenyl)-5-phenoxy-l,3,4-oxadiazol-2(3H)-one (0.6 g, 1.8 mmol) in dimethoxy ethane (20 mL) and water (3 mL) was added pyridin-3- ylboronic acid (0.31 g, 2.52 mmol) and potassium carbonate (0.647 g, 4.68 mmol) Once a solution was obtained, Pd(PPh3)4 (0.104 g, 0.09 mmol) was added and the mixture was heated at 85 0C for 3 h and then allowed to cool to room temperature. The solvent was removed under reduced pressure and the residue was partitioned between 20 % iPrOH- DCM and water. The mixture was filtered to aid separation of the layers, and the organic phase was then washed with water and brine, then dried over MgSO4, and filtered onto activated carbon. After stirring for 10 min., the mixture was filtered through a short silica gel/celite plug and the filtrate was evaporated to leave greenish oil that solidified on standing. Recrystallisation from ethanol gave 5-Phenoxy-3-(4-pyridin-3-yl)phenyl- 1,3,4- oxadiazol-2(3//)-one as greyish powder (0.165 g, 27.7%) of melting point (m.p.) 146-1470C.
Example 2:
5-(Benzyloxy)-3-(3-bromophenvn-1.3.4-oxadiazol-2(3H)-one
a) To an ice-cooled stirred solution of (3-bromophenyl)hydrazine hydrochloride (5.00 g, 22.37 mmol) and pyridine (8.85 g, 112 mmol) in 40 mL of NMP was added 50 % solution of benzyl chloroformate (8.40 g, 24.61 mmol) in toluene dropwise under argon. The reaction was stirred at 0 0C for 30 rain., and then was allowed to warm up to room temperature and stirred for 1 h. The reaction mixture was poured into ice-water; the precipitate was filtered off, washed with water and dried in EtOAc over MgSO4. Evaporation of the solvent afforded 6.77 g of benzyl-2-(3- bromophenyl)hydrazinecarboxylate as yellow solid (yield: 94%).
b) To an ice-cooled mixture of benzyl-2-(3-bromophenyl)hydrazinecarboxylate (6.77 g) and pyridine (8.57 g, mL, l lO mmol) was added 20 % solution of phosgene in toluene (26.6 mL, 50.6 mmol) dropwise. The reaction mixture was stirred for 30 min. in the cold, then for 1 hour at room temperature. Whereupon argon was bubbled through the reaction mixture and diluted with water at 0 0C. The two phases were separated and the organic phase was washed with 2 N HCl solution, water and brine respectively. The organic phase was stirred with charcoal for 30 min. then filtered through a short silica pad. After evaporation of the solvent the crude product was recrystallized from ethanol to give 4.76 g of 5-benzyloxy-3-(3-bromophenyl)-l,3,4-oxadiazol-2(3H)-one as beige solid of melting point (m.p.) 89-9O0C. (Yield 65 %.)
Example 3: 5-(2-bromopyridin-3-yloxyV3-(4-methoxyphenyl)-l,3.4-oxadiazol-2(3//)-one
a) To an ice-cooled solution of phosgene (52.6 mL, 100 mmol) (20% solution in toluene) in DCM (25 mL) was added a mixture of 2-bromopyridin-3-ol (3.48 g, 20 mmol) and pyridine (2.108 g, 26.7 mmol)) in DCM (50 mL)) portion wise over a period of 1 hour under nitrogen. The reaction was allowed to warm up to room temperature and stirred for additional two hours, then nitrogen was bubbled through the reaction mixture for 30 min. It was evaporated to dryness under vacuum, azeotroped with 10O mL of toluene and dried under vacuum. 2-Bromopyridin-3-yl carbonochloridate was obtained as grey hygroscopic powder (6.59 g, 93 %)
b) To an ice-cooled stirred solution of (4-methoxyphenyl)hydrazine hydrochloride (1.746 g, 10.0 mmol) and pyridine (3.95 g, 50 mmol) in 15 mL of NMP was added portion wise 2-Bromopyridin-3-yl carbonochloridate (4.23 g, 12.0 mmol) under nitrogen. The reaction was stirred at 0 0C for 30 min., and then was allowed to warm up to room temperature and stirred for 1 h. The reaction mixture was poured into ice-water; the mixture was extracted with EtOAc and dried over MgSO4. After evaporation of the solvent yellow oil was obtained that was purified by column chromatography in petroleumetherEtOAc = 2:1 mixture to give 1.09 g of 2-bromopyridin-3-yl 2-(4-methoxyphenyl)hydrazinecarboxylate as white solid (yield: 32.2 %)
c) To an ice-cooled mixture of 2-bromopyridin-3-yl
2-(4-methoxyphenyl)hydrazinecarboxylate (1.071 g, 3.17 mmol) and pyridine (1.303 g, 16.47 mmol) was added 20 % solution of phosgene in toluene (4.O mL, 7.6 mmol) dropwise. The reaction mixture was stirred for 30 min. in the cold, then for 1.5 hours at room temperature. Whereupon nitrogen was bubbled through the reaction mixture and diluted with water at 0 0C. The two phases were separated and the aqueous phase was extracted with DCM. The combined organic phases were dried over MgSO4 and filtered. After evaporation the crude 5-(2-bromopyridin-3-yloxy)-3-(4-methoxyphenyl)-l,3,4- oxadiazol-2(3H)-one was purified by column chromatography in petroleumetherrEtOAc =-2:1 mixture. Yield 75 mg beige powder 6.50 %.); m.p. 116.5-117.5°C
Example 4: 5-(4-Bromo-2-methoxyphenoxy)-3-phenyl- 1 ,3,4-oxadiazol-2(3H)-one
a) To an ice-cooled stirred solution of 4-bromo-2-methoxyphenol (4.06 g, 20 mmol) and phosgene (11.58 mL, 22.00 mmol) was added dropwise N,N-dimethylaniline (2.424 g, 20.00 mmol) dissolved in Toluene (9 mL). The reaction was stirred at room temperature for 3 hours. Whereupon nitrogen was bubbled through the reaction mixture for 30 min; and quenched with ice. The organic phase was washed with IN HCl solution and water respectively. After drying over MgSO4 toluene was removed by vacuum and 4-bromo-2- methoxyphenyl carbonochloridate was obtained as oil. Yield: 4.1O g, 77%.
b) To an ice-cooled stirred solution of phenylhydrazine (1.081 g, 10.0 mmol) and pyridine (3.95 g, 50 mmol) in 15 mL of NMP was added portion wise 4-bromo-2- methoxyphenyl carbonochloridate (3.19 g, 12.0 mmol). The reaction was stirred at room temperature for 1 hour. Then, it was poured into ice-lN HCl mixture; the precipitate was filtered off, washed with water and dried under vacuum. 4-Bromo-2-methoxyphenyl 2-phenylhydrazinecarboxylate was obtained as white powder by triturating with petroleumether. Yield: 3.38 g.
c) To an ice-cooled mixture of 4-Bromo-2-methoxyphenyl 2-phenylhydrazinecarboxylate (3.20 g, 9.49 mmol) and pyridine (3.90 g, 49.4 mmol) was added 20 % solution of phosgene in toluene (11.98 mL, 22.78 mmol) dropwise. The reaction mixture was stirred for 15 min. in the cold, then for 45 min. at room temperature. Whereupon nitrogen was bubbled through the reaction mixture and diluted with water at 0 0C. The two phases were separated and the organic phase was washed with IN HCl and water respectively. After drying over MgSO4 the solvent was removed by vacuum. 5-(4- Bromo-2-methoxyphenoxy)-3-phenyl-l,3,4-oxadiazol-2(3H)-one was purified by column chromatography in petroleum etheπEtOAc = 10:1 mixture. Yield: 1.198 g white powder 34.8 %.); m.p. 77-78°C
Example 5: 5-(4-chlorophenoxy)-3-(4-hydroxyphenyl')-l,3,4-oxadiazol-2(3HVone
a) To a stirred solution of 4-methoxyphenylhydrazine hydrochloride (6 g, 34.4 mmol in N-methyl-2-pyrrolidinone (48 mL) at room temperature was added pyridine (13.89 mL,
172 mmol) dropwise and the resulting solution was cooled to O 0C. Thereupon 4-chlorophenyl carbonochloridate (5.29 mL, 37.8 mmol) was added dropwise. The resulting solution was stirred at 00C for 30 min and then allowed to warm to room temperature and stirred for 1 h. The reaction mixture was poured into ice/water and stirred for 1 h. The precipitate was filtered off, washed with water and dried. Recrystallisation from isopropanol gave 4-chlorophenyl 2-(4-methoxyphenyl)hydrazinecarboxyIate as a white solid, (5.74 g, 57 %).
b) To a stirred solution of 4-chlorophenyl 2-(4-methoxyphenyl)hydrazinecarboxylate (5.74 g, 19.61 mmol) in dichloromethane (15O mL) at room temperature was added pyridine (8.25 mL, 102 mmol) and the resulting solution was cooled to 0 0C. A 20 % solution of phosgene (24.76 mL, 47.1 mmol) in toluene was then added dropwise. The mixture was stirred at 0 0C for 30 min and then allowed to warm to room temperature and stirred for 1 h. Nitrogen was bubbled through the mixture for 30 min, which was then cooled to 0° C and diluted with water. The phases were separated and organic phase was washed with 2 N hydrochloric acid, water and brine, then dried (MgSO4) and filtered onto activated carbon. After stirring for 15 min, the suspension was filtered through a short pad of silica and celite. The filtrate was evaporated and the resulting yellow solid was crystallized twice from isopropanol to give 5-(4-chlorophenoxy)-3-(4-methoxyphenyl)- l,3,4-oxadiazol-2(3H)-one as a white solid, (3.14 g, 50 %).
c) A stirred solution of 5-(4-chlorophenoxy)-3-(4-methoxyphenyl)-l,3,4-oxadiazol-2(3H)~ one (3.14 g, 9.85 mmol) in dichloromethane (30 mL) under nitrogen was cooled to - 800C
(suspension) and boron tribromide (1.863 mL, 19.70 mmol) was added dropwise. The resulting pale pink solution was stirred at -800C for 5 min and then allowed to warm to room temperature and stirred for 2 h. The reaction mixture was cooled to O 0C and ice/water was carefully added. The resulting precipitate was filtered, washed with water and dried. Recrystallisation from isopropanol gave 5-(4-chlorophenoxy)-3-(4- hydroxyphenyl)-l,3,4-oxadiazol-2(3H)-one as a white solid, (2.2 g, 73 %) of m.p.
163.5-164.5 0C.
Example 6: 3-(3-aminophenylV5-(2<4-difluorophenoxy')-1.3.4-oxadiazol-2(3H)-one
a) To a stirred solution of 3-nitrophenylhydrazine hydrochloride (1 g, 5.27 mmol) in N-methyl-2-pyrrolidinone (8 mL) at room temperature was added pyridine (2.13 mL, 26.4 mmol) dropwise. The resulting mixture was cooled to 00C and 2,4-difluorophenyl carbonochloridate (1.22 g, 6.33 mmol) was added dropwise. The resulting mixture was stirred at 00C for 30 min and then at room temperature for 1 h, whereupon it was poured onto ice/water. The mixture was extracted with ethyl acetate and the organic extracts were washed with 2 N hydrochloric acid, water and brine, then dried (MgS O4) filtered and evaporated to give 2,4-difluorophenyl 2-(3-nitrophenyl)hydrazinecarboxylate as a yellow oil, (1.6 g, 100%).
b) To a solution of 2,4-difluorophenyl 2-(3-nitrophenyl)hydrazinecarboxylate (1.7 g, 5.50 mmol) in dichloromethane (3O mL) at room temperature was added pyridine (2.312 mL, 28.6 mmol) dropwise and the solution was cooled to 00C. A 20 % solution of phosgene (6.94 mL, 13.19 mmol) in toluene was added dropwise. The resulting pink suspension was stirred at 00C for 30 min and then allowed to warm to room temperature and stirred for 1 h. Nitrogen was bubbled through the mixture for 30 min, which was then cooled to 00C and diluted with water. The phases were separated and organic phase was washed with 2 N hydrochloric acid, water and brine, then dried (MgSθ4), filtered and evaporated. The resulting yellow oil was purified by chromatography (petroleum ether/ethyl acetate, 6/1 to 4/1). Fractions with pure product were pooled and evaporated to give a pink oil that solidified on standing. This was crystallized from heptane and diethyl ether to give 5-(2,4-difluorophenoxy)-3-(3-nitrophenyl)-l,3,4-oxadiazol-2(3H)-one as a white solid, (260 mg, 14 %).
c) To a stirred suspension of 5-(2,4-difluorophenoxy)-3-(3-nitrophenyl)-l,3,4-oxadiazol- 2(3H)-one (251 mg, 0.749 mmol) in methanol (2O mL) at room temperature under nitrogen, was added 10% palladium on carbon (25 mg). Hydrogen gas was then bubbled through the reaction mixture for 1 h. The reaction mixture was filtered through a short pad of celite and the filtrate was evaporated. The resulting yellow solid was purified by column chromatography (petroleum ether/ethyl acetate 6/1 to 4/1). Homogeneous fractions were pooled and evaporated and the resulting pale yellow solid was crystallized from isopropanol to give 3-(3-aminophenyl)-5-(2,4-difluorophenoxy)-l,3,4-oxadiazol-2(3H)- one as a pale yellow solid, (128 mg, 56 %) of m.p. 122-1230C.
Example 7: 3-(4-dH-pyrrol-l-yl)phenylV5-('2.4-difluorophenoxyV1.3.4-oxadiazol-2GH)-one
A stirred solution of 3-(4-aminophenyl)-5-(2,4-difluorophenoxy)-l,3,4-oxadiazol-2(3H)- one (203 mg, 0.665 mmol) and 2,5-dimethoxytetrahydrofuran (0.108 mL, 0.832 mmol) in acetic acid (10 mL) was heated at 95 0C for 1 h becoming a deep red solution. The mixture was allowed to cool to room temperature and the solvent was evaporated. Toluene was added to the residue and re-evaporated. The residue was triturated with boiling ethanol, filtered while hot and washed with ethanol. After drying, there was obtained 3-(4-(1H- pyrrol-l-yl)phenyl)-5-(2,4-difluorophenoxy)-l,3,4-oxadiazol-2(3H)-one as a reddish- brown solid, (109 mg, 46 %), of m.p. 181-1820C. Example 8:
3-(3 '-mcthoxybiphenyl-4-yl)-S-phenoxy- 1 ,3,4-oxadiazol-2(3H)-one
To a stirred suspension of 3-(4-bromophenyl)-5-phenoxy-l,3,4-oxadiazol-2(3H)-one (526 mg, 1.58 mmol), 3-methoxyphenylboronic acid (336 mg, 2.21 mmol) and potassium carbonate (567 mg, 4.10 mmol) in dimethoxyethane (2O mL) and water (1O mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (91 mg, 0.079 mmol). The resulting mixture was stirred at 85 0C for 3 h and then allowed to cool to room temperature.
The solvent was evaporated and the residue partitioned between dichloromethane and water. The organic phase was separated, washed with water and brine, then dried (MgSO4) and filtered onto activated carbon. After stirring for 10 minutes, the suspension was filtered through a short silica gel/celite pad and the filtrate evaporated to leave an oil that solidified on standing. Recrystallisation from dichloromethane/ethanol gave 3-(3'-methoxybiphenyl-
4-yl)-5-phenoxy-l,3,4-oxadiazol-2(3H)-one as white crystals (182 mg, 32 %) of m.p. 102-103 0C.
Example 9: 5-(2,4-difluorophenoxy)-3-(4-hvdroxyphenyl)-l,3,4-oxadiazol-2(3H)-one
a) To a stirred solution of 4-methoxyphenylhydrazine hydrochloride (6 g, 34.4 mmol) in N-methyl-2-pyrrolidinone (48 mL) at room temperature was added pyridine (13.89 mL, 172 mmol) dropwise and the resulting solution cooled to O 0C. 2,4-difluorophenyl carbonochloridate (7.94 g, 41.2 mmol) was then added dropwise. The solution was stirred at 0 0C for 30 min and then allowed to warm to room temperature and stirred for 2 h. The reaction mixture was poured into ice/water and stirred for 1 h. The mixture was extracted with ethyl acetate and the organic extracts were washed with 2 N hydrochloric acid, water and brine, then dried (MgSO4) and filtered onto activated carbon. After stirring for 15 mins, the suspension was filtered through a short pad of silica gel and celite. The filtrate was evaporated and the resulting yellow oil was crystallized from isopropanol to give 2,4-difluorophenyl 2-(4-methoxyphenyl)hydrazinecarboxylate as a white solid, (3.82 g, 38 %). b) To a stirred solution of 2,4-difluorophenyl 2-(4-methoxyphenyl)hydrazinecarboxylate (3.82 g, 12.98 mmol) in dichloromethane (12O mL) at room temperature was added pyridine dropwise (5.46 mL, 67.5 mmol) and the resulting solution was cooled to 0 °C. Thereupon, a 20 % solution of phosgene (16.39 mL, 31.2 mmol) in toluene was added dropwise. The resulting orange solution was stirred at 0 0C for 30 min, then allowed to warm to room temperature and stirred for 1 h. Nitrogen was bubbled through the mixture for 30 min, then cooled to 0 0C and diluted with water. The phases were separated and the organic phase was washed with 2N hydrochloric acid, water and brine, then dried (MgSO4), and filtered onto activated carbon. After stirring for 30 min, the suspension was filtered through short pad of silica gel and celite. The filtrate was evaporated and the resulting pale yellow solid was crystallized from isopropanol to give 5-(2,4- difluorophenoxy)-3-(4-methoxyphenyl)-l,3,4-oxadiazol-2(3H)-one as a white solid (1.77 g, 43 %).
c) A stirred solution of 5-(2,4-difluorophenoxy)-3-(4-methoxyphenyl)-l,3,4-oxadiazol- 2(3H)-one (241 mg, 0.753 mmol) in dichloromethane (5 mL) under nitrogen was cooled to -8O 0C, whereupon boron tribromide (0.142 mL, 1.505 mmol) was added dropwise. The solution was stirred at -800C for 5 minutes and then allowed to warm to room temperature and stirred for 1 h. The reaction mixture was then cooled to 00C and carefully quenched by the addition of water. The mixture was extracted with 30% isopropanol in dichloromethane and the combined organic layers were washed with water and brine, then dried (MgSO4), filtered and evaporated. The resulting off white solid was crystallized from isopropanol to give 5-(2,4-difluorophenoxy)-3-(4-hydroxyρhenyl)-l,3,4-oxadiazol-2(3H)-one as a white solid, (158 mg, 69 %) of m.p. 174.5-176 0C.
Example 10: 5-f4-chlorophenoxy)-3-(2-fluoro-4-hvdroxyphenyl)-1.3,4-oxadiazol-2(3HVone
a) To a stirred solution of 3-fluoro-4-nitrophenol (5 g, 31.8 mmol) in acetone (100 mL) at room temperature was added potassium carbonate (15.4O g, 111 mmol) in one portion followed by dimethyl sulphate (6.04 mL, 63.7 mmol) dropwise. The resulting yellow suspension was stirred at reflux for 2 h. The reaction mixture was then cooled to room temperature, filtered and the filtrate was evaporated. The resulting yellow liquid was purified by column chromatography (petroleum ether/ethyl acetate, 9/1). Homogeneous fractions were pooled and evaporated and the resulting yellow oil was crystallized from diethyl ether/petroleum ether to give 2-fluoro-4-methoxy-l -nitrobenzene as pale yellow crystals, (2.81 g, 52 %).
b) To a stirred solution of 2-fluoro-4-methoxy-l -nitrobenzene (2.76 g, 16.13 mmol) in methanol (5O mL) at room temperature under nitrogen was added 10% palladium on carbon (276 mg). Hydrogen gas was bubbled through the reaction mixture for 1 h, whereupon the suspension was filtered through a short pad of celite. The filtrate was evaporated and the resulting red oil was triturated with petroleum ether. The resulting orange solid was filtered off and dried to give 2-fluoro-4-methoxyaniline, (2.2 g, 97 %).
c) To a stirred solution of 2-fluoro-4-methoxyaniline (2.13 g, 15.09 mmol) in concentrated hydrochloric acid (13.97 mL) at -1O 0C was added a solution of sodium nitrite (1.121 g, 16.25 mmol) in water (6.96 mL) dropwise whilst maintaining the temperature below -100C. The resulting mixture was stirred at -100C for 1 h. Thereupon a solution of tin(II) chloride dihydrate (2.9O mL, 34.8 mmol) in concentrated hydrochloric acid (11.61 mL) was added dropwise whilst maintaining the temperature below -5 0C. The reaction mixture was stirred at -5 0C for 1 h and then allowed to warm to room temperature. The beige suspension was filtered, the filter cake was dissolved in water and the resulting solution was made basic by the addition of 3 N aqueous sodium hydroxide solution. The mixture was then extracted with dichloromethane and the combined extracts washed with water and brine, then dried (MgSO4), filtered and evaporated. The resulting dark red-brown solid was was crystallized from diethyl ether/petroleum ether to afford (2-fluoro-4- methoxyphenyl)hydrazine as a dark pink solid (1.24 g, 53 %).
d) To a stirred solution of (2-fluoro-4-methoxyphenyl)hydrazine (1.22 g, 7.81 mmol) in N-methyl-2-pyrrolidinone (1O mL) at room temperature was added pyridine (3.16 mL, 39.1 mmol) dropwise and the resulting solution was cooled to 0 0C. Thereupon 4-chlorophenyl carbonochloridate (1.64O mL, 11.72 mmol) was added dropwise. The solution was then stirred at O 0C for 30 minutes and then allowed to warm to room temperature and stirred for 1 h. The reaction mixture was poured into ice/water and stirred for 1 h. The precipitate was filtered off, washed with water and dried to give 4-chlorophenyl 2-(2-fluoro-4-methoxyphenyl)hydrazinecarboxylate as a beige solid, (2.5 g, 100 %).
e) To a stirred solution of 4-chlorophenyl 2-(2-fluoro-4- methoxyphenyl)hydrazinecarboxylate (2.5 g, 8.05 mmol) in dichloromethane (40 mL) at room temperature was added pyridine (3.38 mL, 41.8 mmol) dropwise and the resulting solution was cooled to O 0C. A 20 % solution of phosgene in toluene (10.16 mL, 19.31 mmol) was then added dropwise. The resulting red suspension was stirred at 0 0C for 30 minutes and then allowed to warm to room temperature and stirred for 1 h. Nitrogen was bubbled through the mixture for 30 minutes before cooling to 0 0C and diluting with water. The phases were separated and the organic phase was washed with 2 N hydrochloric acid, water and brine. The organic layer was dried (MgSO_j), filtered onto activated carbon and stirred for 30 min. The suspension was filtered through a short pad of silica gel and celite. The filtrate was evaporated and the resulting yellow solid was crystallized twice from isopropanol to give 5-(4-chlorophenoxy)-3-(2-fluoro-4-methoxyphenyl)- 1,3,4- oxadiazol-2(3H)-one as a pale beige solid, (1.2 g, 44 %).
f) A stirred solution of 5-(4-chlorophenoxy)-3-(2-fluoro-4-methoxyphenyl)-l,3,4- oxadiazol-2(3H)-one (1.2 g, 3.56 mmol) in dichloromethane (4O mL) under nitrogen was cooled to -80 0C and boron tribromide (0.674 mL, 7.13 mmol) was added dropwise. The solution was stirred at -80 0C for 5 min, then was allowed to warm to room temperature and stirred for 5 h. The reaction mixture was then cooled to 0 0C and carefully quenched by the addition of water. A mixture of 30 % isopropanol in dichloromethane was added and the phases were separated. The aqueous phase was extracted with dichloromethane and the combined extracts were washed with water and brine. The organic layer was dried (MgSO4), filtered and evaporated. The resulting green solid was dissolved in hot isopropanol and insoluble material filtered off. The filtrate was evaporated and the residue crystallized from dichloromethane/petroleum ether to give a dark pink solid. This solid was dissolved in dichloromethane and activated carbon was added. After stirring for 15 minutes, the suspension was filtered through a short pad of silica gel and celite. The filtrate was evaporated to small volume and PE was added. The resulting solid was filtered off, washed with petroleum ether and dried to give 5-(4-chlorophenoxy)-3-(2-fluoro-4- hydroxyphenyl)-l,3,4-oxadiazol-2(3H)-one as an off-white solid (379 mg, 33 %) of m.p. 180-182 0C.
Example 11 : 3-(4-amino-3-methoxyphenyl)-5-(2.4-difluorophenoxy)-1.3.4-oxadiazol-2(3H)-one hydrochloride
a) Methyl iodide (11.94 mL, 191 mmol) was added dropwise to a stirred suspension of 5-fluoro-2-nitrophenol (10 g, 63.7 mmol) and potassium carbonate (17.59 g, 127 mmol) in acetone (318 mL) at room temperature. The reaction mixture was allowed to stir at room temperature for 4 days, whereupon the acetone was evaporated under reduced pressure and the residue was partitioned between water and ethyl acetate. The aqueous layer was neutralised with concentrated hydrochloric acid. The organic layer was separated, washed with water and brine, dried (MgSO.)), filtered and evaporated to give an off-white solid that was recrystallised from isopropanol/dichloromethane to give 4-fiuoro-2-methoxy-l- nitrobenzene as an off-white solid (9.6 g, 88%).
b) Hydrazine hydrate (5.96 mL, 123 mmol) was added dropwise to a stirred solution of 4-fluoro-2-methoxy-l -nitrobenzene (7g, 40.9 mmol) in ethanol (84 mL) at room temperature. The solution became yellow then bright orange. The reaction mixture was allowed to stir at 1000C for 2 h and then cooled down to 0 0C. The yellow precipitate was separated by filtration and washed with cold ethanol. The mother liquor was evaporated to half the volume, then it was cooled down to 00C and more precipitate formed. The precipitate was collected and washed with cold ethanol. The precipitates were combined to give (3-methoxy-4-nitrophenyl)hydrazine (4.18 g, 56%).
c) 2,4-Difluorophenyl carbonochloridate (4.63 g, 24.02 mmol) was added dropwise to a stirred solution of (3-methoxy-4-nitrophenyl)hydrazine (4 g, 21.84 mmol) and pyridine (8.83 mL, 109 mmol) NIvIP (40 mL) at 00C. The reaction mixture was allowed to stir at 0 0C for 15 min and then at room temperature for 45 min. The solution was then poured into a mixture of ice/1 N hydrochloric acid solution. The product was extracted with ethyl acetate and then with dichloromethane/isopropanol. The combined organic layers were washed with brine, dried (MgSO4), filtered and evaporated to give an orange oil. Column chromatography (silica, petroleum ether/ethyl acetate 2:1 then 1 :1) gave 2,4-difluorophenyl 2-(3-methoxy-4-nitrophenyl)hydrazinecarboxylate as an orange oil/solid (5.84g, 79%).
d) A 20 % solution of phosgene in toluene (21.74 mL, 41.3 mmol) was added dropwise to a stirred solution of 2,4-difiuorophenyl 2-(3-methoxy-4-nitrophenyl)hydrazinecarboxylate (5.84 g, 17.21 mmol) and pyridine (7.24 mL, 90 mmol) in dichloromethane (115 mL) at 0 0C. The solution became dark red and was allowed to stir at 00C for 15 min and then at room temperature for 45 min. Air was bubbled through the solution for 10 min and then water was added at 00C. The organic layer was separated and washed with 1 N hydrochloric acid, followed by water and brine, then dried (MgSO-O, filtered and evaporated to give a dark red oil. Column chromatography (petroleum ether/dichloromethane 2:1 then 1:1) gave a yellow solid that was recrystallised from isopropanol/dichloromethane to give 5-(2,4-difluorophenoxy)-3-(3-methoxy-4- nitrophenyl)- 1 ,3,4-oxadiazol-2(3H)-one (722 mg, 11.5%).
e) 10 % Palladium on carbon (18.5 mg) was added to a stirred solution of 5-(2,4- difluorophenoxy)-3-(3-methoxy-4-nitrophenyl)-l ,3,4-oxadiazol-2(3H)-one (200 mg, 0.548 mmol) in methanol (15 mL) at room temperature. The reaction mixture was allowed to stir at room temperature under an atmosphere of hydrogen gas for 3 h. Further 10 % palladium on charcoal catalyst (9 mg) was added and the reaction mixture was allowed to stir at room temperature under hydrogen for a further 2 h. The solution was then filtered through a short celite pad and the celite was washed with ethyl acetate. The filtrate was evaporated to give a brown solid that was recrystallised from isopropanol to give a beige solid (124 mg). This was taken up in ethyl acetate (5 mL) and cooled to 00C before 2N hydrogen chloride in ether (2 mL) was added dropwise. The precipitate that formed was filtered off, washed with ethyl acetate and dried to give 3-(4-amino-3-methoxyphenyl)-5- (2,4-difluorophenoxy)-l,3,4-oxadiazol-2(3H)-one hydrochloride as a beige solid (120 mg, 90%) ofm.p. 186-188 0C. Example 12:
3-(4-amino-3-(2-methoxyethoxy)DhenylV5-(2.4-difluorophenoxyV1.3.4-oxadiazol- 2(3HV one
a) Sodium iodide (0.191 g, 1.273 mmol) was added to a stirred suspension of 5-fluoro-2- nitrophenol (4 g, 25.5 mmol), potassium carbonate (10.56 g, 76 mmol) and l-chloro-2- methoxyethane (5.1O mL, 56.0 mmol) in DMF (102 mL) at room temperature. The reaction mixture was allowed to stir at 800C overnight. Further l-chloro-2-methoxyethane (6.38 mL, 70.0 mmol) was added and the reaction mixture was allowed to stir at 800C for 4 h. Water and ethyl acetate were added and the organic layer was separated. The aqueous layer was neutralised with 1 N hydrochloric acid and extracted with ethyl acetate. The combined organic layers were washed with water, dried (MgSO4), filtered and evaporated to give a yellow oil. Column chromatography (petroleum ether/ethyl acetate 6:1) gave 4-fluoro-2-(2-methoxyethoxy)-l -nitrobenzene as a clear oil (2.26g, 39%).
b) Hydrazine hydrate (1.531 mL, 31.5 mmol) was added to a stirred solution of 4-fluoro-2- (2-methoxyethoxy)-l -nitrobenzene (2.26 g, 10.50 mmol) in ethanol (21.43 mL) at room temperature. The reaction mixture was allowed to stir at 85 0C for 3 h. The solution was then cooled down to 0 0C causing formation of a precipitate. The solid was separated by filtration and washed with cold ethanol. The mother liquors were evaporated to half the original volume and cooled down to 00C. The precipitate that formed that was separated by filtration and washed with cold ethanol. The combined precipitates of (3-(2- methoxyethoxy)-4-nitrophenyl)hydrazine (1.75 g, 73%) were used in the next step without further purification.
c) 2,4-difluorophenyl carbonochloridate (1.631 g, 8.47 mmol) was added dropwise to a stirred solution of (3-(2-methoxyethoxy)-4-nitrophenyl)hydrazine (1.75 g, 7.70 mmol) and pyridine (3.11 mL, 38.5 mmol) in NMP (14 mL) at 00C. The reaction mixture was allowed to stir for 20 min at 00C and then for 1 h at room temperature. The solution was poured onto a 1 N hydrochloric acid/ice mixture. After stirring for 30 min, ethyl acetate was added and the organic layer was separated, washed with 1 N hydrochloric acid, water and brine. The organic layer was then dried (MgSO4) and evaporated to leave an orange oil. Column chromatography (petroleum ether/ethyl acetate 2:1 then 1:1 then 1:2) gave an orange oil. The oil was dissolved in ethyl acetate and was washed with water. The organic layer was dried (MgSO4), filtered and evaporated to give 2,4-difluorophenyl 2-(3-(2- methoxyethoxy)-4-nitrophenyl)hydrazinecarboxylate as an orange foam (1.54 g, 52%).
d) A 20 % toluene solution of phosgene (5.07 mL, 9.64 mmol) was added dropwise to a stirred solution of 2,4-difluorophenyl 2-(3-(2-methoxyethoxy)-4- nitrophenyl)hydrazinecarboxylate (1.54 g, 4.02 mmol) and pyridine (1.69O mL, 20.89 mmol) in dichloromethane (27 mL) at 0 0C. The deep red solution was allowed to stir at 00C for 15 min and at room temperature for 1 h. Water was added at 0 0C and the organic layer was separated and washed with 1 N hydrochloric acid followed by water and brine. The organic layer was dried (MgSC>4), filtered and evaporated to leave a red oil. Column chromatography (petroleum ether/ethyl acetate 6:1 then 4:1) gave a brown solid that was recrystallised from isopropanol/dichloromethane to give 5-(2,4-difluorophenoxy)- 3-(3-(2-methoxyethoxy)-4-nitrophenyl)-l,3,4-oxadiazol-2(3H)-one as a beige solid (539 mg, 33%).
e) 10 % Palladium on charcoal (35 mg) was added to a stirred solution of 5-(2,4- difluorophenoxy)-3-(3-(2-methoxyethoxy)-4-nitrophenyl)-l,3,4-oxadiazol-2(3H)-one (267 mg, 0.652 mmol) in methanol (18 mL) at room temperature. The reaction mixture was allowed to stir at room temperature under an atmosphere of hydrogen gas for 1 h. The mixture was then filtered through a short celite pad and the celite was washed with ethyl acetate. The filtrate was evaporated to give an orange oil. Column chromatography (petroleum ether/ethyl acetate 4:1 then 2:1) gave an orange oil that crystallised at room temperature. This was recrystallised from isopropanol/dichloromethane to give 3-(4-amino-3-(2-methoxyethoxy)phenyl)-5-(2,4-difluorophenoxy)-l,3,4-oxadiazol-2(3H)- one as a beige solid (118 mg, 45%) of m.p. 74-75 0C.
Example 13:
3-(3-amino-4-methoxyphenvD-5-(2,4-difluorophenoxy)-l,3,4-oxadiazol-2(3H)-one
a) To vigorously stirred fuming nitric acid (5 mL) cooled to 0 0C was added 5-(2,4- difluorophenoxy)-3-(4-methoxyphenyl)-l,3,4-oxadiazol-2(3H)-one (500 mg, 1.561 mmol) in portions. The yellow suspension was stirred at 0 0C for 5 min, then was allowed to warm to room temperature and stirred for 30min. The reaction mixture was poured into ice/water and the resulting precipitate was filtered off, washed with water, and dried to give 5-(2,4- difluorophenoxy)-3-(4-methoxy-3-nitrophenyl)-l,3,4-oxadiazol-2(3H)-one as a pale yellow solid (533 mg, 93 %).
b) To a stirred suspension of 5-(2,4-difluorophenoxy)-3-(4-methoxy-3-nitrophenyl)-l,3,4- oxadiazol-2(3H)-one (520 mg, 1.424 mmol) in methanol (20 mL) at room temperature was added 10 % palladium on carbon (52 mg).Hydrogen gas was bubbled through the mixture for 2 h, whereupon the catalyst was removed by filtration through short pad of celite. The filtrate was evaporated and the resulting pale brown solid was dissolved in dichloromethane. Activated carbon was added and the suspension was stirred for 15 min before filtration through a short pad of silica gel and celite. The filtrate was evaporated and the resulting yellow solid was crystallized from isopropanol to give 3-(3-amino-4- methoxvphenyl)-5-(2,4-difluorophenoxy)-l,3,4-oxadiazol-2(3H)-one as an orange solid, (280 mg, 59 %) ofm.p. of l01°C.
Example 14:
5-(2.4-difluorophenoxyV3-(4-methoxy-3-( 1 H-pyrrol- 1 -vDphenvD- 1 ,3.4-oxadiazol-2(3HV one
A stirred solution of 3-(3-amino-4-methoxyphenyl)-5-(2,4-difluorophenoxy)-l,3,4- oxadiazol-2(3H)-one (162 mg, 0.483 mmol) and 2,5-dimethoxytetrahydrofuran (0.077 mL, 0.598 mmol) in acetic acid (5 mL) was heated at 900C for 1 h and then cooled to room temperature. The solvent was removed under reduced pressure and toluene was added to the residue and re-evaporated. The residue was taken up in dichloromethane and stirred for 30 mins with activated carbon before filtration through a short silica/celite pad. The filtrate was evaporated to leave an oil that solidified after addition of ether. Recrystallisation from isopropanol gave 5-(2,4-difluorophenoxy)-3-(4-methoxy-3-(lH-pyrrol-l-yl)phenyl)-l,3,4- oxadiazol-2(3H)-one as a pale orange solid, (137 mg, 73 %) of m.p. 1360C.
Table 1 shows further compounds that were prepared in a similar manner. For solid materials, the melting point is given. For oils, the NMR data is given in Table 2. Table 1
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
The NMR-data for the obtained oils are indicated in Table 2 below. The NMR spectra were recorded on a Bruker Avance DPX400 spectrometer with solvent used as internal standard. Data are reported in the following order: approximate chemical shift (ppm), number of protons, multiplicity (br, broad; d, doublet; m, multiplet; s, singlet, t; triplet) and coupling constant (Hz). Table 2
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
In-vitro FAAH activity was determined accordingly to the following method:
Frozen brains (without cerebellum) from Wistar rats were used, and each brain was homogenized in 15 mL 1 mM MgCl2, 2OnM HEPES pH 7.0 with Potter Elvejhem (8 strokes at 500 rpm). Homogenates were centrifuged for 20 min at 3600Og at 4°C (Beckman, 70Ti rotor). Pellets were resuspended in 15 mL of the same buffer and centrifuged under the same conditions. Pellets were resuspended in 15 mL of the same buffer and incubated for 15 min at 370C after which they were centrifuged for 20 min at 3600Og at 40C. Each pellet was then resuspended in 15 mL 3 mM MgCl2, 1 mM EDTA, 50 mM Tris pH 7.4 and protein determined with BioRad Protein Assay (BioRad) using a standard curve of BSA (50-250 μg/ml). The membrane suspensions were aliquoted and stored at -800C.
The FAAH activity was determined using AEA (labelled with 3H in the ethanolamine part of the molecule) as substrate and measuring the 3H-ethanolamine formed. Reaction mix (total volume of 200 μl) contained: 2 μM AEA (2 μM AEA + 5 nM 3H-AEA), 0.1 % fatty acid free BSA, 5 μg protein, in 1 mM EDTA, 10 mM Tris pH 7.6 and 10 μM or 100 mM compounds. Stock solutions of the compounds to test (1OmM) were prepared in 100 % DMSO and the DMSO concentration in the assay was 0.1 %. After a 15 min preincubation period at 370C, reaction was started by the addition of the substrate solution (cold EAE + radiolabeled EAE + BSA). Reaction was carried out for 10 min before termination by the addition of 400 μl activated charcoal suspension (8 g charcoal in 32 mL 0.5 M HCI in continuous agitation). After a 30 min incubation period at room temperature with agitation, charcoal was sedimented by centrifugation in microfuge (10 min at 13000 rpm). 200 μl of the supernatant were added to 800 μl Optiphase Supermix scintillation cocktail previously distributed in 24- well plates. Counts per minute (cpm) were dertermined in Microbeta TriLux scintillation counter (10 min counting or until σ=2).
In each assay blanks (no protein, usually below 200 cpm) and controls (no compound) were present. The results are reported in Table 3 as % of control after blank subtraction.
Table 3
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
The in vivo FAAH inhibitory activity in tissues of animals administered with the compounds of the invention was determined accordingly to the following method:
Animal treatment
The animals used for experiments were male NMRI mice (weighing 27-44 g) obtained from Interfauna Iberica (Spain). Mice were kept 5 per cage, under controlled environmental conditions (12 hr light/dark cycle and room temperature 22±1°C). Food and tap water were allowed ad libitum and the experiments were all carried out during daylight hours.
Animals were administered 30 mg/kg BIA compounds via oral route (8 mL/kg; compound suspended in 0.5 % carboxymethylcellulose (CMC) or solubilized in water) or 8ml/kg 0.5 % CMC (controls) using animal feeding stainless steel curve needles (Perfectum, U.S.A.). Fifteen minutes before sacrifice animal were anesthetized with pentobarbital 60 mg/kg administered intraperitoneally. A fragment of liver, left lung lobe and brain without cerebellum were removed and put in plastic vials containing membrane buffer (3 mM MgCl2, 1 mM EDTA, 50 mM Tris HCl pH 7.4). Tissues were stored at -3O0C until analysis.
Animals were fasted overnight before administration of compounds except for time periods of >18h, where food was removed on the morning of the day of administration and the compound was administered in the afternoon of the same day. Animals were then given water but nothing else.
All animal procedures were conducted in the strict adherence to the European Directive for Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (86/609CEE) and Portuguese legislation (Decreto-Lei 129/92, Portarias 1005/92 e 1131/97). The number of animals used was the minimum possible in compliance with current regulations and scientific integrity.
Reagents and Solutions
Anandamide [ethanolamine -1-3H-] (40-60Ci/mmol) was obtained from American Radiochemicals. All other reagents were obtained from Sigma-Aldrich. Optiphase Supermix was obtained from Perkin Elmer and activated charcoal were obtained from Sigma-Aldrich.
Tissue Preparation
Tissues were thawed on ice and were homogenized in 10 volumes of membrane buffer (3 mM MgCl2, 1 mM EDTA, 50 mM Tris HCl pH 7.4) with either Potter-Elvejhem (brains - 8 strokes at 500 rpm) or Heidolph Diax (livers - 2 strokes at position 5 for 20 sec with 30 sec pauses).
Total protein in tissues was determined with the BioRad Protein Assay (BioRad) using a standard curve of BSA (50-250 μg/ml).
Enzymatic assay
Reaction mix (total volume of 200 μl) contained: 2 μM AEA (2 μM AEA + 5 nM 3H- AEA), 0.1 % fatty acid free BSA, 15 μg (brain), 5 μg (liver) or 50 μg (lung) protein, in 1 mM EDTA, 10 mM Tris pH 7.6. After a 15 min pre-incubation period at 37°C, reaction was started by the addition of the substrate solution (cold AEA + radiolabeled AEA + BSA). Reaction was carried out for 10 min (brain and lung) or 7 min (liver) before termination by the addition of 400 μl activated charcoal suspension (8 g charcoal in 32 mL 0.5 M HCl in continuous agitation). After a 30 min incubation period at room temperature with agitation, charcoal was sedimented by centrifugation in microfuge (10 min at 13000 rpm). 200 μl of the supernatant were added to 800 μl Optiphase Supermix scintillation cocktail previously distributed in 24-well plates. Counts per minute (cpm) were determined in a MicrobetaTriLux scintillation counter.
In each assay blanks (without protein) were prepared.
The percentage of remaining enzymatic activity was calculated with respect to controls (no compound) and after blank subtraction.
The results are reported in Table 4:
Table 4
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
As is evident from the above tests, the compounds of the invention, all of which are characterized by a 5-0-substituted 3-N-phenyl-l,3,4-oxadiazolone structural unit, have unexpectedly high inhibition of FAAH, making these novel compounds promising candidates for medicaments for the treatment or prevention of FAAH-related medical conditions. Furthermore, the surprisingly high FAAH inhibition is evident not only in- vitro but also in-vivo. Furthermore, a comparison of the in-vivo data also demonstrates that the FAAH inhibitory activity of compounds having a 5-0-substituted 3-N-phenyl-l,3,4-oxadiazolone structural unit is characterized by a peripheral selectivity when compared with activity in the central nervous system (CNS).
The above data for a wide range of highly active compounds shows that the 5-0- substituted 3-N-phenyl-l,3,4-oxadiazolone structural unit of the following structure (III),
Figure imgf000115_0001
(HI),
is a highly potent pharmacophore for FAAH inhibition and allows a high degree of variability with regard to the choice of the substituents present on this pharmacophore.
It will be appreciated that the invention may be modified within the scope of the appended claims.

Claims

1. Compound of formula (I),
Figure imgf000116_0001
wherein
R1 to R5 independently from each other represent: hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-C6-alkoxy, Cό-Cio-aryloxy, C6-Cio-aryl-Ci-Cg-alkoxy, Ci-Cβ-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl, C6-Cio-aryl-Ci-C8-alkoxycarbonyl, Ci-Cδ-alkylcarbonyl, Co-Cio-arylcarbonyl, Cβ-Cio-aryl- Ci-Cg-alkylcarbonyl, Ci-Cβ-alkylcarboxy, Cβ-Cio-arylcarboxy, Cj-Ce-alkyhnercaptyl, Ce-Cio-arylmercaptyl, C i-Cβ-alkylmercaptocarbonyl, Cs-Cg-cycloalkylmercaptocarbonyl, C6-Ci0-arylmercaptocarbonyI, d-Cδ-alkylmercaptocarboxy, Cό-Cio-arylmercaptocarboxy, Ci-C6-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-Cό-alkylsulfoxy, C6-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by
Ci-Ce-alkyl; Ci-C6-alkoxy; C6-Ci0-aryloxy; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or Ce-Cio-aryl-Q-C-ralkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, Cβ-Cio-aryl, C6-Cio-aryl- Ci-C4-alkyl, Ci-Cό-alkylcarbonyl, Cδ-Cio-arylcarbonyl, d-Cβ-alkylsulfonyl and C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl,
Cβ-Cio-aryl-Ci-Cβ-alkyl, Ci-Ce-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cβ-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000117_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C6-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, Cό-Cio-aryl or C6-Cio-aryl-Ci-C6-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3,
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
C-Ce-alkyl; C,-C6-alkoxy; COOH; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cδ-alkyl, C6-C10-aryl or C6-CiO-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cιo-aryl, C6-Cio-aryl-Ci-C4-alkyl, Ci-Cβ-alkylcarbonyl, Q-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and
Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 Or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n represents 0 or 1 ; m represents 0, 1, 2, 3, 4, 5 or 6;
X represents O or S;
Y represents: a) hydrogen; b) Ci-Cig-alkyl, mono or polyunsaturated C2-Ci8-alkylene, C3-C8-cycloalkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-C6-alkoxy, C6-Cio-aryloxy, C6-C 10-aryl-C i-Cg-alkoxy, C 1 -C6-alkoxycarbonyl, C6-C 10-aryloxycarbonyl, C6-C 10-aryl-C 1 -Cβ-alkoxycarbonyl, C 1 -Q-alkylcarbonyl, C6-C 10-arylcarbonyl, C6-C 10-aryl-C i-Cs-alkylcarbonyl, Ci-Cό-alkylcarboxy, Cβ-Cio-arylcarboxy, Ci-C6-alkylmercaptyl, CO-C1 o-arylmercaptyl, C 1 -Co-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, C6-C 1 o-arylmercaptocarbony 1, C 1 -Cό-alkylmercaptocarboxy , Cβ-C w-arylmercaptocarboxy, Ci-Cό-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cδ-Cio-arylsulfoxy, or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, wherein each is optionally substituted once or several times by: bl) Ci-Cβ-alkyl, C}-C8-cycloalkyl, C6-Ci0-aryl, C6-C 10-aryl-C i-C8-alkyl, Ci-Cδ-alkoxy, Cβ-Cio-aryloxy, C6-C 10-aryl-C i-C8-alkoxy, Ci -Cβ-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl, C6-C 10-aryl-C 1 -Cβ-alkoxycarbonyl, Ci-Cδ-alkylcarbonyl, Co-Cio-arylcarbonyl, C6-C 10-aryl-C i-Cβ-alkylcarbonyl, Ci-Cβ-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Ce-Cio-arylmercaptyl,
C 1 -Cβ-alkylmercaptocarbonyl, Cs-Cs-cycloalkylmercaptocarbonyl,
C6-Ci o-arylmercaptocarbonyl, C 1 -C6-alky lmercaptocarboxy,
C6-Cio-arylmercaptocarboxy, Ci-C6-alkylsulfonyl, C6-Ci0-arylsulfonyl, Ci-C6-alkylsulfoxy, Cβ-Cio-arylsulfoxy; wherein each is optionally substituted once or several times by Ci-Cβ-alkyl; Ci-C6-alkoxy; CONH2, SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-C6-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, Cδ-Cio-aryl, Cβ-Cio-aryl-Ci-Cβ-alkyl, Ci-Ce-alkylcarbonyl, Co-Cio-arylcarbonyl, CrCδ-alkylsulfonyl and
Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3; wherein several of the substituents in bl) may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or by b2) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; CO2H; SO3H; OCF3; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, C6-Cjo-aryl or Cό-Cio-aryl-Ci-Cβ-alkyl and wherein in the case of a di-Ci-C6-alkyl-substituted amino functionality, the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Ci0-aryl, Cδ-Cio-aryl-Ci-Cg-alkyl, d-Cό-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and Cό-Cio-arylsulfonyl; or a disubstituted amino of the following formula (II)
Figure imgf000119_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Q-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cδ-alkyl, fluoro or chloro; or by b3) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Cj-Cβ-alkyl; Ci-Cβ-alkoxy; COOH; SO3H; CONH2, SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or Cό-Cio-aryl-Ci-Cij-alkyl and wherein in case of a di-Ci-Cή-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, Ci-Cβ-alkylcarbonyl, Cό-Qo-arylcarbonyl, CrCβ-alkylsulfonyl and C6-Cιo-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; c) SO3H; amino; amino substituted one or more times with residues selected from Ci-Ce-alkyl, C6-Ci0-aryl, Ce-Qo-aryl-Ci-Cg-alkyl, Ci-C6-alkylcarbonyl,
Ce-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and C6-Ci0-arylsulfonyl; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cδ-alkyl, Cβ-Cio-aryl or Cβ-Cio-aryl-Ci-Cβ-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo; CF3; or OCF3;
or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof for inhibition of fatty acide amide hydrolyse (FAAH).
2. Compound according to claim 1 wherein R1 to R5 independently from each other represent hydrogen; hydroxyl;
Ci-C6-alkyl, C6-Cio-aryl, CpCό-alkoxy, Cβ-Cio-aryloxy, Cδ-Cio-aryl-Ci-Cδ-alkoxy,
Ci-Co-alkylcarboxy, Ce-Cio-arylcarboxy, Ci-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Cj-Cδ-alkoxy, amino, Ci-Cβ-alkylamino, di-Ci-Cβ-alkylamino, hydroxy, fluoro, chloro, bromo, cyano,
CF3 or OCF3; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl;
1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, optionally substituted with one or more residues selected from Ci-C6-alkyl, amino, fluoro, chloro or CF3; or a disubstituted amino of the following formula (II)
Figure imgf000121_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and d-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Q-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from CrCβ-alkyl or Cβ-Cio-aryl; fluoro; chloro; bromo;
CF3; or
OCF3.
3. Compound according to claim 1 or 2 wherein one or more of R1 to R5 represent hydrogen, fluorine or chlorine.
4. Compound according to claim 3 wherein R1 or R5 represents hydrogen or fluorine.
5. Compound according to any one of claims 1 to 4 wherein one or more of R1 to R5 represent: hydroxy; or
Ci-C6-alkoxy, C6-Ci0-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy, d-Cβ-alkylcarboxy, Cβ-Cio-arylcarboxy, Cj-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cβ-alkoxy, amino, Ci-Cβ-alkylamino, di-Ci-Cδ-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cδ-alkyl or C6-Cιo-aryl, hydroxy, fluoro, chloro, bromo, cyano, CF3 or OCF3.
6. Compound according to claim 5 wherein one of R2, R3 or R4 represents: hydroxy; or Ci-Cό-alkoxy, Cβ-Cio-aryloxy, or Ce-Cio-aryl-Cj-Cβ-alkoxy, each of which is optionally substituted once or several times by Ci-Cδ-alkyl, Ci-C6-alkoxy, amino, Ci-C6-alkylamino, di-Ci-Cό-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with C|-C6-alkyl or Cό-Cio-aryl, hydroxy, fluoro, chloro, or bromo.
7. Compound according to any one of claims 1 to 6 wherein one or more of R1 to R5 represent: amino; amino substituted one or more times with residues selected from Ci-Ce-alkyl, Cβ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000122_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Cj-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Cj-Cό-alkyl, fluoro or chloro.
8. Compound according to claim 7 wherein one of R2, R3 or R4 represents: amino; amino substituted once or twice with residues selected from d-Cβ-alkyl, Cό-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000122_0002
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C6-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cδ-alkyl, fluoro or chloro.
9. Compound according to any one of claims 1 to 8 wherein n represents 0; m represents 0, 1, 2, 3, 4, 5 or 6; and Y represents C3-C6-cycloalkyl or Cό-Cio-aryl, each of which is optionally substituted once or several times by:
a) CrC6-alkyl, C6-Ci0-aryl, C6-Cio-aryl-Cj-C4-alkyl, Ci-C6-alkoxy, C6-Ci0-aryloxy, C6-Cio-aryl-Ci-C4-alkoxy, wherein each is optionally substituted once or several times by:
Ci-C6-alkyl; C»-C6-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 substituted once or twice with Ci-Cδ-alkyl or Cδ-Cio-aryl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl, C6-Ci0-aryl-Ci-C4-alkyl, CrC6-alkylcarbonyl,
Ce-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
or by
b) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-C^-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Cj-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted once or several times with CrC6-alkyl or phenyl; a disubstituted amino of the following formula (II)
Figure imgf000123_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C-j-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro; or by
c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
Ci-C6-alkyl; Ci-C6-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 substituted once or twice with Ci-Cδ-alkyl or Cg-Cio-aryl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Ce-Cio-aryl,
Figure imgf000124_0001
Ci-C6-alkylcaτbonyl,
Cβ-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3.
10. Compound according to claim 9 wherein n represents O; m represents O or 1; and Y represents a phenyl, 1-naphthyl, 2-naphthyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl ring system.
11. Compound according to claim 10 wherein Y is substituted once or several times by Cϊ-Cβ-alkyl; phenyl; Ci-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cβ-alkyl wherein these optional Cj-Cg-alkyl residues may be combined to form 5 or 6-membered rings.
12. Compound according to claim 11 wherein m represents 0 and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo.
13. Compound according to claim 11 wherein m represents 0 and Y represents phenyl which is substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
14. Compound according to claim 1 wherein m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-Cβ-alkyl.
15. Compound according to claim 14 wherein Y represents phenyl which is substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro.
16. Compound according to claim 14 or 15 wherein R1 or R5 represents hydrogen or fluorine.
17. Compound according to any one of claims 14 to 16 wherein R2 or R3 and R4 represent hydroxy.
18. Compound as claimed in any of claims 1 to 17 for treatment of a disorder that is positively influenced by inhibition of FAAH.
19. Compound as claimed in claim 18 wherein the disorder is selected from pain, dizziness, vomiting, and nausea, eating disorders, neurological and psychiatric pathologies, acute and chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, cancers, disorders of the immune system, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions and gastrointestinal diseases.
20. Use of a compound as claimed in any of claims 1 to 17 for inhibition of FAAH.
21. Use of a compound as claimed in any of claims I to 17 for treatment of a disorder that is positively influenced by inhibition of FAAH.
22. Use of a compound as claimed in any of claims 1 to 17 for manufacture of a medicament for the treatment of a disorder that is positively influenced by inhibition of FAAH.
23. Use as claimed in claim 21 or 22 wherein the disorder is selected from pain, dizziness, vomiting, and nausea, eating disorders, neurological and psychiatric pathologies, acute and chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, cancers, disorders of the immune system, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions and gastrointestinal diseases.
24. Compound of formula (I),
Figure imgf000126_0001
(I)5
wherein
R1 to R5 independently from each other represent: hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, Ce-Cio-aryl-Cj-Cg-alkyl, d-Ce-alkoxy,
C6-Cio-aryloxy, Cό-Cio-aryl-Q-Cβ-alkoxy, d-Cβ-alkoxycarbonyl, CO-C1 o-aryloxycarbonyl,
Cδ-Cio-aryl-Ci-Cg-alkoxycarbonyl, Ci-Cδ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Cό-Cio-aryl-
Ci-Cg-alkylcarbonyl, Ci-Cδ-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-Cό-alkylmercaptyl,
Cδ-Cio-arylmercaptyl, Ci-Cό-alkylmercaptocarbonyl, Cs-Cs-cycloalkylmercaptocarbonyl,
Cδ-Cio-arylmercaptocarbonyl, Ci-Cβ-alkylmercaptocarboxy, Cβ-Cio-arylmercaptocarboxy,
Ci-C6-alkylsulfonyl, C6-Cio-arylsulfonyl, d-Cδ-alkylsulfoxy, Co-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by
Ci-C6-alkyl; Ci-C6-alkoxy; C6-Ci0-aryloxy; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from
Figure imgf000126_0002
Cό-do-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from d-Cό-alkyl, Cδ-Cjo-aryl, Cδ-Cjo-aryl- Ci-C4-alkyl, Ci-Cό-alkylcarbonyl, Co-Cio-arylcarbonyl, Q-Cβ-alkylsulfonyl and Ce-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cό-alkyl, Cβ-Cio-aryl,
C6-Cio-aryl-Ci-C6-alkyl, C^Ce-alkylcarbonyl, C6-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cδ-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000127_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or Cβ-Cto-aryl-Ci-Cδ-alkyl and wherein in the case of a di-Ci-Cg-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
CrCe-alkyl; Ci-C6-alkoxy; COOH; SO3H;, CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or Cδ-Cio-aryl-Ci-Ct-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl, C6-Cio-aryl-C1-C4-alkyl, Ci-Cδ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and
Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n represents 0 or 1; m represents 0, 1, 2, 3, 4, 5 or 6;
X represents O or S;
Y represents: a) hydrogen; b) Ci-Cis-alkyl, mono or polyunsaturated C2-Ci8-alkylene, C3-C8-cycloaIkyl, Cβ-Cio-aryl, C6-C|o-aryl-Ci-C8-alkyl, CrCβ-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cs-alkoxy, Ci-C6-alkoxycarbonyl, Ce-Cio-aryloxycarbonyl, Ce-Cio-aryl-Ci-Cβ-alkoxycarbonyl, Ci-Co-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Co-Cio-aryl-Ci-Cs-alkylcarbonyl, Ci-Cβ-alkylcarboxy, Ce-C io-arylcarboxy, Cj-Cβ-alkylmercaptyl, Cβ-Cio-arylmercaptyl, Ci-Cs-alkylmercaptocarbonyl, Cs-Cβ-cycloalkymiercaptocarbonyl, Cδ-Cio-arylmercaptocarbonyl, Ci-Cβ-alkylmercaptocarboxy, Cδ-Cio-arylmercaptocarboxy, Ci-Cδ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cδ-Cio-arylsulfoxy, or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, wherein each is optionally substituted once or several times by: bl) Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, Ce-Cio-aryl-d-Cβ-alkyl, Ci-Cβ-alkoxy,
Figure imgf000128_0001
Cβ-Cio-aryl-Ci-Cs-alkoxy, Ci-Cδ-alkoxycarbonyl, CO-C [o-aryloxycarbonyl, CO-C 10-aryl-C 1 -Cs-alkoxycarbonyl, C 1 -Cβ-alkylcarbonyl, C6-Cj o-arylcarbonyl, C6-C 1 o-ary 1-C 1 -Cβ-alkylcarbonyl, C i -Cβ-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Ce-Cio-arylmercaptyl,
C 1 -Cδ-alkylmercaptocarbonyl, Cs-Cs-cycloalkylmercaptocarbonyl,
C6-Cio-arylmercaptocarbonyl, Ci-Cδ-alkylmercaptocarboxy,
C6-Cio-aryImercaptocarboxy, Ci-Cβ-alkylsulfonyl, Ce-Cto-arylsulfonyl, Ci-C6-alkylsulfoxy, C6-Cio-arylsulfoxy; wherein each is optionally substituted once or several times by Ci-C6-alkyl; Ci-C6-alkoxy; CONH2, SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-Q-alkyl, C6-C10-aryl, Cβ-Cio-aryl-Ci-Cδ-alkyl, Ci-Cδ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and
Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3; wherein several of the substituents in bl) may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or by b2) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; CO2H; SO3H; OCF3; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cg-alkyl, Cδ-Cio-aryl or Cό-Cio-aryl-Ci-Q-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality, the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl, Ce-Cio-aryl-Ci-Cs-alkyl, Ci-Ce-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cβ-Cto-arylsulfonyl; or a disubstituted amino of the following formula (II)
→r\
MO ' (II)
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro; or by b3) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cδ-alkyl; Cj-Cβ-alkoxy; COOH; SO3H;, CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cto-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cό-Cto-aryl, Cβ-Cio-aryl-Ci-C-j-alkyl, Ci-Cδ-alkylcarbonyl, Cό-Cio-arylcarbonyl, CrCδ-alkylsulfonyl and Cg-Cto-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; c) SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Ci0-aryl, Cβ-Cio-aryl-CrCg-alkyl, d-Cβ-alkylcarbonyl,
Ce-Cio-arylcarbonyl, CrC6-alkylsulfonyl and C6-Cio-arylsulfonyl; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, C6-Cκraryl or Cβ-Cio-aryl-CrCδ-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo; CF3; or OCF3;
with the proviso that in case n represents 0 and m represents 0:
a) R2 or R4 do not represent the substituent C(=A)-N(B)-SO2-NR6R7, wherein A represents O or S, B represents hydrogen, cyano, Ci-Cβ-alkyl, Ci-Cβ-alkoxy-alkyl, C3-C7-cycloalkyl, C3-C6-alkenyl, C3-C6-alkynyl or optionally substituted benzyl derivatives, and R6 and R7 independently from each other represent hydrogen or an organic residue, or together an organic cyclic structure; that
b) R1 to R5 independently from each other do not represent hydrogen, fluoro, bromo, chloro, iodo or an alkyl radical when Y represents unsubstituted phenyl; that
c) R2 or R4 do not represent a pyrazol-3-yl-derivative; and that
d) the phenyl ring substituted with R1 to R5 and Y do not represent the following combinations:
Figure imgf000131_0001
and with the further proviso that in case n represents 0 and m represents 1 that Y does not represent unsubstituted phenyl if R1, R2 and R5 represent hydrogen, R4 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, benzyloxy, phenoxy, phenyl, 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl and
R3 represents hydrogen, trifluoromethoxy, trifluorobutoxy,
3,3,5,5-tetramethylcyclohexyloxy, phenoxy, 4-chlorophenoxy, cyclohexyl, phenyl, morpholinosulfonyl, 3,3,5-trimethylcyclohexylaminosulfonyl, 2,2,6,6-tetramethylpiperidin-4-ylaminosulfonyl, 2-(diisopropylaminoethyl)aminosulfonyl, 4-methylpiperazin-l-yl-sulfonyl, 3,3-dimethylpiperidinocarbonyl or 3,5-dichlorophenoxy 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl;
and with the further proviso that in case m=0 and n=0 Y does not represent Ci-C-j-alkyl;
and with the further proviso that the compound is not one of the following compounds:
5-phenoxy-3-phenyl-(l,3,4)-oxadiazolin-2-one
5-Dodecyloxy-3- (4-trifluoπnethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3- (4-trifluoπnethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one
5-Octyloxy-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3- (3-trifluormethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3-(4-(4-chlorphenoxy)-phenyl)-3H-(l,3,4)-oxadiazol-2-one
5-Octyloxy-3-phenyl-3H- (1 ,3,4)-oxadiazol-2-one
5-Octyloxy-3- (3-fluor-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3- (3-fluor-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3- (3-benzyloxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3-phenyl-3H- (1 ,3,4)-oxadiazol-2-one
5-Hexadecy!oxy-3- (4-nitro-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3- (4-methoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Hexadecyloxy-3- (4-benzyloxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Decyloxy-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Undecyloxy-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-Tetradecyloxy-3- (4-trifluormethoxy-phenyl)-3H- (1 ,3,4)-oxadiazol-2-one
5-Tridecyloxy-3-(4-trifluoromethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one
5- (2- (2-Hexyloxy-ethoxy)-ethoxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-
2- one
5- ((Z)-Octadec-9-enyloxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one 5-
(Dodecyloxy-ethoxy)-3- (4-trifluormethoxy-phenyl)-3H- ( 1 ,3,4)-oxadiazol-2-one
5- (2- (4-Fluorphenyl)-ethoxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-((3ss-Cholestan-3-yl)-oxy)--3-(4-trifluoromethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one
5-(2-Butoxy-ethoxy)-3-(4-trifluormethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one 5- (7-Phenyl-heptyloxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one ,
5- (Docosyloxy-ethoxy)-3- (4-trifluoπnethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5- (2- (l-Naphthloxy)-ethoxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5-(4-Octylphenoxy)-3-(4-trifluormethoxy-phenyl)-3H-(l,3,4)-oxadiazol-2-one
5- (3-Phenoxy-phenoxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5- (Dodecyloxy)-3- (4-trifluormethoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5- (Dodecyloxy)-3- (3, 4-dichlor-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5- (Dodecyloxy)-3- (3, 5-dichlor-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5- (Dodecyloxy)-3- (3-methoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one
5- (Dodecyloxy)-3- (4-methoxy-phenyl)-3H- (l,3,4)-oxadiazol-2-one; or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
25. Compound according to claim 24 wherein R1 to R5 independently from each other represent hydrogen; hydroxyl;
Ci-Cβ-alkyl, Cό-Cio-aryl, Ci-C6-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cό-alkoxy, Cj-C6-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Cβ-alkylsulfonyl, Cό-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Cj-Cβ-alkoxy, amino, Ci-Cβ-alkylamino, di-Ci-Cό-alkylamino, hydroxy, fluoro, chloro, bromo, cyano, CF3 or OCF3; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, Cδ-Cio-aryl; 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, optionally substituted with one or more residues selected from CpCβ-alkyl, amino, fluoro, chloro or CFj1 a disubstituted amino of the following formula (H)
Figure imgf000133_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cδ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cό-alkyl, fluoro or chloro; CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl or C6-Cio-aryl; fluoro; chloro; bromo;
CF3; or
OCF3.
26. Compound according to claim 24 or 25 wherein one or more of R1 to R5 represent hydrogen, fluorine or chlorine.
27. Compound according to claim 26 wherein R1 or R5 represents hydrogen or fluorine.
28. Compound according to any one of claims 24 to 27 wherein one or more of R1 to R5 represent: hydroxy; or
Ci-Cδ-alkoxy, Cβ-Cio-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy, Ci-Cβ-alkylcarboxy, Cβ-Cio-arylcarboxy, Ci-Cβ-alkylsulfonyl,
Figure imgf000134_0001
wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cδ-alkoxy, amino, Ci-Cδ-alkylamino, di-Ci-Cβ-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-C6-alkyl or Cδ-Cio-aryl, hydroxy, fluoro, chloro, bromo, cyano, CF3 or OCF3.
29. Compound according to claim 28 wherein one of R2, R3 or R4 represents: hydroxy; or
Cj-Cό-alkoxy, Cβ-Cio-aryloxy, or Cβ-Cio-aryl-Ci-Cβ-alkoxy, each of which is optionally substituted once or several times by Ci-Cδ-alkyl, Ci-Cδ-alkoxy, amino, Ci-Cβ-alkylamino, di-CrC6-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cβ-alkyl or Cό-Cio-aryl, hydroxy, fluoro, chloro, or bromo.
30. Compound according to any one of claims 24 to 29 wherein one or more of R1 to R5 represent: amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cό-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000135_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cδ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with d-Cό-alkyl, fluoro or chloro.
31. Compound according to claim 30 wherein one of R2, R3 or R4 represents: amino; amino substituted once or twice with residues selected from C]-C6-alkyl, Cβ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000135_0002
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cδ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro.
32. Compound according to any one of claims 24 to 31 wherein n represents 0; m represents 0, 1, 2, 3, 4, 5 or 6; and Y represents C3-C6-cycloalkyl or Cβ-Cio-aryl, each of which is optionally substituted once or several times by:
a) Ci-C6-alkyl, C6-Ci0-aryl,
Figure imgf000135_0003
C6-C10-aryloxy, Cδ-Cio-aryl-Ci-C^alkoxy, wherein each is optionally substituted once or several times by; d-Cβ-alkyl; Ci-C6-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 substituted once or twice with Ci-Cβ-alkyl or C6-Cio-aryl; SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl, C6-C|0-aryl-Ci-C4-alkyl, Ci-Cβ-alkylcarbonyl,
C6-C10-arylcarbonyl, d-Cβ-alkylsulfonyl and C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
or by
b) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or Cδ-Cio-aryl-Ci-C-t-alkyl and wherein in case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted once or several times with Cj-Cό-alkyl or phenyl; a disubstituted amino of the following formula (II)
Figure imgf000136_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C-j-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C-ralkyl, fluoro or chloro;
or by
c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
C,-C6-alkyl; C,-C6-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 substituted once or twice with Ci-Cβ-alkyl or C6-Cio-aryl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3.
33. Compound according to claim 32 wherein n represents 0; m represents 0 or 1; and Y represents a phenyl, 1-naphthyl, 2-naphthyl, 2-pyridinyl, 3-pyridinyl or 4-pyridinyI ring system.
34. Compound according to claim 33 wherein Y is substituted once or several times by Ci-C6-alkyl; phenyl; Ci-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cδ-alkyl wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6-membered rings.
35. Compound according to claim 34 wherein m represents 0 and Y represents phenyl which is substituted once or twice by hydroxy, fluoro, chloro or bromo.
36. Compound according to claim 34 wherein m represents 0 and Y represents phenyl which is substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
37. Compound according to claim 24 wherein m is 0; n is 0; Y represents phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Cj-Cό-alkyl.
38. Compound according to claim 37 wherein Y represents phenyl which is substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, or in the 2- and 4-position by chloro.
39. Compound according to claim 37 or 38 wherein R1 or R5 represents hydrogen or fluorine.
40. Compound according to any one of claims 37 to 39 wherein R2 or R3 and R4 represent hydroxy.
41. Compound of formula (I),
Figure imgf000138_0001
(IX
wherein
R1 to R5 independently from each other represent: hydrogen;
CrC6-alkyl, C3-C8-cycloalkyl, C6-C10-aryl, Ce-Cio-aryl-d-Cβ-alkyl, Ci-C6-alkoxy, Cδ-Cio-aryloxy, Cό-Cio-aryl-CrCs-alkoxy, d-Cό-alkoxycarbonyl,
Figure imgf000138_0002
Cδ-Cio-aryl-Ci-Cg-alkoxycarbonyl, Q-Ce-alkylcarbonyl, Cό-Cio-arylcarbonyl, C6-Cio-aryl- d-Ce-alkylcarbonyl, Ci-Cδ-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Cδ-Cjo-arylmercaptyl, Ci-Cβ-alkylmercaptocarbonyl, Cs-Cβ-cycloalkylmercaptocarbonyl, Cό-Cio-arylmercaptocarbonyl, Ci-C6-alkyknercaptocarboxy, Cδ-Cio-arylmercaptocarboxy, Ci-Cδ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cδ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by
Ci-Ce-alkyl; Ci-C6-alkoxy; C6-Ci0-aryloxy; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or C6-Cio-aryl-Cj-C4-alkyl and wherein in case of a di-Ci-Cδ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl, Cδ-Cio-aryl- Ci-C4-alkyl, Ci-Cδ-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and CO-C1 o-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cδ-alkyl, Cβ-Cio-aryl, C6-Cio-aryl-C|-C6-alkyl, Ci-Cβ-alkylcarbonyl, Co-Cio-arylcarbonyl, d-Cό-alkylsulfonyl and C6-Cio-arylsulfonyl; a disubstituted amino of the following formula (H)
Figure imgf000139_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cό-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Cj-Cβ-alkyl, Cβ-Cio-aryl or Cβ-Cio-aryl-Ci-Cό-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
Ci-Ce-alkyl; Ci-Ce-alkoxy; COOH; SO3H;, CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-C6-alkyl, Cβ-Cio-aryl or C6-CiO-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-Cβ-alky .-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl, Cβ-Cio-aryl-Ci-C-ralkyl, Ci-Cδ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, d-Cό-alkylsulfonyl and
Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n represents 0; m represents 0;
Y represents phenyl which is optionally substituted once or several times by
a) Ci-Cδ-alkyl, Cό-Cio-aryl, Cδ-Cio-aryl-Ci-Cg-alkyl, Ci-C6-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Q-Cβ-alkoxy, Ci-Cβ-alkoxycarbonyl, Cδ-Cio-aryloxycarbonyl, Cό-Cio-aryl- CrCβ-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Ce-do-arylcarbonyl, Cβ-Cio-aryl- Ci-Cβ-alkylcarbonyl, Ci-Cό-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Ce-alkylmercaptyl, Ce-Cio-arylmercaptyl, Ci-Cβ-alkyhnercaptocarbonyl, C3-Cg-cycloalkylmercaptocarbonyl, Cό-Cjo-arylmercaptocarbonyl, Ci-Cβ-alkylmercaptocarboxy, C6-Cio-arylmercaptocarboxy, Ci-Cβ-alkylsulfonyl, C6-Cio-arylsulfonyl, Cj-Cδ-alkylsulfoxy, Cδ-Cio-arylsulfoxy;
each of which is optionally substituted once or several times by Ci-C6-alkyl; Ci-Cβ-alkoxy; CONH2 or SO2NH2, optionally substituted once or twice with d-Cβ-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl, Cβ-Cio-aryl-Ci-C-ralkyl, Ci-Cό-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Cό-alkylsulfonyl and
Cβ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
wherein several of these optional substituents may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or
b) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Cj-Cβ-alkyl; Ci-Cβ-alkoxy; COOH; CONH2 or SO2NH2, optionally substituted once or twice with Ci-Cδ-alkyl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cδ-alkyl, Cό-Cio-aryl, Ce-C1O-BTyI-Ci-C4-OIlCyI, Ci-Cό-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; or
c) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cδ-Cio-aryl or Cβ-Cio-aryl- Ci-C-t-alkyl and wherein in case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Cϊ-Cδ-alkyl, C6-Cio-aryl, Cβ-Cio-aryl- Ci-Cs-alkyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-Cό-alkylsulfonyl and Cδ-Qo-arylsulfonyl; a disubstituted amino of the following formula (FV)
Figure imgf000141_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Cj-C4-alkyl and wherein the methylene groups in formula (IV) may optionally be substituted once or twice with Ci-C4-alkyl, fluoro or chloro;
or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof with the proviso that
a) R2 or R4 do not represent the substituent Q=A)-N(B)-SO2-NR6R7, wherein A represents O or S, B represents hydrogen, cyano, Ci-Cβ-alkyl, Ci-Cδ-alkoxy-alkyl, C3-C7-cycloalkyl, C3-C6-alkenyl, C3-C6-alkynyl or optionally substituted benzyl derivatives, and R6 and R7 independently from each other represent hydrogen or an organic residue, or together an organic cyclic structure; that
b) R1 to R5 independently from each other do not represent hydrogen, fluoro, bromo, chloro, iodo or an alkyl radical when Y represents unsubstituted phenyl; that c) R2 or R4 do not represent a pyrazol-3-yl-derivative; and that
d) the phenyl ring substituted with R1 to R5 and Y do not represent the following combinations:
Figure imgf000142_0001
42. Compound according to claim 41 wherein R1 to R5 independently from each other represent: hydrogen; hydroxy 1;
Ci-Cβ-alkyl, Cβ-Cio-aryl, Cj-Cβ-alkoxy, C6-Cio-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy,
Ci-Co-alkylcarboxy, C6-Cio-arylcarboxy, d-C6-alkylsulfonyl, C6-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-C6-alkyl, Ct-Cβ-alkoxy, amino, Ci-C6-alkylamino, di-Ci-Cβ-alkylamino, hydroxy, fluoro, chloro, bromo, cyano,
CF3 or OCF3; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl;
1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, optionally substituted with one or more residues selected from Ci-Cβ-alkyl, amino, fluoro, chloro or CF3, a disubstituted amino of the following formula (II)
Figure imgf000143_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cδ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Cj-Cβ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl or Cό-Cio-aryl; fluoro; chloro; bromo;
CF3; or
OCF3.
43. Compound according to claim 41 or 42 wherein one or more of R1 to R5 represent hydrogen, fluorine or chlorine.
44. Compound according to claim 43 wherein R1 or R5 represents hydrogen or fluorine.
45. Compound according to any one of claims 41 to 44 wherein one or more of R1 to R5 represent: hydroxy; or
Ci-C6-alkoxy, Cβ-Cio-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy, Cj-Cδ-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Cβ-alkylsulfonyl, Cδ-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-C^-alkyl, Ci-Cβ-alkoxy, amino, Cj-Cβ-alkylamino, di-Ci-Cδ-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Q-Cό-alkyl or Cβ-Cio-aryl, hydroxy, fluoro, chloro, bromo, cyano, CF3 or OCF3.
46. Compound according to claim 45 wherein one of R2, R3 or R4 represents hydroxy; or Ci-Cό-alkoxy, Cβ-Cio-aryloxy, or Cδ-Cio-aryl-Ci-Cδ-alkoxy, each of which is optionally substituted once or several times by Ci-Cβ-alkyl, d-Cβ-alkoxy, amino, Ci-Cδ-alkylamino, di-Ci-Cβ-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cβ-alkyl or C6-Cio-aryl, hydroxy, fluoro, chloro, or bromo.
47. Compound according to any one of claims 41 to 46 wherein one or more of R1 to R5 represent amino; amino substituted one or more times with residues selected from Ci-Cδ-alkyl, Cβ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000144_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cδ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro.
48. Compound according to claim 47 wherein one of R2, R3 or R4 represents amino; amino substituted once or twice with residues selected from Ci-Cβ-alkyl, C6-C10-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000145_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro.
49. Compound according to any one of claims 41 to 48 wherein Y representing phenyl is substituted once or several times by:
a) d-Cβ-alkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C6-alkyl, C|-C6-alkoxy, C6-Cio-aryloxy, Ce-Cio-aryl-CrCδ-alkoxy, wherein each is optionally substituted once or several times by: Ci-Cβ-alkyl; Cj-Cβ-alkoxy; SO3H; CO2H; amino; amino substituted one or more times with residues selected from CpQ-alkyl, Cβ-Cio-aryl, Cβ-Cio-aryl- Ci-Cβ-alkyl, Ci-Ce-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; CONH2; SO2NH2; OCF3; or CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl; or by b) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; or CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cό-alkyl, Cό-Cio-aryl, Cβ-Cio-aryl-Ci-Ce-alkyl, wherein in the case of a di-Ci-Cβ-alkyl substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted once or several times with Ci-Cβ-alkyl or phenyl; a disubstituted amino of the following formula (II)
Figure imgf000145_0002
(II) wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and CrCβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Cj -Cs -alky], fluoro or chloro; or by c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl; Ci-Cβ-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl which may be combined to form 5 or 6-membered rings; SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Ci0-aryl, C6-Ci0-aryl-Ci-C6-alkyl, d-Ce-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and Cό-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3.
50. Compound according to claim 49 wherein Y is phenyl substituted once or several times by Ci-C6-alkyl; phenyl; Q-Cδ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Ci-Cβ-alkyl, wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6-membered rings.
51. Compound according to claim 50 wherein Y is phenyl substituted once or twice by hydroxy, fluoro, chloro or bromo.
52. Compound according to claim 50 wherein Y is phenyl substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
53. Compound according to claim 41 wherein Y is phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-Cβ-alkyl.
54. Compound according to claim 53 wherein Y is phenyl substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro or in the 2- and 4-position by chloro.
55. Compound according to claim 53 or 54 wherein R1 or R5 represents fluorine or hydrogen.
56. Compound according to any one of claims 53 to 55 wherein R3 or R3 and R4 represent hydroxy.
57. Compound of formula (I),
Figure imgf000147_0001
(I),
wherein R1 or R5 is hydrogen or fluorine;
any one of R2 to R4 represents hydroxyl and remaining R residues are hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, C6-C10-aryl-Ci-Cg-alkyl, Ci-C6-alkoxy,
Cβ-Cio-aryloxy, C6-Cιo-aryl-Ci-C8-alkoxy, Ci-Cδ-alkoxycarbonyl, Cβ-Qo-aryloxycarbonyl,
C6-Cio-aryl-Ci-C8-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Cό-Cio-aryl-
Cϊ-Cg-alkylcarbonyl, Ci-C6-alkylcarboxy, Ce-Cio-arylcarboxy, Ci-Cδ-alkylmercaptyl,
Cδ-Cio-arylmercaptyl, Ci-Co-alkylmercaptocarbonyl, Cs-Cg-cycloalkymiercaptocarbonyl,
Cβ-Cio-arylmercaptocarbonyl, Ci-Cβ-alkylmercaptocarboxy, Cό-Cio-arylmercaptocarboxy,
Ci-Cβ-alkylsulfonyl, Cβ-Cto-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cβ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-C6-alkoxy,
Cδ-Cio-aryloxy, CO2H, SO3H, amino, C[-C6-alkylamino, di-Ci-Cβ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
CO2H;
SO3H; amino; amino substituted one or more times with residues selected from Ci-CValkyl, Cβ-Cio-aryl, Cό-Cio-aryl-Ci-Cό-alkyl, Ci-Qs-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and C6-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000148_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cή-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or Ce-Cio-aryl-Ci-Cβ-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; and wherein two or more of R2 to R4 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n and m are O; and Y is phenyl substituted once or several times by Ci-Cβ-alkyl; phenyl; CpCβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with C|-C6-alkyl wherein these optional Ci-C6-alkyl residues may be combined to form 5 or 6-membered rings; or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
58. Compound of formula (I),
Figure imgf000149_0001
(I), wherein R1 or R5 is hydrogen or fluorine;
any one of R2 to R4 represents amino and remaining R residues are hydrogen;
Ci-Cβ-alkyl, C3-C8-cycloalkyl, C6-Cio-aryl, C6-C,0-aryl-Ci-C8-aIkyl, d-C6-alkoxy,
Cδ-Cio-aryloxy, C6-Cio-aryl-Ci-C8-alkoxy, Ci-C6-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl,
C6-Cio-aryl-Ci-C8-alkoxycarbonyl, Cj-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, C6-Cio-aryl-
Ci-Cg-alkylcarbonyl, Ci-Cό-alkylcarboxy, Cβ-Cio-arylcarboxy, d-Cδ-alkylmercaptyl,
Co-Cio-arylmercaptyl, Cj-Ce-alkylmercaptocarbonyl, Cs-Cg-cycloalkylmercaptocarbonyl,
C6-Cio-arylmercaptocarbonyl, Ci-C6-alkylmercaptocarboxy, C6-Cio-arylmercaptocarboxy,
CrC6-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-Cδ-alkylsulfoxy, C^-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, d-Cδ-alkoxy,
C6-Cio-aryloxy, CO2H, SO3H, amino, C]-C6-alkylamino, di-Ci-Cδ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
CO2H;
SO3H; amino; amino substituted one or more times with residues selected from CpCβ-alkyl, Cβ-Cio-aryl,
Ce-Cio-aryl-Ci-Cβ-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Cj-Cό-alkylsulfonyl and Cβ-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000150_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Q-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cδ-alkyl, Cβ-Cio-aryl or Cβ-Cio-aryl-Ci-Cδ-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-C6-alkyl, Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; and wherein any two or more of R2 to R4 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n and m are O; and
Y is phenyl substituted once or several times by Ci-Cβ-alkyl; phenyl; Ci-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Ci-C6-alkyl wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6-membered rings, or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
59. Compound of formula (I),
Figure imgf000151_0001
(I),
wherein R1 or R5 is hydrogen or fluorine;
one of R3 or R4 is Ci-C6-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cs-alkoxy, Ci-Cβ-alkylcarboxy, Ce-Cio-arylcarboxy, Ci-Cό-alkylmercaptocarboxy,
Cδ-Cio-arylmercaptocarboxy, Ci-Cβ-alkylsulfoxy, Cδ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cβ-alkoxy, Cβ-Cio-aryloxy, CO2H, SO3H, amino, Ci-Cβ-alkylamino, di-Cj-Cβ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
the other of R3 or R4 is amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Ci0-aryl, Cβ-Cio-aryl-d-Cβ-alkyl, Ci-Cβ-alkylcarbonyl,
Cό-Cio-arylcarbonyl, Ci-Cg-alkylsulfonyl and Cό-Cio-arylsulfonyl;
and R2 is: hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Cio-aryl, C6-C,o-aryl-Ci-C8-aIkyl, d-Ce-alkoxy, C6-Cio-aryloxy, C6-Ci0-aryl-CrC8-alkoxy, Ci-C6-alkoxycarbonyl, Cδ-Cio-aryloxycarbonyl, C6-Cio-aryl-Ci-Ce-alkoxycarbonyl, Ci-Cδ-alkylcarbonyl, Co-Cio-arylcarbonyl, C6-C10-aryl- C^Cs-alkylcarbonyl, Ci-C6-alkylcarboxy, Cβ-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, Co-Cio-arylmercaptyl, Ci-Ce-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, C6-Ci o-arylmercaptocarbonyl, C 1 -Cβ-alkylmercaptocarboxy , C6-C lo-arylmercaptocarboxy , Ci-C6-alkylsulfonyl, Cβ-Cio-arylsulfonyl, d-Cό-alkylsulfoxy, Cδ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cδ-alkoxy,
Cδ-Cio-aryloxy, CO2H, SO3H, amino, Ci-Cδ-alkylamino, di-Ci-Cβ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
CO2H;
SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl,
Cό-Cio-aryl-Ci-Cβ-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cό-alkylsulfonyl and Cό-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000152_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Cj-Cβ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or C6-Cio-aryl-Ci-C6-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3,
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
n and m are 0; and
Y is phenyl substituted once or several times by Ci-Cβ-alkyl; phenyl; Cj-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Ci-Cβ-alkyl wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6-membered rings, or a stereoisomer, pharmaceutically acceptable salt or ester, or prodrug thereof.
60. Compound according to any of claims 57 to 59 wherein Y is phenyl substituted once or several times by Ci-Cδ-alkyl; phenyl; Ci-Cβ-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; or CONH2 optionally substituted once or twice with Ci-Cβ-alkyl, wherein these optional Ci-Cβ-alkyl residues may be combined to form 5 or 6-membered rings.
61 Compound according to claim 60 wherein Y is phenyl substituted once or twice by hydroxy, fluoro, chloro or bromo.
62. Compound according to claim 60 wherein Y is phenyl substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
63. Compound of formula (I),
Figure imgf000153_0001
(I)
wherein R1 to R5 independently from each other represent: hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, Q-Cio-aryl-Ci-Cs-alkyl, Ci-C6-alkoxy, Cβ-Cio-aryloxy, Cβ-Cio-aryl-Ct-Cg-alkoxy, Ci-Cβ-alkoxycarbonyl, Cδ-Cio-aryloxycarbonyl, Cβ-Cio-aryl-Ci-Cg-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Co-Cw-aryl- Ci-Cg-alkylcarbonyl, Ci-C6-alkylcarboxy, Cδ-Cio-arylcarboxy, Ci-Cό-alkylmercaptyl, Cβ-Cio-arylmercaptyl, Ci-C6-alkylmercaptocarbonyl, Cs-Cg-cycloalkylmercaptocarbonyl, C6-Cio-arylmercaptocarbonyl, Ci-Cβ-alkylmercaptocarboxy, Cδ-Cio-arylmercaptocarboxy, Ci-Cβ-alkylsulfonyl, Cβ-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cό-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by
Ci-Ce-alkyl; CrC6-alkoxy; C6-Ci0-aryloxy; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Ci-Cδ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl, C6-Cio-aryl- Ci-Gt-alkyl, Ci-Ce-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cδ-Cto-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; CO2H; SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, Cδ-Cio-aryl, C6-Cio-aryl-Ci-C6-alkyl, Ci-Cό-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and Cδ-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000154_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Cj-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cδ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cβ-alkyl, C6-Cιo-aryl or Cδ-Cio-aryl-Ci-Cδ-alkyl and wherein in the case of a di-Ci-Cδ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3;
OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by
Ci-Cβ-alkyl; C,-C6-alkoxy; COOH; SO3H;, CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl or C6-Cio-aryl-Ci-C4-alkyl and wherein in case of a di-Cj-Cό-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl, Ce-C io-aryl-Ci -Chalky 1, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cg-alkylsulfonyl and
C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
n represents O; m represents 1 ; Y represents phenyl which is optionally substituted once or several times by a) Ci-Qs-alkyl, C6-Ci0-aryl, C6-Cio-aryl-Ci-C8-alkyl, Ci-C6-alkoxy, C6-Ci0-aryloxy, C6-Cio-aryl-Ci-C8-alkoxy, Ci-Cβ-alkoxycarbonyl, Cδ-Cw-aryloxycarbonyl, C6-CiO-aryl- Ci-Cg-alkoxycarbonyl, Ci-Cό-alkylcarbonyl, Cό-Cio-arylcarbonyl, C6-Cio-aryl- Ci-Cβ-alkylcarbonyl, Ci-Cβ-alkylcarboxy, Cβ-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl, C6-C i o-ary lmercaptyl, C i -C6-alky Imercaptocarbonyl, C3 -Cs-cycloalkylmercaptocarbonyl, Ce-C 1 o-arylmercaptocarbonyl, C 1 -Cβ-alkylmercaptocarboxy, Cδ-C 1 o-ary lmercaptocarboxy, Ci-Cδ-alkylsulfonyl, C6-Cio-arylsulfonyl, Ci-Cβ-alkylsulfoxy, Cβ-Cio-arylsulfoxy;
each of which is optionally substituted once or several times by Ci-Cβ-alkyl; Ci-C6-alkoxy; CONH2 or SO2NH2, optionally substituted once or twice with Ci-Cδ-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl, C6-Cio-aryl-Ci-C4-alkyl, Ci-Ce-alkylcarbonyl, Cδ-C^-arylcarbonyl, Ci-C6-alkylsulfonyl and
Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3;
wherein several of these optional substituents may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or
b) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cδ-alkyl; Ci-Cβ-alkoxy; COOH; CONH2 or SO2NH2, optionally substituted once or twice with d-Cό-alkyl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryi, C6-Cio-aryl-Ci-C4-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3 or OCF3; or
c) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl or C6-Cio-aryl- Ci-C4-alkyl and wherein in case of a di-Ci-C6-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-Q-alkyl, Cδ-Cio-aryl, Cζ-Cio-aryl- Ci-Cβ-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and Cβ-Cto-arylsulfonyl; a disubstituted amino of the following formula (IV)
Figure imgf000157_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C-j-alkyl and wherein the methylene groups in formula (IV) may optionally be substituted once or twice with Ci-Gj-alkyl, fluoro or chloro;
with the proviso that Y does not represent unsubstituted phenyl if R1, R2 and R5 represent hydrogen, R4 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, benzyloxy, phenoxy, phenyl, 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl and R3 represents hydrogen, trifluoromethoxy, trifluorobutoxy, 3,3,5,5-tetramethylcyclohexyloxy, phenoxy, 4-chlorophenoxy, cyclohexyl, phenyl, morpholinosulfonyl, 3,3,5-trimethylcyclohexylaminosulfonyl,
2,2,6,6-tetramethylpiperidin-4-ylaminosulfonyl, 2-(diisopropylaminoethyl)aminosulfonyl, 4-methylpiperazin-l-yl-sulfonyl, 3,3-dimethylpiperidinocarbonyl or 3,5-dichlorophenoxy 2-dimethylaminoethyloxy or 3-methylphenoxy-methyl.
64. Compound according to claim 63 wherein R1 to R5 independently from each other represent: hydrogen; hydroxyl;
Ci-C6-alkyl, Cβ-Cio-aryl, d-Cδ-alkoxy, C6-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cδ-alkoxy,
Ci-C6-alkylcarboxy, Ce-Cio-arylcarboxy, CrCδ-alkylsulfonyl, C6-Cio-arylsulfonyl, wherein each is optionally substituted once or several times by Cj-Cβ-alkyl, Ci-C6-alkoxy, amino, Ci-Cδ-alkylamino, di-Ci-C6-alkylamino, hydroxy, fluoro, chloro, bromo, cyano,
CF3 or OCF3; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl; 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, optionally substituted with one or more residues selected from Cj-Cβ-alkyl, amino, fluoro, chloro or CF3> a disubstituted amino of the following formula (II)
Figure imgf000158_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-C6-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cό-alkyl or Cβ-Cio-aryl; fluoro; chloro; bromo;
CF3; or
OCF3.
65. Compound according to claim 63 or 64 wherein one or more of R1 to R5 represent hydrogen, fluorine or chlorine.
66. Compound according to claim 65 wherein R1 or R5 represents hydrogen or fluorine.
67. Compound according to any one of claims 63 to 66 wherein one or more of R1 to R5 represent hydroxy; or
Ci-C6-alkoxy, Cό-Cio-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy, C]-C6-alkylcarboxy, Cή-Cjo-arylcarboxy, Ci-Cβ-alkylsulfonyl, C6-Ci0-arylsulfonyl, wherein each is optionally substituted once or several times by Ci-Cβ-alkyl, Ci-Cβ-alkoxy, amino, Ci-Cβ-alkylamino, di-Ci-Cβ-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with d-Cδ-alkyl or Cβ-Cio-aryl, hydroxy, fluoro, chloro, bromo, cyano, CF3 or OCF3.
68. Compound according to claim 67 wherein one of R2, R3 or R4 represents hydroxy; or Ci-Cό-alkoxy, Cδ-Cio-aryloxy, or Cβ-Cio-aryl-Ci-Cβ-alkoxy, each of which is optionally substituted once or several times by Ci-C6-alkyl, Ci-Cβ-alkoxy, amino, Ci-Cβ-alkylamino, di-Cj-Cό-alkylamino, CONH2 or SO2NH2 optionally substituted once or twice with Ci-Cβ-alkyl or Cβ-Cio-aryl, hydroxy, fluoro, chloro, or bromo.
69. Compound according to any one of claims 63 to 68 wherein one or more of R1 to R5 represent amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, Cβ-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000159_0001
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cδ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro.
70. Compound according to claim 69 wherein one of R2, R3 or R4 represents amino; amino substituted once or twice with residues selected from Ci-Cβ-alkyl, Q-Cio-aryl; or a disubstituted amino of the following formula (II)
Figure imgf000159_0002
wherein o represents 0 or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro.
71. Compound according to any one of claims 63 to 70 wherein Y representing phenyl is substituted once or several times by:
a) Ci-C6-alkyl, C6-Ci0-aryl, C6-Cl0-aryl-CrC6-alkyl, d-C6-alkoxy, C6-Ci0-aryloxy, C6-Cio-aryl-Ci-C6-alkoxy, wherein each is optionally substituted once or several times by: Ci-Cό-alkyl; Ci-Cβ-alkoxy; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, Cβ-Cio-aryl, Co-Cio-aryl- Ci-Cβ-alkyl, Ci-Cδ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-Cβ-alkylsulfonyl and C6-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; CONH2; SO2NH2; OCF3; or CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-C6-alkyl; or by b) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; OCF3; CO2H; SO3H; CONH2; SO2NH2; or CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl, Cβ-Cio-aryl, C6-Cio-aryl-Ci-C6-alkyl, wherein in the case of a di-Ci-Cδ-alkyl substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted once or several times with Ci-Cβ-alkyl or phenyl; a disubstituted amino of the following formula (II)
Figure imgf000160_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-C6-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cδ-alkyl, fluoro or chloro; or by c) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Q-Cβ-alkyl; Ci-Cβ-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl which may be combined to form 5 or 6-membered rings; SO3H; amino; amino substituted one or more times with residues selected from Ci-Ce-alkyl, C6-Ci0-aryl, C6-Cio-aryl-Ci-C6-alkyl, Ci-Cδ-alkylcarbonyl, Cδ-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and C6-Ci0-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3.
72. Compound according to claim 71 wherein Y is phenyl substituted once or several times by Ci-C6-alkyl; phenyl; Ci-C6-alkoxy; hydroxy; fluoro; chloro; bromo; CF3; OCF3; amino; CONH2 optionally substituted once or twice with Ci-Cό-alkyl wherein these optional CpCβ-alkyl residues may be combined to form 5 or 6-membered rings.
73. Compound according to claim 71 wherein Y is phenyl substituted once or twice by hydroxy, fluoro, chloro or bromo.
74. Compound according to claim 72 wherein Y is phenyl substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro, in the 2- and 4-position by chloro, or in the 4-position by phenyl.
75. Compound according to claim 63 wherein Y is phenyl substituted once or twice by fluoro, chloro or bromo; and any one of R2 to R4 represents OR7 wherein R7 is selected from hydrogen and Ci-Cβ-alkyl.
76. Compound according to claim 75 wherein Y is phenyl substituted in the 4-position by fluoro or by chloro, in the 2- and 4-position by fluoro or in the 2- and 4-position by chloro.
77. Compound according to claim 75 or 76 wherein R1 or R5 represents fluorine or hydrogen.
78. Compound according to any one of claims 75 to 77 wherein R3 or R3 and R4 represent hydroxy.
79. Compound comprising a pharmacophore of the following substructure (III),
Figure imgf000162_0001
for the inhibition of fatty acid amide hydrolase (FAAH).
80. A pharmaceutical composition comprising a compound accord to any one of claims 24 to 79 and a pharmaceutically acceptable carrier.
81. Compound according to any of claims 24 to 79 for use as a medicament.
82. Compound according to any of claims 24 to 78 for inhibition of fatty acid amide hydrolase (FAAH).
83. Compound according to any of claims 24 to 79 for treatment of a disorder that is positively influenced by inhibition of fatty acid amide hydrolase (FAAH).
84. Compound according to claim 83 wherein the disorder is selected from pain, dizziness, vomiting, and nausea, eating disorders, neurological and psychiatric pathologies, acute and chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, cancers, disorders of the immune system, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions and gastrointestinal diseases.
85. Use of a compound according to any of claims 24 to 79 for inhibition of fatty acid amide hydrolase (FAAH).
86. Use of a compound according to any of claims 24 to 79 for treatment of a disorder that is positively influenced by inhibition of FAAH.
87. Use of a pharmacophore of the following substructure (III),
Figure imgf000163_0001
(HI),
for the preparation of a compound for the treatment of a disorder which is positively influenced by the inhibition of fatty acid amide hydrolase (FAAH).
88. Use according to claim 86 or 87 wherein the disorder is selected from pain, dizziness, vomiting, and nausea, eating disorders, neurological and psychiatric pathologies, acute and chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, cancers, disorders of the immune system, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions and gastrointestinal diseases. ...
89. Process for the preparation of a compound according to any one of claims 1 to 17, and 24 to 79 wherein a compound of formula (IV),
Y
Figure imgf000163_0002
(IV), wherein
R1 to R5 independently from each other represent: hydrogen;
Ci-C6-alkyl, C3-C8-cycloalkyl, C6-Ci0-aryl, C6-Ci0-aryl-Ci-C8-alkyl, Ci-C6-alkoxy,
Cό-Cio-aryloxy, Cβ-Cio-aryl-Ci-Cg-alkoxy, Q-Cό-alkoxycarbonyl, Cβ-Cio-aryloxycarbonyl,
Cό-Cio-aryl-Ci-Cg-alkoxycarbonyl, Ci-Cβ-alkylcarbonyl, Cό-Cio-arylcarbonyl, Cβ-Cio-aryl-
Ci-Cs-alkylcarbonyl, Ci-C6-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-Cβ-alkylmercaptyl,
Ce-C lo-arylmercaptyl, C i-Cβ-alkylmercaptocarbonyl, C3-C8-cycloalkylmercaptocarbonyl, Cβ-Cio-arylmercaptocarbonyl, Ci-C6-alkylmercaptocarboxy, Cδ-Cio-arylmercaptocarboxy,
Ci-Cβ-alkylsulfonyl, Cδ-Cio-arylsuIfonyl, Ci-Cδ-alkylsulfoxy, Cβ-Cio-arylsulfoxy, wherein each is optionally substituted once or several times by Ci-C6-alkyl, Ci-Cβ-alkoxy,
Cβ-Cio-aryloxy, CO2H, SO3H, amino, Ci-Cό-alkylamino, di-Ci-Cδ-alkylamino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3;
CO2H;
SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-C10-aryl,
C6-Cio-aryl-Ci-C6-alkyl, Ci-Cβ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Q-alkylsulfonyl and Cό-Cio-arylsulfonyl; a disubstituted amino of the following formula (II)
Figure imgf000164_0001
wherein o represents O or 1 and W represents O, CH2, or NR with R being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro;
CONH2;
SO2NH2;
CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-C6-alkyl, C6-Cio-aryl or Ce-Cio-aryl-CrCό-alkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fiuorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo;
CF3; OCF3; or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Cι-C6-alkyl, d-Cβ-alkoxy, COOH, SO3H, amino, thiol, hydroxyl, nitro, cyano, fluoro, chloro, bromo, iodo, CF3 or OCF3; and wherein any two or more of R1 to R5 may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems;
m represents 0, 1 , 2, 3, 4, 5 or 6;
Y represents: a) hydrogen; b) C]-Ci8-alkyl, mono or polyunsaturated C2-Ci8-alkylene, Ca-Cs-cycloalkyl, Cβ-Cio-aryl, Cδ-Cio-aryl-Ci-Cg-alkyl, Ci-C6-alkoxy, C6-Cio-aryloxy, C6-Cio-aryl-CrC8-alkoxy, C 1 -Cδ-alkoxycarbonyl, Ce-C lo-aryloxycarbonyl, Ce-C 10-aryl-C 1 -Cg-alkoxycarbonyl, C 1 -Cδ-alkylcarbonyl, C6-C10-arylcarbonyl, Ce-C nj-aryl-C 1 -Cg-alkylcarbonyl, Ci-C6-alkylcarboxy, CO-C1 o-arylcarboxy, CrCo-alkylmercaptyl, Ce-Cio-arylmercaptyl, C 1 -Ce-alkylmercaptocarbonyl, C3-Cg-cycloalkylmercaptocarbonyl, CO-C 1 o-arylmercaptocarbonyl, C 1 -Co-alkylmercaptocarboxy , Ce-C 1 o-arylmercaptocarboxy, Ci-C6-alkylsulfonyl, C6-Cio-arylsulfonyl, Ci-C6-alkylsulfoxy, C6-Cio-arylsulfoxy, or a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, wherein each is optionally substituted once or several times by: bl) Ci-Ce-alkyl, C3-C8-cycloalkyl, C6-Cio-aryl, Ce-Cio-aryl-Ci-C8-alkyl, Ci-Cβ-alkoxy, C6-Cio-aryloxy, Ce-Cio-aryl-Ci-Cg-alkoxy, Ci-C6-alkoxycarbonyl, Cβ-C i o-aryloxycarbonyl, Cβ-C 10-aryl-C 1 -Cg-alkoxycarbonyl, C i -Ce-alkylcarbonyl, Cβ-Cio-arylcarbonyl, C6-C 10-aryl-Ci -Cg-alkylcarbonyl, CrCβ-alkylcarboxy, Cό-Cio-arylcarboxy, Ci-Cό-alkylmercaptyl, Cβ-Cio-arylmercaptyl,
C 1 -Cδ-alkylmercaptocarbonyl, C3-Cg-cycloalkylmercaptocarbonyl,
Cό-Cio-arylmercaptocarbonyl, Ci-C6-alkylmercaptocarboxy,
Cό-Cio-arylmercaptocarboxy, Ci-C6-alkylsulfonyl, Cβ-Cio-arylsulfonyl,
Ci-C6-alkylsulfoxy, Ce-Cio-arylsulfoxy; wherein each is optionally substituted once or several times by CrC6-alkyl; Ci-C6-alkoxy; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl; SO3H; CO2H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl, Ce-Cio-aryl-Ci-Cδ-alkyl, CrCδ-alkylcarbonyl, Cβ-Cio-arylcarbonyl, Ci-Cδ-alkylsulfonyl and
Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; or OCF3; wherein several of the substituents in bl) may be combined to form anellated saturated, unsaturated or aromatic homo- or hetero-ring systems; or by b2) hydroxy; thiol; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; CO2H; SO3H; OCF3; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with residues selected from Ci-Cό-alkyl, Cδ-Cio-aryl or Cδ-Cϊo-aryl-Q-Cβ-alkyl and wherein in the case of a di-Ci-C6-alkyl-substituted amino functionality, the alkyl residues may be combined to form 5 or 6-membered rings; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Ci0-aryl, C6-Cio-aryl-Cι-C8-alkyl, Ci-Ce-alkylcarbonyl, Cό-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and Cβ-Cio-arylsulfonyl; or a disubstituted amino of the following formula (II)
Figure imgf000166_0001
wherein o represents O or 1 and W represents O, CH2, or NR6 with R6 being selected from hydrogen and Ci-Cβ-alkyl and wherein the methylene groups in formula (II) may optionally be substituted once or twice with Ci-Cβ-alkyl, fluoro or chloro; or by b3) a saturated, unsaturated or aromatic heterocyclic ring system of up to 10 atoms, optionally substituted once or several times by Ci-Cβ-alkyl; Ci-Cβ-alkoxy; COOH; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice with Ci-Cβ-alkyl; SO3H; amino; amino substituted one or more times with residues selected from Ci-Cβ-alkyl, C6-Cio-aryl, Cδ-Cio-aryl-CrCβ-alkyl, Ci-Cβ-alkylcarbonyl, Ce-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and
Cδ-Cio-arylsulfonyl; thiol; hydroxyl; nitro; cyano; fluoro; chloro; bromo; iodo; CF3; Or OCF3; c) SO3H; amino; amino substituted one or more times with residues selected from Ci-C6-alkyl, C6-Cio-aryl, Ce-Cjo-aryl-Ci-Cg-alkyl, Ci-Cβ-alkylcarbonyl,
Ce-Cio-arylcarbonyl, Ci-C6-alkylsulfonyl and C6-Cio-arylsulfonyl; CONH2; SO2NH2; CONH2 or SO2NH2 wherein the amino functionality is substituted once or twice times with residues selected from Cj-Cό-alkyl, Cβ-Cio-aryl or C6-Cjo-aryl-Ci-C4-aJkyl and wherein in the case of a di-Ci-Cβ-alkyl-substituted amino functionality the alkyl residues may be combined to form 5 or 6-membered rings; thiol; hydroxyl; nitro; cyano; fluorosulfonyl; halogen selected from fluoro, chloro, bromo or iodo; CFy, or OCF3;
is cyclised to form an oxadiazolone ring system,
with the proviso that the obtained product is not a compound disclaimed in claim 24.
90. Process according to claim 89, wherein the cyclisation to the oxadiazolone ring system is achieved by phosgene, carbonyldiimidazole, or a carbonic acid ester.
PCT/PT2008/000054 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use WO2009084970A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP08866782A EP2238131A1 (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
MX2010006995A MX2010006995A (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use.
CN2008801276810A CN101959881A (en) 2007-12-27 2008-12-23 The 5-O-that is used for medical use replaces 3-N-phenyl-1,3,4-oxadiazole ketone
BRPI0821482-4A BRPI0821482A2 (en) 2007-12-27 2008-12-23 5-O-substituted 3-n-phenyl-1,3,4-oxadiazolone, its use, its composition and its preparation process
CA2710743A CA2710743A1 (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
JP2010540610A JP2011507952A (en) 2007-12-27 2008-12-23 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolones for medical use
AU2008344032A AU2008344032A1 (en) 2007-12-27 2008-12-23 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolones for medical use
IL206419A IL206419A0 (en) 2007-12-27 2010-06-16 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
ZA2010/05306A ZA201005306B (en) 2007-12-27 2010-07-26 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US930207P 2007-12-27 2007-12-27
US61/009,302 2007-12-27

Publications (1)

Publication Number Publication Date
WO2009084970A1 true WO2009084970A1 (en) 2009-07-09

Family

ID=40361548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PT2008/000054 WO2009084970A1 (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use

Country Status (14)

Country Link
EP (1) EP2238131A1 (en)
JP (1) JP2011507952A (en)
KR (1) KR20100111691A (en)
CN (1) CN101959881A (en)
AR (1) AR069970A1 (en)
AU (1) AU2008344032A1 (en)
BR (1) BRPI0821482A2 (en)
CA (1) CA2710743A1 (en)
CL (1) CL2008003895A1 (en)
IL (1) IL206419A0 (en)
MX (1) MX2010006995A (en)
TW (1) TW200932732A (en)
WO (1) WO2009084970A1 (en)
ZA (1) ZA201005306B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074587A3 (en) * 2008-12-23 2010-11-11 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
WO2010151160A1 (en) * 2009-06-24 2010-12-29 Bial - Portela & Ca., S.A. O-substituted 3-n-heteroaryl-1,3,4-oxadiazolones for medical use
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
JP2012527467A (en) * 2009-05-18 2012-11-08 インフイニトイ プハルマセウトイカルス インコーポレイテッド Isoxazolines as fatty acid amide hydrolase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419918A2 (en) * 1989-09-23 1991-04-03 Bayer Ag Substituted 1,3,4-oxa(thia)-diazolinones, process for their preparation and their use in controlling endoparasites
WO2001017981A1 (en) * 1999-09-04 2001-03-15 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
WO2003043997A1 (en) * 2001-11-15 2003-05-30 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
WO2003072555A1 (en) * 2002-02-28 2003-09-04 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments
WO2007061862A2 (en) * 2005-11-18 2007-05-31 Janssen Pharmaceutica N.V. 2-keto-oxazoles as modulators of fatty acid amide hydrolase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419918A2 (en) * 1989-09-23 1991-04-03 Bayer Ag Substituted 1,3,4-oxa(thia)-diazolinones, process for their preparation and their use in controlling endoparasites
WO2001017981A1 (en) * 1999-09-04 2001-03-15 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
WO2003043997A1 (en) * 2001-11-15 2003-05-30 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
WO2003072555A1 (en) * 2002-02-28 2003-09-04 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments
WO2007061862A2 (en) * 2005-11-18 2007-05-31 Janssen Pharmaceutica N.V. 2-keto-oxazoles as modulators of fatty acid amide hydrolase

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074587A3 (en) * 2008-12-23 2010-11-11 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
JP2012527467A (en) * 2009-05-18 2012-11-08 インフイニトイ プハルマセウトイカルス インコーポレイテッド Isoxazolines as fatty acid amide hydrolase inhibitors
WO2010151160A1 (en) * 2009-06-24 2010-12-29 Bial - Portela & Ca., S.A. O-substituted 3-n-heteroaryl-1,3,4-oxadiazolones for medical use
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain

Also Published As

Publication number Publication date
KR20100111691A (en) 2010-10-15
IL206419A0 (en) 2010-12-30
JP2011507952A (en) 2011-03-10
MX2010006995A (en) 2010-08-18
ZA201005306B (en) 2011-04-28
CA2710743A1 (en) 2009-07-09
AU2008344032A8 (en) 2010-08-19
BRPI0821482A2 (en) 2015-07-14
AR069970A1 (en) 2010-03-03
AU2008344032A1 (en) 2009-07-09
CN101959881A (en) 2011-01-26
EP2238131A1 (en) 2010-10-13
CL2008003895A1 (en) 2010-06-25
TW200932732A (en) 2009-08-01

Similar Documents

Publication Publication Date Title
Alafeefy et al. Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives
US6159979A (en) Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
AU2007316248B2 (en) Indazole derivatives useful as L-CPT1 inhibitors
KR101715190B1 (en) Pharmaceutical compounds
AU2004242624A1 (en) Novel substituted 3-sulfur indoles
CA2653424A1 (en) Novel indazole derivative having spiro ring structure in side chain
AU2007333902A1 (en) 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
EP2238131A1 (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
DK173261B1 (en) Trisubstituted benzoic acid derivative
EP2128156A1 (en) Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibiting activity
WO2009127943A1 (en) Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
CA2738776A1 (en) 7-azaspiro [3.5] nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase
JP2008266320A (en) New pyridinecarboxylic acid (2-aminophenyl)amide derivative having urea structure
EP1003738B1 (en) Bicyclic compounds as ligands for 5-ht1 receptors
ZA200100418B (en) Aryl alkanoylpyridazines.
Serwar et al. Synthesis, urease inhibition and antimicrobial activities of some chiral 5-aryl-4-(1-phenylpropyl)-2H-1, 2, 4-triazole-3 (4H)-thiones
Bhat et al. Synthesis, characterization and biological activity studies of 1, 3, 4-Oxadiazole analogs
PT1590321E (en) Aryl alkyl carbamate derivatives production and use thereof in therapy
WO2009127944A1 (en) Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
US5504095A (en) Aminobenzosultam derivatives as lipoxygenase inhibitors
IE910185A1 (en) Novel 1,3-dicarbonyl compounds and their use
EP2834235A1 (en) Processes for preparing rivaroxaban
SK281934B6 (en) 5-(hydroxymethyl) oxazolidin-2-one derivatives, their preparation and pharmaceutical composition
WO2010074587A2 (en) 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
Mokhtar Synthesis of Trisubstituted Pyrazoles with Possible Antimicrobial Activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880127681.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08866782

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 586360

Country of ref document: NZ

Ref document number: MX/A/2010/006995

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2710743

Country of ref document: CA

Ref document number: 2008344032

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12010501464

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2010540610

Country of ref document: JP

Ref document number: 1351/MUMNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107015516

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008344032

Country of ref document: AU

Date of ref document: 20081223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010129480

Country of ref document: RU

Ref document number: 2008866782

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PI 2010003011

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0821482

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100628